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Abstract 
 
 
Lung cancer is the commonest cancer killer worldwide. The appearance of 
distant metastasis is one of the main reasons for failing to cure patients with this 
disease. Thus, understanding the mechanisms regulating lung cancer metastasis should 
highlight novel therapeutic strategies to improve clinical outcome. 
We performed an RNA interference screen for cell migration using A549 non-
small cell lung cancer (NSCLC) cells. Seventy kinases modulating A549 cell motility 
were identified, including several members of the ribosomal-S6 kinase (Rsk) family. 
Indeed, Rsk1 silencing increased, while Rsk2 and Rsk4 downregulation decreased, cell 
migration. We then assessed the ability of our candidates to regulate A549 cell 
invasiveness in a 3-D invasion assay. We found that 38 of these similarly regulated cell 
migration and invasion, including Rsk1 and Rsk4 but not Rsk2. Further work 
demonstrated that the motility effects of Rsk1, but not Rsk2 or 4, silencing were 
reproduced in additional NSCLC cell lines. Hence, we focussed on Rsk1 as the 
principal Rsk isoform regulating NSCLC cell motility. In silico analysis and 
biochemical experimentation revealed that Rsk1 interacted with the actin regulators 
Vasp and Mena. This correlated with the ability of Rsk1 to phosphorylate Vasp on Thr-
278, a site regulating Vasp-mediated actin dynamics. Furthermore, Vasp and Mena 
downregulation prevented the migratory effects of Rsk1 silencing. To assess the in vivo 
relevance of our findings, we developed a zebrafish metastasis model and showed that 
Rsk1 silencing enhanced the metastatic potential of A549 cells. Moreover, 
immunohistochemical staining of human isogenically-matched samples demonstrated 
that Rsk1 expression decreased, while Rsk2 or 4 expression increased, in metastatic 
versus primary lung cancer lesions. Also, patients with Rsk1-negative primary tumours 
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showed an increased number of metastases. Taken together, our findings establish that 
Rsk1 is a metastasis suppressor in NSCLC and may be a biomarker for the progression 
of this disease. 
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1.1 Cancer 
1.1.1 Cancer is a leading cause of death worldwide 
Cancer is a leading cause of death worldwide with 7.6 million deaths in 2008. In 
2030, cancer is projected to kill 13.2 million individuals worldwide [1] (Figure 1). Yet, 
cancer burden shows strong inequalities. These include: 
• Inequalities between sexes as men are at significantly greater risk than women 
for nearly all cancer types common to both genders. 
• Inequalities between ethnic groups as genetic background influences the 
propensity to certain cancer types [2]. However, socioeconomic parameters also 
influence ethnic groups’ predisposition to cancer [3]. 
• Inequalities between developed and developing countries as the proportion of 
all deaths due to cancer vary from only 4% in Africa to 23% in Northern 
America. However, the lack of infrastructure to diagnose and register cancer in 
a developing country might partly explain this discrepancy. Indeed, the real 
impact of cancer in developing countries might be far higher than reported [4]. 
 
In the United Kingdom, cancer was killing one in four persons (21.8%) in 2005 
making it the third biggest killer behind cardiovascular and chronic diseases. 2030 
projections for the UK show no improvement in this situation with 22.6% of all deaths 
likely to be attributed to Cancer [5].  
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Figure 1: Cancer is a leading cause of death worldwide. (A) Projected global death for selected causes 
between 2005 and 2030 worldwide. Chart obtain from [6] 
(http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf). 
 
 
 
27 
 
The vast majority of cancers (~ 85%) are carcinomas that arise from epithelial 
cells. To better comprehend this complex disease, it is essential to understand the 
biology and environment of epithelial cells. 
1.1.2 General structure of an epithelium 
Epithelial cells constitute the structural unit of epithelia. They show a strong 
apical–basolateral polarity and the capacity to establish cell-cell contacts with 
neighbouring epithelial cells as well as with the surrounding extracellular matrix. 
Epithelia are supported by a semi-permeable basement membrane, a stroma and, 
depending on the organ, a layer of muscle or bone [7] (Figure 2). Both basement 
membrane and stroma form the extra cellular matrix (ECM) and are constituted of three 
types of macromolecules: (1) the fibrous structural proteins, such as the collagens, 
fibrillin and elastins; (2) the adhesive glycoproteins including fibronectin and laminin; 
and (3) the gel-forming proteoglycans and hyaluronan. There are important differences 
in the structure and composition of the basement membrane and stroma (Figure 2). 
• The basement membrane is a fine layer of 30 to 70 nm made of a network of 
macromolecules secreted by epithelial and mesenchymal cells. Its main function 
is to anchor the epithelium to the loose stroma. It consists of a mixture of 
nonfibrillar amorphous collagen (mostly type IV), laminin, heparan sulphate, 
proteoglycans, and other glycoproteins [8].  
• The stroma (also called mesenchyme) takes its name from the Greek word for 
“bed” or “bed covering”.  It is a loose connective and supportive framework that 
hosts the blood and lymphatic vessels allowing the diffusion of nutrient and 
waste to and from the epithelium, respectively. Various cell types can be found 
in the stroma such as fibroblasts, immune and inflammatory cells (Figure 2). 
The composition of the stroma consists of fibrillar (types I, III, V) as well as 
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nonfibrillar collagens, elastin, fibronectin, proteoglycans, hyaluronan, and other 
components. Besides its support function for the epithelium, the ECM plays an 
active role in the epithelium’s biology. For example, by sequestering water and 
minerals, it provides turgor or rigidity to the underlying skeletal tissues. It acts 
as a reservoir for growth factors influencing directly the proliferation of 
epithelial cells [9]. During the metastatic process, it constitutes both a 
mechanical barrier preventing the invasion of the deeper tissue and a substratum 
allowing malignant cells to adhere and migrate. 
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Figure 2: Epithelial cells and their environment. Schematic representation of a prototypical epithelium 
showing the epithelial and stromal compartments (left panel). Various cell types are highlighted together 
with structural elements (Modifed from [7]). Right, the corresponding image of an epithelial tissue from 
the upper respiratory track is stained with haematoxylin and eosin. Haematoxylin reveals the nuclei in 
blue while the eosin stains the protein rich structures. 
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1.2 From abnormal growth to metastatic cells 
In 1836, Johannes Muller, a German physiologist, showed that tumours were 
made up of cells [10]. Although the exact mechanisms leading to a cancer are not fully 
understood and differ between cancer types, several cellular traits are commonly 
accepted to characterise cancer cells [7, 11]. These include:  
 
(1) Uncontrolled cell proliferation and immortalisation; 
(2) Qualitative and/or quantitative changes in the response to growth factor 
stimulation;  
(3) Modifications in cell-cell and ECM-cell contacts that prevent cancer cells 
from maintaining normal tissue organisation;  
(4) Resistance to cell death; 
(5) Ability to promote the formation of new vessels (neoangiogenesis) and 
(6) Increased tissue invasiveness. 
 
Because of the limited scope of this thesis, we will here elaborate only on the 
latter process of invasion / metastasis. 
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1.2.1 The Metastatic process 
Metastasis is the spread of a disease from one organ (or part of an organ) to 
another. Although it was previously believed that the systemic dissemination of tumour 
cells is associated with advanced disease, recent evidence suggests that appearance of 
micrometastasis can occur concomitant to the development of early lesions both in 
mouse and human [12]. In extreme cases, the development at the metastatic site can 
overtake that of the primary tumour. Hence, in approximately 3% of all cancers the 
primary tumour is undetectable and the metastatic lesion is classified as a cancer of 
unknown primary origin (CUP) [13]. One alternative explanation for CUPs may be the 
spontaneous regression of the primary tumour following the appearance of secondary 
metastatic sites.  
A series of steps are commonly associated with the establishment of metastasis 
(Figure 3). These include: 
 
(1) Invasion and infiltration of tumour cells into the surrounding tissue and 
attraction towards nearby blood or lymphatic vessels; 
(2) Intravasation into the lumen of the colonised vessel; 
(3) Survival in the circulation; 
(4) Arrest in the capillary beds of distant organs; 
(5) Extravasation and proliferation to form a secondary tumour. 
 
Although breaking the metastatic process into this organised series of steps 
simplifies its visualisation, the exact process of metastatic invasion remains to be fully 
demonstrated. 
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Figure 3: The main steps of the metastastatic process. (A) Invasion and infiltration of tumour cells 
into the surrounding tissue and attraction towards nearby blood or lymphatic vessels. (B) Intravasation 
into the lumen of the colonised vessel. (C) Tumour cells interact with circulating host cells including 
platelets and lymphocytes. (D) Transport of tumour cells throughout the body. Few cells survive this 
step. (E) Arrest and extravasation in the capillary beds of distant organs. This step may involve 
circulating host cells that agregate with the tumour cells and form micro emboli. (F) Proliferation to form 
a secondary tumour (here illustrated in the liver). Figure adapted from [7]. 
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1.2.1.1 Step by step overview of the metastasis process 
1.2.1.1.1 Invasion and infiltration of tumour cells into the surrounding 
tissue 
In order to invade the surrounding tissue tumour cells need to acquire increased 
deformability and/or be capable of breaking-down the basement membrane and the 
surrounding extra-cellular matrix (ECM). This process has been described for both 
single cell and multiple cell invasion [14]. 
1.2.1.1.1.1 Single cell invasion 
In the case of single cell invasion, it is proposed that epithelial cells undergo a 
transition leading to the acquisition of mesenchymal traits. This epithelial to 
mesenchymal transition (EMT) is characterised by the loss of cell-cell contacts and cell 
polarity, and acquisition of a mesenchymal appearance with pro-migratory and pro-
invasive properties that allow the detachment of the cancer cells from the primary 
tumour [15]. The EMT and its reverse; the mesenchymal to epithelial transition (MET), 
are critical processes followed by stem cells during normal development (e.g. 
gastrulation, neural crest formation and tissue differentiation) [15]. Thus, it has been 
hypothetised that cancer cell undergoing EMT acquire stem cell-like characteristics [16]. 
At the molecular level, cells undergoing EMT downregulate the expression of epithelial 
marker such as E-Cadherin [17] and up-regulate the expression of mesenchymal markers 
including N-Cadherin, Vimentin and Fibronectin [16]. A number of transcription factors 
have been identified that orchestrate these changes. These include Snail homologue 1 
(Snail) and 2 (Slug), the basic helix-loop-helix Twist and E47, the kruppel-like factor 8 
(Klf8) and the zinc finger E-box binding homeobox (Zeb1 and 2) [15, 18-19]. Changes in 
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expression of these transcription factors correlate with increased malignancy and 
metastasis in many neoplasms [19] including lung cancer [20]. In keeping with the cancer 
stem cell hypothesis, it has been proposed that heterogeneous tumours contain a 
subpopulation of cells (11 to 35%) that show stem cell-like properties and are 
characterised by high levels of CD44 and low levels of CD24 expression [21]. Further 
work has proposed that the EMT process generates cells with this molecular signature 
[16]. However, conflicting evidence presented below suggest that the relevance of this 
signature might be controversial. 
The P-selectin receptor CD24 is an adhesion molecule that facilitates cellular 
interaction with platelets and endothelial cells [22]. Previous reports showed that high 
levels of CD24 are associated with poor prognosis in multiple neoplasms including 
NSCLC [23], breast [24], prostate [25], pancreatic [26] and colorectal cancers [27] and 
correlates with cancer metastasis. Hence, the reasons why EMT might decrease CD24 
protein levels and how this impacts on the metastatic process remain to be clarified. 
CD44 is a transmembrane glycoprotein involved in the regulation of cell 
adhesion, growth, survival, differentiation and motility [28]. Previous studies have 
highlighted the importance of both CD44 expression and mRNA splicing in cancer. 
Indeed, the splice variants CD44v4-7 have been linked to metastatic progression [29]. In 
colorectal cancer, up-regulation as well as specific splicing of CD44 correlates with 
poor prognosis [30] [31] [32]. However, in neuroblastoma and prostate cancer, the absence 
of CD44 (including its splice variants) correlates with transformation and poor 
prognosis [33] [34]. In prostate cancer, over expression of CD44 abrogates metastatic 
behaviour [35]. Thus, the role of CD44 in metastasis seems to be tissue-specific and 
depends on both the variants and the total amount of CD44 expressed. 
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1.2.1.1.1.2 Multiple cell invasion 
In the case of multiple cell invasion, invading cells maintain cell-cell contact to 
form a moving clump. By preserving cell-cell junctions, the cells synchronise their 
actin cytoskeleton to generate traction and protrusion forces at a multicellular level [14, 
36]. This mechanism also called tumour budding has been reported in renal and 
colorectal cancer [37] [38] [39]. At the molecular level, these cells do not undergo the 
switch between epithelial and mesenchymal markers characteristic of EMT. Wicki et al. 
recently highlighted the ability of the small mucin-type transmembrane glycoprotein, 
podoplanin, to induce collective tumour cell invasion [40]. This correlated with an 
increase in filopodia formation and the inhibition of small Rho family GTPases [40]. 
Podoplanin is up-regulated in various neoplasms [40] including lung cancer [41] and 
correlates with lymph node metastasis [42]. Interestingly, podoplanin is specifically 
expressed by lymphatic endothelial cells and is widely used as a marker for 
lymphangiogenesis [43]. Hence, the up-regulation of this protein by malignant tumour 
cells may reveal a mechanism by which tumour cells mimic the multicellular 
lymphovascular invasion. 
 
1.2.1.1.1.3 ECM degradation and remodelling 
The remodelling of the ECM has been shown to play a critical role in tumour 
progression and the ability of cancer cells to invade [44-45]. However, there are 
contradictory reports on the requirement for metastatic cells to use matrix proteases in 
order to remodel and invade the surrounding tissue [46-47]. At least three parameters will 
influence the requirement for metastatic cells to harbour proteolytic activity. 
(1) The type of invasion (e.g. single cell or multicellular) as a single cell will 
be less affected by the mechanical constraints of the ECM than a clump of cells [44]. 
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(2) The composition and structure of the ECM surrounding the tumour. In 
vivo observation of the interstitial tissue has revealed long fibres of collagen together 
with fibrillar meshwork [48]. The density, spatial alignment and structure of the collagen 
define the mechanical properties of the ECM and influence the invasion process [49]. 
Indeed, a low collagen fibre concentration promotes amoeboid type invasion while an 
increase in collagen fibre density reduces the “pores” size of the matrix forcing the cell 
and its nucleus to deform. A further increase in collagen fibre density generates a 
“pore” size below the cell diameter. This may block the invasion process or induce a 
switch to a proteolytic type of invasion where cells cleave and realign the collagen 
fibres to form tracks that can then be re-used by following invading cells [45]. 
(3) The presence of stromal cells that can substitute for the need of cancer cells 
to display proteolytic activity. Stromal cells such as fibroblasts and macrophages have 
been shown to infiltrate malignant lesions where they participate in the onset of 
inflammation and provide paracrine factors stimulating cell invasion [50]. Expression of 
various membrane-bound and secreted proteases confers upon these cells intrinsic 
invasiveness including ECM remodelling capabilities. By doing so, stromal cells create 
migration tracks between the tumour and the nearby blood vessels. This remodelling 
includes the deposition of basement membrane components and changes to the 
architecture/orientation of collagen fibres [45, 51-52]. Once formed by the stromal cells, 
these tracks can be followed by tumour cells devoid of intrinsic proteolytic activity 
thereby promoting tumour cell dissemination [51]. 
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1.2.1.1.1.4 Transcoelomic spread 
Malignant cells can escape the primary tumour by invading through the serosal 
lining of an organ in a process known as transcoelomic spread. Here, malignant cells 
trigger an inflammatory response resulting in serous exudates that excrete tumour cells 
into the peritoneal or pleural cavities [53]. From there, tumour cells can colonise other 
organs contained within the same cavity. This mechanism highlights another way in 
which tumour cells can use the immune system to promote their metastatic potential. 
This is a mode of invasion commonly found in ovarian and lung cancer [54]. Indeed, it is 
noteworthy that a large proportion of lung cancer cell lines have been established from 
patients’ pleural effusions [55]. 
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Figure 4: Invasion and infiltration of tumour cells into the surrounding tissue. (A) Carcinoma in situ 
(B) Microinvasion (C) Vascular colonisation. Left panels are schematic representations with various 
structural components highlighted (For the clarity of the schematic representations, the legend described 
in (A) is not repeated in (B) and (C).  Right panels are representative haematoxylin and eosin staining 
illustrating these three steps. Haematoxylin reveals the nuclei in blue while the eosin stains the protein 
rich structures. Magnification of all pictures is not identical. Images were courtesy of Dr Francesco 
Mauri. 
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1.2.1.1.2 Intravasation  
The increase in the number of new vessels within or adjacent to the tumour 
correlates with the appearance of metastasis and worsening prognosis [56] [56]. These 
new vessels usually result from an intense angiogenesis and/or lymphangiogenesis 
triggered by the tumour. The vessels are characterised by a discontinuous basement 
membrane, a lack of a surrounding layer of pericytes and poor inter-endothelial 
junctions. Thus, tumour-associated vessels are disorganised, leaky structures that offer 
poor resistance to invading tumour cells. Although the increase in hydrostatic pressure 
commonly observed within the tumour mass goes against the presence of lymphatic 
vessels within solid tumours, recent studies using specific lymphatic markers have 
shown the presence of lymphatic vessel around and within tumour masses [57]. This 
supports clinical observations showing that carcinomas can spread via the lymphatic 
system to colonise the lymph nodes [58].  
Using human tumour cells injected into translucent zebrafish and high-
resolution confocal microscopy, Stoletov et al. were able to image the intravasation 
process [59]. This work has revealed a cross-talk between tumour cells and the 
vasculature. Indeed, the authors showed that tumour cells develop dynamic actin-based 
protrusions penetrating the blood vessel wall at sites of vascular remodelling but not at 
regions of intact vessels. This vascular remodelling requires tumour cells to secrete 
Vegf and generates portholes for tumour cells to enter the circulation.  
Further work using intra-vital imaging in mouse has shown the importance of 
tumour associated macrophages to promote tumour cell intravasation in the absence of 
local angiogenesis [52]. In this study, although the macrophages have not been shown to 
associate directly with tumour cell, they do interact directly with the vasculature and 
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promote tumour cell intravasation by secreting paracrine factors such as epidermal 
growth factor (Egf) and colony-stimulating factor 1 (Csf-1). 
1.2.1.1.3 Survival in the circulation 
Reaching the circulation provides cancer cells with a very efficient way to 
disseminate. However, circulating tumour cells are exposed to stressful conditions 
including high pressure, sheer stress, absence of cell-cell or cell-ECM contacts and the 
presence of immune cells that can potentially detect and eliminate cancer cells. Hence, 
this step in the metastatic process is very stringent with less than 0.01% of cells 
successfully initiating a secondary tumour [60], suggesting that the appearance of 
metastasis is statistically favoured by the high number of circulating tumour cells. This 
number increases with disease progression and is associated with poor prognosis [61] [62].  
1.2.1.1.3.1 Anoikis 
Amongst the stress affecting circulating tumour cells is the absence of adhesion 
to substratum. This usually triggers a cell death programme closely related to apoptosis 
called anoikis [63] [64]. Indeed, Frisch et al. showed that cells deprived of attachment to 
the ECM underwent classical apoptosis that could be rescued by overexpression of the 
pro-survival protein B-cell lymphoma 2 (Bcl2) [63]. Furthermore, they showed that 
activation of the ECM receptors of the integrin family is critical for cells to resist 
anoikis. Indeed, the exogenous re-expression of integrins has been shown to protect 
cells from anoikis by providing survival signals to the cell [65] although different 
isoforms seem to mediate this effect depending on the cell system considered [65]. 
Finally, they demonstrated that oncogenic transformation (e.g. overexpression of H-
Ras, see section 1.5.1.1) could render epithelial cells resistant to anoikis suggesting that 
loss of anoikis sensitivity is linked to the malignant process. Three phases can be 
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distinguished during the apoptotic and anoikic cascade: initiation, effector and 
degradation [66] [67]. While the initiating insult differs between anoikis and apoptosis, the 
subsequent effector and degradation phases are common to both processes. 
Contradictory reports have highlighted the role of various signalling pathways in 
anoikis, suggesting broad differences amongst cellular systems (reviewed in [68]). 
Amongst the proteins shown to prevent the initiation phase of anoikis is the 
neurotrophic tyrosine kinase receptor TrkB [69-70]. TrkB is a membrane located receptor 
that gets activated upon binding of its ligand, the brain-derived neurotrophic factor 
(BDNF). Overexpression of TrkB has been shown in several human malignancies, 
including neuroblastoma, prostate and pancreatic cancer [71]. Ectopic expression of 
TrkB in epithelial cells has been shown to protect cells from anoikis by promoting 
growth in suspension of cellular aggregates [69]. This mechanism requires TrkB kinase 
activity [70].  
1.2.1.1.4 Arrest and extravasation into distant organs 
The most common places for circulating tumour cells to arrest and form 
secondary tumours are the lung, liver, brain, and bones. This can be seen as a 
consequence of a slower local blood flow and the presence of thin capillaries that offer 
little resistance to invading cancer cells. However, different cancer types will 
metastasise preferentially to certain organs suggesting that physical constraints are not 
the only decisive factor in this process.  For example, neuroblastoma commonly 
metastasizes to the liver while osteosarcomas and breast cancer will commonly target 
the lung. In the case of lung cancer, the main organs affected are in order of preference, 
brain, bone, liver and adrenal glands. Two hypotheses have been advanced to explain 
these patterns. 
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The first hypothesis, called mechanistic theory, was proposed by James Ewing 
in 1928. It postulated that the anatomy and haemodynamics of the vasculature 
determine the dissemination pattern of the tumour cells [72]. One supporting evidence 
for this hypothesis is the case of bowel cancer that frequently spreads to the liver via 
the portal veins that drain blood flow from the bowel to the liver. However, several 
facts challenge this hypothesis. Organs such as the kidney and the muscle receive large 
amounts of blood. Yet they are rarely subject to the development of metastasis. 
Likewise, breast cancer commonly metastasises to the liver but not to the equally 
vascularised spleen. 
The second hypothesis was proposed by Stephen Paget in 1889 and named the 
“seed and soil” hypothesis by analogy to plant seeding [73]. Stephen Paget wrote: 
“When a plant goes to seed, its seeds are carried in all directions but they can only live 
and grow if they fall on congenial soil.” The tumour cells (seeds) will find in some 
organs a more fertile environment (soil) where to develop a metastasis [73]. This 
hypothesis was later confirmed by Hart et al. using ectopic transplantation of various 
organ tissue such as lung and kidney into the muscle mass of a mouse left hind leg. 
This procedure was followed by intravenous (i.v.) injection into syngeneic mouse of 
radiolabelled B16-F10 melanoma cells. Using such procedure, Hart et al. were able to 
show that melanoma cells were equally delivered to the kidney and lung graft but only 
able to develop metastases in the lung graft [74]. Thus, the blood flow cannot alone 
explain the organ specificity observed during metastasis. 
Further studies have shown that arrest in the capillary beds and extravasation are 
supported by interaction between tumour cells and host cells such as lymphocytes and 
platelets forming micro emboli (Figure 3) [75] [76]. However, in situ imaging of 
fluorescently labelled circulating tumour cells in the mouse lung capillary suggests that 
43 
 
neither the interaction with the lymphocytes and platelets nor the extravasation are 
required for the development of a secondary tumour [77]. Indeed, Al-Mehdi et al. have 
been able to observe interactions between tumour cells and the capillary endothelium 
followed by the development of a secondary tumour site within the haematogenous 
compartment. They suggest that this mechanism is predominant compared to the rare 
extravasations of tumour cells. Furthermore, they do not observe a passive filtering of 
tumour cells by the lung capillary but rather an active adhesion of tumour cell to the 
capillary wall involving actin-based protrusions, called invadopodia, that insert 
themselves in between endothelial cells. These observations suggest that the reason for 
organ selectivity during tumour cell metastasis lies at the interface between the tumour 
cell and the endothelium. Microarray analysis of metastatic lesions in specific organs 
has highlighted changes in the expression of several genes known to play an active role 
in the dynamics of the endothelium [78]. These include, the cytokines stromal cell 
derived factor-1 (Sdf-1) and its receptor the chemokine cxc motif receptor 4 (Cxcr4) 
shown to be determinant in the homing of prostate cancer to the bone marrow [79]. 
Similarly, expression of the Platelet-derived growth factor receptor (Pdgfr) at the 
surface of the endothelial cells is essential for the specific metastasis of hepatocellular 
carcinomas to the lung as well as that of pancreatic tumour cells to the liver [80] [81]. 
Hence, while the blood flow might predispose tumour cell dissemination to particular 
distant organs (as in bowel cancer), molecular determinants seem to dictate the 
successful colonisation of metastatic sites by circulating cancer cells. 
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1.3 Cell Motility  
Alongside the two types of invasion (e.g. single cell and collective cell 
invasion), both collective and single cell migration have been described during 
physiologic processes [14, 82]. During embryonic development, cell migration involving 
both mechanisms drives gastrulation and organogenesis [14-15]. In the adult, cell 
migration contributes to tissue regeneration as well as wound healing and immune 
surveillance. Aberrant acquisition of cell motility has been shown to occur in several 
pathological processes such as vascular disease, osteoporosis, chronic inflammation, 
mental retardation and cancer [82]. Identifying the signalling pathways, temporal triggers 
and/or spatial cues that regulate cell migration during these pathological processes is 
critical for the development of new therapy. 
During metastasis, migration through the tumour microenvironment is mediated 
by both mesenchymal and amoeboid type migration [83-84]. During amoeboid migration, 
cells appear rounded and lack mature adhesion foci and stress fibres to create pro-
motile traction forces. Instead, the movement is mediated by actin protrusions called 
blebs that generate propulsive force (Figure 5B) [85]. In contrast, mesenchymal 
migration is characterised by more elongated cells displaying filopodia protrusions at 
the leading edge that generate adhesive contact with the surrounding matrix (Figure 5C) 
[44, 86]. 
In vivo studies of tumour cell movement have shown increased speed and 
persistence as compared to their slow random mode of migration in vitro [87]. One 
reason for this difference is thought to lie in the production of a growth factor gradient 
by the tumour microenvironment that promotes cancer cell migration [87-88]. The 
presence of ECM components providing an optimal adhesive substratum has also been 
advanced [48], although, cell migration velocity in vivo will heavily depend on the 
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composition and concentration of these ECM components [45, 89]. Alternatively, cells 
that migrate away to establish distant metastasis might show inherent genetic 
differences that distinguish them from other cells within the primary tumour. Isolation 
of a subpopulation of invasive cells from primary mammary tumours has suggested the 
existence of a gene expression signature for invasive cells that include a minimum 
motility machinery [90]. This machinery has been extensively studied using an in vitro 
2-dimensional migration model [82] leading to the identification of a series of 
coordinated steps that cells need to perform in order to migrate. These include: (1) cell 
polarisation, (2) appearance of protrusions at the leading edge, (3) cellular adhesion to 
the substratum and (4) retraction of the cell trailing edge (Figure 5). Each step involves 
tightly regulated modifications to the actin and microtubule cytoskeleton and changes 
in cell adhesion [82]. 
  
46 
 
 
 
Figure 5: Different types of cellular motility. (A) 2D migration showing a series of four steps. Figure 
modified from [82]. (B) 3D matrix amoeboid type migration. (C) 3D matrix mesenchymal type migration. 
(B and C) Extra cellular matrix (ECM) components such as collagen are represented in blue. 
 
 
 
  
NucleusA.
(1) Cell polarisation
(2) Protrusion at the leading edge
(3) Cellular adhesion to the substratum
(4) Retraction of the 
cell trailing edge
B. Amoeboid C. Mesenchymal
ECM components
Blebs
Filopodia
New adhesions
Translocation
Actin filaments
MTOC
Microtubules
Golgi apparatus
Adhesions
Vesicles
Adhesions
47 
 
1.3.1 Molecular mechanisms driving cell migration 
1.3.1.1 Actin Cytoskeleton 
Actin is a globular protein that polymerises in a helical fashion to form a 
polarised actin filament with a fast growing “barbed” end and a slow growing “pointed” 
end. Actin filaments form a three-dimensional network that provides a mechanical 
support for cell shape. During cell migration, actin polymerisation enables sheet-like 
membrane protrusion (lamellipodia), finger-like protrusions (filopodia) and participates 
to cell junctions [91]. Three main mechanisms drive actin dynamics during cell motility, 
(1) polymerisation of actin filaments at the leading edge of the migrating cell, (2) 
depolymerisation of the actin filaments’ pointed end and (3) coupling of the actin fibres 
to myosin II leading to actomyosin contraction [82, 91]. The initiation of new actin 
filaments is promoted by two main actin nucleators, the actin related protein 2 and 3 
(Arp2/3) complex and the Formins [92]. While lamellipodia protrusions are mainly 
driven by the Arp2/3 complex that generates a dense actin filament network, finger-like 
filopodia protrusions result from long parallel bundles of actin filament [91-93]. 
1.3.1.1.1 Arp2/3 mediated actin polymerisation 
Arp2/3 complex is an evolutionarily conserved protein complex containing 
seven polypeptides that include the actin-related proteins Arp2 and Arp3 and five 
additional subunits, p41 Arp2/3 complex (p41-Arc), p34-Arc, p21-Arc, p20-Arc and 
p16-Arc [94]. Critical upstream activators of the Arp2/3 complex include members of the 
Wiskott-Aldrich syndrome protein (Wasp) family. Wasp was initially identified on the 
basis of its mutations that are responsible for a range of immune system dysfunctions 
known as the Wiskott-Aldrich syndrome [95]. Three groups form the structurally 
homologous Wasp family in mammals. Wasps (Wasp and N-Wasp); the suppressor of 
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cyclic AMP receptor mutation and Wasp family, verprolin homologue proteins 1-3 
(Scar/Wave1–3); and a newly discovered third group containing the Wasp family 
homolog (Wash), Wasp homolog associated with actin, golgi membranes and 
microtubules (Whamm) and the junction mediating and regulatory protein, p53 cofactor 
(Jmy) [92]. While Wasps are activated by the Rho-GTPase Cdc42 (see section 1.3.1.4) 
and the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2), Scare/Waves 
appear to be specifically controlled by the Ras-related GTPases Rac proteins. In its 
inactive state, Wasps are found in a ‘closed’ auto-inhibited conformation.  Upon 
activation, Wasp switches to an ‘open’ conformation capable of binding and activating 
the Arp2/3 complex [92]. 
Two models have been proposed to explain the mechanism by which actin 
polymerisation drives membrane protrusion from the Arp2/3 complex (Figure 6). 
In the first model (Figure 6A), the activated Arp2/3 complex nucleates to the 
side of an existing actin filament initiating a new barbed end with a 70° angle from the 
pre-existing filament [91, 96]. By doing so, Arp2/3 promotes a branched actin filament 
network driving the formation of sheet-like lamellipodia protrusions [91] (Figure 6A). 
In the second model proposed by Urban et al. (Figure 6B), activation of Wasp 
family proteins at the membrane induce Arp2/3 complex activation in the sub-
membrane compartment. The Arp2/3 complex can then initiate a new actin filament 
from the plasma membrane. This model supports the idea of an un-branched actin 
filament network as the driving force behind the formation of lamellipodia protrusions 
[93] (Figure 6B). 
1.3.1.1.2 Formin-mediated actin polymerisation 
Formins are a large family of proteins containing the two highly conserved 
Formin homology 1 and 2 (FH1 and 2) domains [97]. These allow Formins to generate a 
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new filament seed by recruiting actin monomers while remaining continuously 
associated with the elongating barbed end [98]. This processive association prevents 
capping proteins from binding to the filament’s barbed end to stop actin polymerisation 
[97]. Furthermore, the association of Formins to the barbed end stimulates the addition of 
Profilin–actin units (see below) at a 5 to 10 fold faster rate than free-actin monomers 
[99]. Thus, by promoting the assembly of long actin filaments, Formins cooperate with 
the Arp2/3 complex to form filopodia and lamellipodia [92]. 
1.3.1.1.3 Regulation of the actin monomer reservoir by Profilin, 
Thymosin-β4 and Cofilin 
1.3.1.1.3.1 Profilin 
Profilin is a small protein (15kDa) that binds actin monomers in a 1:1 ratio. In 
mammals, four Profilin genes have been identified: Profilin I that is ubiquitously 
expressed [100], Profilin II [101] predominantly found in the brain and kidney [102] and 
Profilin III and IV found in the testis [103] [104]. Profilin-actin complexes enable the 
elongation of the barbed ends of actin filaments at rates similar to free-actin monomers 
but prevent the binding of actin to the filaments’ pointed ends (Figure 6A) [91]. 
Moreover, Profilin has been shown to bind to the poly-proline rich region of actin 
nucleators such as the Formins and protein regulating barbed end elongation including 
N-Wasp and vasodilator stimulated phosphoprotein (VASP) [105] [106]. This binding is 
critical for Profilin to promote actin filament growth and act as an anti-capping protein 
[107]. 
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1.3.1.1.3.2 Thymosin-β4 
In contrast to Profilin, Thymosin-β4 binding to actin monomer blocks all actin 
assembly reactions and prevents actin binding to Profilin [91]. Hence, while Thymosin-
β4 regulates the actin reservoir, Profilin maintains a pool of actin monomers ready for 
elongation. This situation is dynamic as both Thymosin-β4 and Profilin exchange actin 
monomers on a sub-second time scale (Figure 6A) [108] [91]. 
1.3.1.1.3.3 Cofilin 
Cofilin is part of the Cofilin/Actin depolymerising factor (ADF) family that 
contains several isoforms including Cofilin-1, 2 and ADF. While Cofilin-1 is 
ubiquitously expressed, Cofilin-2 expression is limited to the muscle [109]. During actin 
polymerisation, Cofilin activity mediates the severing of actin filament pointed ends. 
This activity allows the depolymerisation of actin filaments and recycling of actin 
molecules to the pool of actin monomers [110] [111]. By severing actin filaments, Cofilin 
also creates new free barbed ends for actin polymerisation at the leading edge [112] [113]. 
Hence the localisation and regulation of Cofilin activity is critical for directed cell 
migration [114] [115]. Regulation of Cofilin activity includes its inhibition following 
binding to PIP2 [116] or Cortactin [109]. Cofilin is also regulated by Lim domain kinase 
(Limk) phosphorylation that inhibits its binding to actin [117]. These regulation 
mechanisms are particularly important as the Cofilin pathway has recently been 
identified as a major determinant of metastasis (Figure 6A) [118]. 
1.3.1.1.4 Actomyosin contraction 
Following the formation of cellular adhesion to the substratum (see section 
1.3.1.3), actin filaments establish links between adhesion complexes and interact with 
myosin II to promote actomyosin-based contraction [119]. This ATP-dependent 
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phenomenon generates intracellular contractile forces similar to the one observed 
during muscle contraction. In migrating cells, this mechanism is critical to retract the 
rear end of the cell [82]. Myosin II activity depends on the state of myosin light chain 
(Mlc) phosphorylation that is regulated by the opposing action of Mlc Kinase (Mlck) 
and Mlc Phosphatase. Upstream regulators of this pathway include the Rho Kinase 
(Rock) which triggers actomyosin-based contraction by both activating Mlck and 
inhibiting Mlc phosphatase through differential phosphorylation of these two targets 
[82].   
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Figure 6: Alternative models of actin polymerisation through the Arp2/3 complex. (A) Dendritic 
branching view of actin polymerisation [91]. (B)  Unbranched view of actin polymerisation [93]. PM: 
Plasma Membrane. Figure adapted from [91] and [93]. 
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1.3.1.2 Microtubule dynamics 
Tubulin is a globular protein that polymerises to form a polarised hollow tube, 
called microtubule (MT), with a fast-growing “plus” end and a slow-growing “minus” 
end. MTs form a three-dimensional network in which their minus ends are centralised 
at the microtubule-organizing center (MTOC) while their plus ends are projected 
towards the periphery of the cell (Figure 5). During cell migration, the MT cytoskeleton 
has been shown to play a crucial role in determining cell polarity. Indeed, MTs are 
required to maintain the polarised distribution of the actin-dependent protrusions at the 
leading edge allowing for the proper localisation of actin polymerisation- and 
contraction-based activity [120]. Hence, disruption of MT dynamics leads to the random 
localisation and reduced amplitude of lamellipodia [121]. 
MTs also collaborate with the actin-myosin machinery to regulate the 
localisation of the nucleus, the Golgi apparatus and the Microtubule Organising Center 
(MTOC) in respect to the leading edge of the migrating cell [120]. The regulation of the 
MT-driven cell polarity is orchestrated by a complex constituted by the partitioning 
defective protein 3 and 6 (Par3 and 6) together with the atypical protein kinase Cs 
(aPkc), Pkcζ and Pkcλ. This complex is activated downstream of the small RhoGTPase 
cell division cycle 42 (Cdc42) [122]. The “plus end” of MTs is characterised by dynamic 
instability with successive phases of growth and shrinkage at the periphery of the cell 
[123]. Recent studies have shown the involvement of MT “plus end” tracking proteins in 
MT dynamics. The MT “plus end” tracking proteins include the cytoplasmic linker 
protein 170 (CLIP-170), Adenomatosis polyposis coli (Apc), Cytoplasmic linker 
associated protein 1 and 2 (Clasp1 and 2) and the End binding protein 1 (Eb1) [124]. 
They have been shown to promote MT stabilisation at the leading edge, but also MT 
capture at cortical sites. MT “plus end” tracking proteins also promote relaxation 
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signals for the focal adhesion complexes in a process that involves dynamin and focal 
adhesion kinase (Fak) [125]. During the dynamic instability, the targeting frequency of 
the adhesion foci by the MT is inversely proportional to the focal contact lifetime [120]. 
Hence, induced depolymerisation of the MT using chemicals such as nocodazole leads 
to a delay in the normal turnover of the focal adhesion complexes [126] associated with 
an increased formation of stress fibres [127].  
1.3.1.3 Integrin mediated cell adhesion 
Integrins are α/β heterodimeric trans-menbrane glycoproteins. Their large 
ectodomains interact with ECM proteins while their short cytoplasmic tails engage the 
cytoskeleton [128]. 18 α-subunits and 8 β-subunits of integrins have been shown to 
assemble into 24 distinct receptors in mammals. These receptors are involved in various 
adhesion structures including focal adhesion complexes, podosomes, immunological 
synapses and fibrillar adhesions. The composition and morphology of these structures 
vary with the cell type, ECM and integrin considered. 
Focal adhesion complexes, also known as adhesion foci, are molecular 
complexes that link the ECM to the actin cytoskeleton via integrins. These assemble 
and disassemble in response to intra- and extra-cellular cues. During cell migration, a 
quick turnover at the leading edge is associated to nascent adhesion foci. Pre-existing 
adhesions can stabilise and grow into larger complexes called focal adhesions [129]. At 
the opposite end of the cell, the disassembly of focal adhesions triggers the retraction of 
the trailing edge through actomyosin-based contraction. However, the size and 
dynamics of the adhesion foci highly depend on the cell type (slower or faster-moving 
cells) and microenvironment (in vivo, 3D ECM or in vitro 2D culture dishes) 
considered [83]. Over 50 different components have already been identified at focal 
adhesions including Fak, Src, Talin, Vinculin, Paxillin, and p21/Cdc42/Rac1 activated 
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kinase (Pak) [130] (Figure 7). Some of these molecules enter the adhesion site with the 
same kinetics suggesting that they exist as part of preformed cytoplasmic complexes. 
The recruitment of other components such as Talin and Paxillin follow a faster kinetic 
profile that is consistent with nascent adhesions [131]. Post-translational modifications of 
some of these components also regulate the dynamics of these foci. Indeed, 
phosphorylation of Paxillin by the Fak-Src complex correlates with the turnover of 
existing focal adhesions [129, 132]. The molecular mechanisms regulating the dynamics of 
adhesion complexes are controlled by feedback signalling from adhesion-related 
proteins themselves as well as actin, MT associated proteins and small GTPases. 
Adhesion disassembly is achieved through dissolving of these complexes by 
phosphatases such as calcineurin, or by proteolysis of some adhesion components 
including talin by proteases such as Calpain [133]. The activity of both calcineurin and 
calpain is calcium dependent. Thus, the intracellular calcium concentration is a key 
modulator of adhesion disassembly. 
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Figure 7: Structure of a Focal Adhesion complex. The α- and β-Integrin subunits (α and β on the 
scheme) cluster to link the extracellular matrix with the actin cytoskeleton.  Following integrin 
clustering, the recruitment of Paxillin and Talin leads to the binding of Fak, Src, p130Cas and vinculin to 
the focal contact. α-Actinin, an actin filament-bound protein phosphorylated by Fak, crosslinks the actin 
stress fibres and connects them to the focal contact by binding Vinculin. Zyxin joins the mature focal 
contacts by binding both α-Actinin and the stress fibres. Figure modified from [134]. 
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1.3.1.4 Rho-GTPase signalling and the regulation of cell migration 
Small Rho-GTPases are molecular switches that control a variety of cellular 
processes [135]. They cycle between two conformational states; the GTP-bound or 
activated state and the GDP-bound or inactivated state. Small GTPase activity is 
promoted by Guanine exchange factor (GEFs) and inhibited by GTPase activating 
proteins (GAPs). Once activated, the Rho-GTPases can interact with their downstream 
targets which include protein kinases or lipid modifying enzymes [135-136]. The Rho-
GTPase family includes Rac1, Cdc42 and RhoA that have been implicated in each step 
of cell migration [136]. 
During cell polarisation, Cdc42 through its interaction with Par6 and atypical 
Pkcs regulates the repositioning of the MTOC and Golgi apparatus toward the leading 
edge. 
During actin-based membrane protrusion RhoA and Cdc42 respectively regulate 
the two formins mDia1 and mDia2 while Rac1 activates the Wasp/Scar complex 
leading to actin polymerisation. 
During cell adhesion, Rho-GTPases are critical effectors controlled by signals 
emanating from adhesion-related signalling molecules such as Fak, Src, Paxillin, and 
Pak. 
During Actomyosin-based contraction Cdc42, Rac and RhoA play antagonistic 
roles [137]. RhoA activates Rock and Cdc42 activates Mrck (myotonic dystrophy kinase-
related Cdc42-binding kinase) to promote contractility [138]. Conversely, Rac activates 
Pak, which phosphorylates and inactivates Mlc kinase, thus leading to decreased 
contractility and increased cell spreading. However, Pak can also phosphorylate Mlc 
directly, resulting in increased contractility. 
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Interestingly, recent studies have shown that Mena, a member of the actin-
binding proteins family Ena/Vasp interacts with and regulates the activity of Rac1 [139]. 
The Ena/Vasp family has been shown to play a crucial role during cell migration and 
invasion [107, 140]. 
1.3.1.5 Vasp, Mena and Evl 
The Ena/Vasp family of actin-binding proteins is involved in various processes 
including cell migration, cell-cell contact, phagocytosis and neurite outgrowth [107, 141-
142] by remodelling and promoting actin filament formation [143-144]. Three human family 
members exist; Mena, Vasp, and Evl. Their overlapping function is modulated by both 
homo- [145-146] or hetero-tetramerisation [147] [148] and phosphorylation events [149]. In 
migratory cells, they localise within cellular compartments where actin polymerisation 
takes place. These include the adhesion foci, the rim of the lamellipodium and the tips 
of filopodia [144]. Structurally, Ena/Vasp family members share conserved functional 
domains including a central proline-rich region surrounded by two Ena/Vasp homology 
domains 1 and 2 (EVH1 and 2) (Figure 8A). While the EVH1 domain is crucial to 
localise Ena/Vasp to the focal adhesion complexes by interacting with proteins such as 
Zyxin and Vinculin [150] [151], the EVH2 mediates the binding of this protein to F- and 
G-actin [145, 152]. The central proline-rich region is required for the binding of profilin 
[153]. Finally, the C-terminal extremity of the EVH2 domain contains a tetramerisation 
site mediating the oligomerisation of Ena/Vasp family members [145, 147]. Three main 
phosphorylation sites have been described to regulate Vasp function (Figure 8). These 
are the Ser-157 (conserved in Mena and Evl) and Ser-239 (conserved in Mena only) 
characterised as cAMP/cGMP-dependent protein kinase (Pka/Pkg) substrates [149] [154] 
and the Thr-278, targeted by the AMP-activated protein kinase (Ampk) (Figure 8A) [155] 
[149]. While Ser-157 phosphorylation mainly regulates Vasp localisation to the plasma 
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membrane and adhesion foci, the Ser-239 and Thr-278 influence Vasp-driven actin 
filament formation [149]. 
Although, the exact mechanisms of action of the Ena/Vasp family members 
remain controversial, these protein have been shown to promote F-actin assembly using 
anti-capping [156] [157], anti-branching [158] [159] and bundling [145] [160] [161] activities and 
promoting profilin-actin recruitment [162].  Also, Ena/Vasp proteins have recently been 
involved in directing the E-cadherin/catenin complexes to cell-cell contacts [141, 163] as 
well as in the integrin-mediated control of cell adhesion and migration [164]. 
Triple knockout mice for Vasp, Mena and Evl are lethal after embryonic stage 
E16.5 [165] demonstrating that these proteins are required for normal development. 
Study of the early embryos revealed a lack of axon fibre tract formation during 
corticogenesis resulting in exencephaly and cobblestone cortex [165]. This severe 
neuronal phenotype was supplemented by disruption in endothelial barrier function. 
Indeed, loss of Vasp, Mena and Evl disrupted stress fibre formation, compromising 
actinomyosin contraction and resulting in weakened cell-cell junctions [166]. 
Surprisingly, reintroduction of a single Mena allele was sufficient to recover viability 
and fertility in these mice (although with reduced frequency). However reintroduction 
of two Vasp or two Evl alleles was not sufficient to recover viability. Thus Mena 
appears to be critical for survival [165]. Mouse models with disrupted expression of 
individual Ena/Vasp family members are viable and present with only minor defects 
suggesting a partial functional overlap between family members. Vasp knockout mice 
show reduced, cAMP- and cGMP-mediated inhibition of platelet aggregation [167] as 
well as a hyperplasia of megakaryocytes in the bone marrow and the spleen [168]. Mena-
deficient mice suffer from neuronal malformations due to a defect in axon guidance 
during neurulation and commisure formation [169]. Finally Evl knockout mice did not 
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have an obvious phenotype [165]. In cancer, increased expression of Ena/Vasp family 
members has been shown to enhance tumour cell invasiveness in vitro and in vivo [140, 
170] and correlates with tumour progression in several malignancies [170-172], including 
lung adenocarcinoma [173]. 
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Figure 8: Ena/Vasp family members. (A) Conserved functional domains of the Ena/Vasp family 
members. (B) Model of regulation of Vasp activity by phosphorylation. Vasp binds to Vinculin, Zyxin 
and Profilin irrespective of its phosphorylation status and localises to the focal adhesion complexes. 
Phosphorylation of Ser-157 affects mainly Vasp localisation while phosphorylation of Ser-239 or Thr-
278 disrupts its ability to induce F-actin polymerisation. α and β stand for the two integrin subunits [149]. 
(Figure modified from [154])  
 
A.
B.
VASP (39,8 kDa)
Mena (66,5 kDa)
EVL (44,6 kDa)
PRR Tetra.EVH1 EVH2
P
EVH1 PRR Tetra.EVH2
EVH1 PRR Tetra.EVH2
Ser-157
P
Ser-160
Ser-236
P
Ser-376
P
Ser-239
P
Thr-278
P
PKA PKG AMPK
P
EVH1 PRR Tetra.EVH2
Ser-157 Ser-239
P
Thr-278
P
Zyxin
Vinculin
Talin
α β
F-actin
Profilin - actin
62 
 
1.4 Modulation of the cell migration machinery 
1.4.1 Kinases and phosphorylation 
Cells have developed various levels of control to modulate the motility 
machinery. Amongst these, changes in the phosphorylation status of molecular 
effectors play a central role. Systematic analysis of the human genome for sequence 
similarity has revealed 518 kinases classified in 134 families [174]. Phospho-proteomic 
analysis performed in the quiescent cervical cancer HeLa cell line revealed 6,600 
phosphorylation sites on 2,244 different proteins with a relative distribution of 1.8% 
phosphotyrosine, 11.8% phosphothreonine and 86.4% phosphoserine [175]. Stimulation 
of these cells with the promigratory chemo-attractant, epidermal growth factor (Egf) 
modulated 14% of these phosphosites by at least 2 fold, highlighting the scale of 
changes in phosphorylation events in response to this growth factor [175].  
The addition of a phosphoryl group modifies the overall charge of a protein 
leading to changes in its 3-dimensional structure and its affinity to binding partners.  In 
turn, these changes will modulate the activation status or the subcellular localisation of 
the target proteins [176]. These changes are dynamic as phosphorylations are reversed by 
another family of proteins, the phosphatases, that catalyses the hydrolysis of the 
phosphoryl groups. 
Abnormal activity of kinases can drive cancer progression as demonstrated by 
the fusion protein Breakpoint cluster region-Abelson murine leukemia viral (Bcr-Abl) 
responsible for the chronic myelogenous leukemia (CML) [177] or Egfr mutations in 
various malignancies [178]. While phosphatases demonstrate a low specificity, kinases 
harbour a relatively high degree of stringency for their substrates [176]. Hence, kinases 
are very amenable targets for therapeutic drug discovery [179]. A number of signalling 
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pathways have been involved in the regulation of the motility machinery [82]. Amongst 
these are the Ras/Raf/Mek/Erk signalling pathway also called mitogen activated protein 
kinase (MAPK) pathway and the Pi3k/Pten/Pkb/mTor signalling pathway. 
1.5 The main signalling pathways of cancer 
1.5.1 The MAPK signalling pathway 
MAPK signalling is evolutionarily highly conserved [180]. Figure 9 shows a 
simplified representation of the pathway. A wide range of stimuli have been shown to 
initiate its activation leading to various biological outcomes including cell migration, 
differentiation, proliferation, survival and metabolism (reviewed by [181] and [182]) 
(Figure 9). 
Amongst the many proteins capable of initiating the activation of the MAPK 
pathway are the membrane-localised receptor tyrosine kinases (RTKs). Activation of 
these receptors involves ligand binding to their extracellular part and subsequent 
dimerisation (except for the insulin and hepatocyte growth factor (Hgf) RTKs which 
pre-exist as dimers). Once activated, the receptors undergo allosteric rearrangement 
leading to auto- and trans-phosphorylation of tyrosine residues within their cytoplasmic 
tail [183-185]. These phosphotyrosine residues act as docking sites for the src homology-2 
(SH-2) domain-containing proteins [186] including adaptor proteins (Nck, Grb2), 
scaffolds (slp76, Shc), kinases (Btk, Src, Fps), phosphatases (Shp1/2), phospholipases 
(PLCγ) and transcription factors (Stats) [187]. Upon recruitment to the receptor, these 
molecules propagate the signal to downstream effectors.  For instance, following 
binding to the RTK, Grb2 recruits Son of sevenless (Sos) via its SH3 domain [188]. Sos, 
as a GTP exchange factor (GEF), activates the small rho GTPase p21 Ras  
(Ras) by exchanging the GDP bound to Ras (GDP-Ras inactive) for a GTP (GTP-Ras 
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active). The reverse inactivating reaction is catalysed by GTPase activating proteins 
(GAPs) such as type I neurofibromatosis (NF1) that hydrolyse the GTP to GDP [189] 
[190]. Upon activation, Ras binds the N-terminal part of p74 Raf (Raf) and promotes its 
activation [191] [192] [193] [194]. Activated Raf in turn phosphorylates and activates mitogen 
activated protein kinase kinase also known as the dual-specificity protein kinases 1 and 
2 (Mek1/2, the term Mek will thereafter refer to both isoforms, unless specified) [195] 
[194] [193]. Similarly, Mek activates p42 and p44 mitogen activated protein kinase 
(p42/44MAPK) also known as extracellular signal regulated kinases 1 and 2 (Erk1/2, 
the term Erk will thereafter refer to both isoforms, unless specified). Once activated 
Erk1/2 can phosphorylate a variety of substrates in all cellular compartments. These 
include various plasma membrane proteins (CD120a, Syk, and Calnexin), cytosolic 
proteins (eg. Rsk1/2/3/4, Msk1/2, the term Rsk and Msk will refer to both isoforms, 
unless specified), cytoskeletal proteins (e.g. Neurofilaments protein, Paxillin) as well as 
nuclear substrates such as transcription factors (e.g. Paired box gene 6 (Pax6), Nuclear 
Factor of Activated T Cell (Nfat), Elk-1, Mad box transcription enhancer factor 2 
(Mef2), c-Fos, c-Myc and Signal Transducer and Activator of Transcription 3 (Stat3)) 
[196-197]. The ability of Erk to interact with such a diverse range of substrates is 
explained by the wide representation of the two Erk docking sites, D-domain and DEF 
domain within the proteome [197-198] (Figure 9). 
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Figure 9: Schematic representation of the MAP Kinase pathway activated by a receptor tyrosine 
kinase (Rtk). Grb2; Growth factor receptor-bound 2, Sos; Son of Sevenless, Raf; Raf murine leukaemia 
viral oncogene homolog, Mek; Mitogen-acivated Erk kinase, Erk; extracellular signal regulated kinase, 
S6k1; p70 S6 kinase, Dapk1; Death-associated protein kinase 1, Bcl2; B-cell leukaemia/lymphoma-2, 
Mcl1; Myeloid cell leukemia sequence 1, Bad; Bcl2-associated agonist of cell death, Creb; cAmp 
response element-binding protein, Elk-1; ETS-like gene 1, c-fos; cellular-fbj murine osteosarcoma viral 
oncogene homolog. Figure modified from [182]. 
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The apparent simplicity of this linear canonical MAPK signalling representation 
hides complexity at each levels of this pathway. 
Several mammalian isoforms exist for each signalling intermediate. This 
applies to both the RTKs of which more than 50 have been cloned [184, 199] and 
downstream signalling mediators (H/K/N-Ras, A/B/c-Raf, Mek1/2, Erk 1/2/3/5). 
Although these isoforms are closely related, they can have very selective functions. For 
example, Erk2, but not Erk1, has been shown to specifically mediate a pro-invasive 
programme [200]. 
The spatial localisation of the proteins taking part in the pathway. Post-
translational modifications such as farnesylation allow the recruitment of Ras in close 
proximity with the RTK adaptors and are required for Ras activity [190]. In the cytosol, 
co-localisation of these signalling intermediates is mediated by scaffolding proteins 
such as Kinase suppressor of Ras (Ksr) that simultaneously bind Raf, Mek and Erk [182]. 
On the other hand, the focal adhesion protein Paxillin harbours scaffolding properties 
similar to Ksr by binding Raf, Mek and Erk. Once activated, Erk can phosphorylate 
Paxillin to promote the binding of focal adhesion kinase (Fak). Hence paxillin can 
specifically localise MAP Kinase activity to focal adhesions in order to regulate their 
turnover. 
The duration and amplitude of the signal mediated by the MAP Kinase 
pathway affects its biological function.  Transient stimulation of the pathway (e.g. by 
the epidermal growth factor receptor (Egfr) and Insulin receptor) in the neuronal cell 
line PC12, stimulates cell proliferation while sustained and robust MAPK stimulation 
(e.g., by nerve growth factor receptor (Ngfr), fibroblast growth factor receptor (Fgfr)) 
promotes neuronal differentiation in the same cell system. Thus, the biological outcome 
of activating this pathway can be determined by signal strength and duration [180, 184, 
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201]. One explanation for this is the ability of Erk proteins to become bistable. 
According to Markevich et al. : “A system is termed bistable if it can switch between 
two distinct stable steady states but cannot rest in intermediate states”. The transition 
from one state to the other is mediated by a stimulus that must exceed a predetermined 
threshold [202]. The passage of this threshold switches the protein to an activated steady 
state at which it remains in absence of stimulus [202]. This process is tightly regulated by 
feed-back loops initiated by phosphatases such as the dual-specificity protein 
phosphatases (Dusp1 and 6) [202] [203]. Other feed-back loops affecting specific growth 
factor-mediated pathways have also been identified. These include the Sprouty and 
Spred protein families identified as transcriptionally-induced inhibitors of Fgf 
signalling. This effect is mediated by the binding of these proteins to and inactivation of 
B-Raf in an Fgf dependent manner [204]. 
Mutations within the Ras-Mek-Erk pathway have been reported in greater than 
30% of human cancers [205]. These are typically gain of function mutations in 
components located upstream of Erk1/2, such as RTKs, Ras and Raf [190] [206]. Although 
all these mutations will lead to increased Erk activation, the effective outcome will 
depend on the nature of the upstream mutation. For example, cells harbouring a 
mutation of the valine 600 to a glutamic acid (V600E) in B-Raf will display a specific 
transcriptional response that differs from that elicited by Ras or RTKs mutations [204]. 
1.5.1.1 Ras 
The Sarcoma virus-associated oncogene Ras is part of a family of small 
GTPases made of 39 proteins [207]. Similarly to small Rho-GTPases, Ras behaves as a 
molecular switch with an active (GTP-bound) and inactive (GDP-bound) state (see 
section 1.3.1.4). Once activated, Ras has been shown to interact and activate various 
downstream target such as the phosphatidylinositol 3-kinase catalytic subunit 
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(Pi3KCA) [208], c-Raf [209], phospholipase Cε [210] the Rac-specific GEF T-cell 
lymphoma invasion and metastasis-1 (Tiam1) [211] (reviewed by [207]) (Figure 10). The 
variety of these downstream targets explains the involvement of Ras in multiple cellular 
processes ranging from cell growth, differentiation, survival, endocytosis, cytoskeleton 
remodelling and motility. Amongst the Ras family, three main members, Harvey- (H-), 
Kirsten (K-) and Neuroblastoma (N-) Ras share a high degree of homology (85% 
Amino acid sequence identity) and are widely expressed [190]. 
1.5.1.1.1 Oncogenic Ras mutations 
H-, K- and N-Ras have been found to have activating mutations in 20% of 
human cancers. Amongst these mutations, 85% are found in K-Ras, 15% in N-Ras and 
less than 1% in H-Ras (reviewed by [207], [190] and [212]). These mutations inhibit Ras 
GTPase activity and prevent GAP induced hydrolysis of Ras-bound GTP resulting in 
the accumulation of active Ras. Ras activating mutations have been shown to drive 
several fundamental oncogenic traits including uncontrolled cell proliferation, 
resistance to programmed cell death, and increased invasiveness [190]. The accumulation 
of these oncogenic traits is commonly named cellular transformation. Increased Ras 
activation can also be mediated by mutation in Ras associated GAP protein such as Nf1 
[213]. Indeed Nf1 mutations are frequent in human cancer including NSCLC [206, 214]. 
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Figure 10: Ras signalling pathway. Schematic representation of Ras signalling pathway downstream of 
activation by a receptor tyrosine kinase (RTK). Activation of Ras is mediated by the ejection of the GDP 
to facilitate the loading of the GTP. This is catalysed by guanine-nucleotide exchange factors (GEFs) 
such as son of sevenless (Sos) or GTP-releasing proteins/factors (RasGRPs or RasGRFs). Conversely, 
Ras inactivation is mediated by its intrinsic GTPase activity that cleaves off the loaded GTP into GDP. 
This activity is promoted by GTPase-activating proteins (GAPs) such as p120GAP, RasGAP or type I 
neurofibromatosis NF1. Upon activation, Ras interacts with multiple downstream effectors. 
Representative Ras effectors are indicated together with downstream effectors and the main function 
being regulated. Af6, acute lymphoblastic leukaemia‑1 fused gene on chromosome 6; Cdc42, cell 
division cycle-42; DAG, Diacylglycerol; Erk, extracellular signal regulated kinase; Mek, mitogen-
activated protein kinase/Erk kinase; Pi3k, phosphoinositide 3‑kinase; Pkb, protein kinase B; Plcε, 
phospholipase Cε; Rassf, Ras association domain- containing family; Rin1, Ras interaction/interference 
protein-1; Tiam1, T‑cell lymphoma invasion and metastasis-1. (Figure adapted from [207])  
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1.5.1.1.2 Other Ras family members 
Other family members include the related Ras viral oncogene homolog (R-Ras) 
subfamily that share over 50% of homology with H- K- and N-Ras [215]. Similarly to H-, 
K- and N-Ras, R-Ras proteins can promote cell growth, transformation and impair 
cellular differentiation [216] via common downstream effectors such as 
phosphatidylinositol 3-kinase [217]. However, in contrast to other Ras family members, 
activated R-Ras binds but does not activate Raf and thus does not induce Erk activation 
[218] [217]. Furthermore, R-Ras activation is independent of the ubiquitous Ras GEF Sos 
[219]. Instead, R-Ras gets activated by the Ras protein-specific guanine nucleotide-
releasing factor 1 and 2 (RasGFR1 and 2) [216]. Another R-Ras specificity is the 
capacity to promote integrin-mediated cell adhesion in contrast to H-Ras that 
suppresses integrin signalling via c-Raf [220] [221]. Moreover, R-Ras has been shown to 
regulate Rac1 and modulate cell motility, invasiveness and metastasis [222] [223]. 
1.5.1.1.3 Ras localisation 
Once synthesised in the cytoplasm, Ras family members undergo multiple post-
translational modifications. First, a farnesyl isoprenyl lipid is added to Ras C-terminal 
CAAX sequence by a farnesyltransferase that address Ras to the endoplasmic reticulum 
(ER) where the AAX amino acids are removed and the new C-terminal cysteine residue 
is methylated. While this modification is enough to address K-Ras to the inner part of 
the plasma membrane, H-Ras and N-Ras travel to the Golgi where one or two palmitate 
chains are added to them before shuttling to the plasma membrane [224]. Upon 
localisation to the membranous compartment Ras family members can interact with 
their activators, receptor-associated adaptator proteins (e.g. Sos) and downstream 
targets (e.g. Raf and Pi3k) [190] [207]. In the case of K-Ras, further phosphorylation by 
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protein kinase C (Pkc) within its polybasic region relocalises K-Ras to the intracellular 
compartments including the endoplasmic reticulum (ER) and the outer membrane of the 
mitochondria. The later localisation allows K-Ras to interact with Bcl2-related protein, 
long isoform (Bcl-XL) and induce apoptosis [225]. K-Ras recycling from the plasma 
membrane can also be promoted by the calcium dependent Calmodulin that sequesters 
the polybasic domain of K-Ras [226]. On the other hand, H- and N-Ras can be re-
localised to the Golgi apparatus following depalmitoylation at the membrane [224]. This 
re-localisation does not abrogate their activity. Instead, endogenous (e.g. Golgi 
apparatus and ER) activated H- and N-Ras promote a delayed activation of the MAPK 
pathway [227]. In the case of R-Ras proteins, addition of a geranyl isoprenyl lipid by the 
geranylgeranyltransferase is responsible for its membrane targeting and is required for 
R-Ras to regulate integrin activation [216, 228]. Hence, the sub-cellular distribution of Ras 
family members is critical for the regulation of their activation and functions. 
1.5.2 Pi3k/Pten/Pkb/mTor signalling pathway 
The Pi3k/Pten/Pkb/mTor signalling pathway has been extensively studied for its 
involvement in cell growth, proliferation, survival, metabolism, inflammation and is 
commonly activated in human cancers [229]. There are three classes of Pi3k (class I to 
III), divided according to their structural characteristics and substrate specificity [230]. 
Pi3k consists of a p85 regulatory subunit together with a p110 catalytic subunit (also 
named Pi3kCA). Binding of p85 to p110 is necessary for Pi3k to be active. Following 
growth factor or hormone stimulation, many RTKs can activate Pi3k. This activation is 
mediated either by the recruitment of Pi3k to the RTK or via activation of Ras which in 
turn binds and activates Pi3k [231]. Upon activation, Pi3kCA catalyses the 
phosphorylation of plasma membrane-located phosphatidylinositol lipids converting 
phosphatidylinositol-4,5- bisphosphate (PIP2) into phosphatidylinositol-3,4,5-
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trisphosphate (PIP3) [232]. The reverse reaction from PIP3 to PIP2 is catalysed by the 
tumour suppressor, the phosphatase and tensin homolog (Pten) [233]. PIP3 acts as a 
docking site recruiting to the plasma membrane pleckstrin-homology (PH) domain-
containing proteins such as protein kinase B (Pkb also named Akt) and 
phosphatidylinositol dependent kinase 1 (Pdk1) [230, 234]. Thus, the tight regulation of the 
PIP2 / PIP3 balance by Pi3k and Pten is critical to control signalling downstream of this 
pathway. Indeed, loss of Pten protein or function is associated with uncontrolled Pi3k 
signalling and cancer [235] [236]. Pdk1 is a constitutively active kinase in the cytoplasm. 
Upon its recruitment to the plasma membrane, Pdk1 can phosphorylate Pkb on Thr-308 
[237]. In addition, Pdk1 directly phosphorylates and promotes the activation of ribosomal 
S6 kinase 1 (S6k1) [238] and p90 ribosomal S6 kinase isoforms (Rsk) [239]. Activated Pkb 
then phosphorylates the mammalian target of rapamycin (mTor) to promote its 
activation. 
mTor is found as part of two multi-protein complexes named mTorC1 and 
mTorC2 (reviewed by [240]). mTorC1 is both rapamycin- and nutrient-sensitive and 
contains the regulatory associated protein of mTor (Raptor), mammalian lethal with 
Sec13 protein 8 (mLst8, also known as GβL); proline-rich Akt substrate 40 kDa 
(Pras40); and DEP-domain-containing mTor-interacting protein (Deptor) [240]. In 
contrast mTorC2 is formed by the association of mTor with the rapamycin-insensitive 
companion of mTor (Rictor) [240], mammalian stress-activated protein kinase interacting 
protein (mSin1); protein observed with Rictor-1 (Protor-1); mLst8; and Deptor [241] [240]. 
Upon activation, Pkb de-represses mTorC1 by inhibiting phosphorylation of Pras40, a 
component of mTorC1 that suppresses the function of this complex [242] [243]. Pkb also 
activates mTorC1 by inhibiting tuberous sclerosis complex 2 (Tsc2) phosphorylation, 
relieving the inhibitory effect of this protein on mTorC1 via the Ras homolog enriched 
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in brain (Rheb) [244]. There are many substrates of mTorC1 including S6k1 [245] that 
regulate protein translation; the transcription factor sterol regulatory element-binding 
protein 1 (Srebp1) involved in the regulation of metabolism and the cytoplasmic linker 
protein 170 (Clip170) that regulates microtubule plus end dynamics [241, 246]. On the 
other hand, reported substrates of mTorC2 include Pkb and serum- and glucocorticoid-
induced protein kinase 1 (Sgk1) [241]. mTorC2 mediated phosphorylation of Pkb on Ser-
473 and Sgk1 on Ser-422 leads to full activation of both kinases and is critical for 
mTorC2 dependant regulation of cellular metabolism [247] [248]. Other substrates of Pkb 
include the actin binding protein Girdin also named Akt-phosphorylation enhancer 
(APE). Phosphorylation of Girdin by Pkb promotes its recruitment to the leading edge 
of migrating cells where it interacts with the actin cytoskeleton to regulate the 
formation of lamellipodia and stress fibres [249]. Pkb has also been reported to 
phosphorylate the ADP-ribosylation factor directed GTPase-activating protein 1 
(ACAP1). Upon phosphorylation by Pkb, ACAP1 participates in the recycling of 
integrin β1 from the membrane and promotes cell migration [250]. 
1.5.3 p90Rsk 
The 90 kDa ribosomal S6 kinase (Rsk) family is composed of  four isoforms 
(Rsk 1, 2, 3 and 4) and two related homologues, mitogen- and stress-activated kinase 
(Msk1 and 2) in human [251]. While Rsks are activated by Erk, Msks integrate both 
mitogen and stress signals from Erk and mitogen activated protein kinase 14 (also 
known as p38), respectively [197]. Increased expression of Rsks has been shown in 
breast [252] and prostate cancer [253] while Rsk2 activity has been linked to cell 
transformation [254-255] and metastatic progression in head and neck squamous cell 
carcinomas (HNSCC) [256]. Originally identified on the basis of their ability to 
phosphorylate the 40S ribosomal subunit protein S6 (RpS6) [257-258], the four Rsk 
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isoforms display a high degree of homology (75 to 80% amino-acid sequence identity) 
(Figure 11B). They are characterised by the presence of two distinct kinase domains 
that do not originate from a gene duplication [259] (Figure 11). The N-terminal kinase 
domain (NTKD) is homologous to the kinase domain found in the AGC kinase family 
(Pka, Pkg and Pkc). In contrast, the C-terminal kinase domain (CTKD) is similar to that 
found in calcium/calmodulin dependent protein kinases (Camks). Both kinase domains 
are separated by a conserved linker region (also called turn motif) and flanked by N- 
and C-terminal tails. The latter contains a sequence termed the D-domain sequence that 
allows the docking of Erk [260] ; an event required for further Rsk activation [261] (Figure 
11 and Figure 12). 
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Figure 11: Rsk domain organisation. (A) Rsk exhibit two kinase domains (N-terminal kinase domain 
(NTKD) and the C-terminal kinase domain (CTKD)) separated by a conserved linker region also named 
turn motif and flanked by N- and C-terminal tails. The latter contains a sequence termed the D-domain 
sequence (D-d) that allows the docking of Erk. Phosphorylation sites required for Rsk activation are 
conserved in all four isoforms. The Amino-acid numbering refers to human RSK1 sequence. (Figure 
modified from [251]). (B) Multiple alignement of Rsk 1, 2, 3 and 4 amino-acid sequence showing the 
high degree of homology between isoforms. Alignement performed using ClustaX2 [262]. ‘*’; identical 
residue. ‘:’; conserved substitutions. ‘.’; semi-conserved substitution. 
B.
RSK1 KKAYSFCGT...FTSRTPKDSPGIP...FRGFSFVAT...KTVEYLHSQ...GLLMTPCYT...MAATYSALN...LAQRR-VRKLPSTTL
RSK2 KKAYSFCGT...FTAKTPKDSPGIP...FRGFSFVA-...KTVEYLHAQ...GLLMTPCYT...MAATYSALN...LAQRRGIKKITSTAL
RSK3 KRAYSFCGT...FTARTPTDSPGVP...FRGFSFVAS...KTMDYLHSQ...GLLMTPCYT...MAATYFALN...LAQRRGMKRLTSTRL
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1.5.3.1 Mechanism of activation of Rsks 
Activated Erk phosphorylates Rsk on Thr-573 located in the activation loop of 
the CTKD. This activates, the CTKD that autophosphorylates Rsk on Ser-380 located 
in the central linker region. This motif might also be a substrate of additional kinases 
(Figure 12). Further phosphorylation of Thr-359 and Ser-363, probably by Erk itself, 
leads to the recruitment of Pdk1 to the phosphorylated hydrophobic motif in the linker 
region [263]. Pdk1 in turn phosphorylates Ser-221 located in the activation loop of the 
NTKD leading to a fully active Rsk. The NTKD is responsible for phosphorylation of 
Rsk substrates. Finally, autophosphorylation of Ser-749 near the Erk docking site (D-
domain) by the NTKD may result in the dissociation of Erk from Rsk thereby 
mediating a negative feedback loop on Rsk activation [260]. Recent reports revealed the 
phosphorylation of Rsk isoforms directly by RTKs including Fgfr1, Fgfr3 and Kgfr as 
well as by Src and Fyn downstream of Egfr [255] [264] [265] [266] [267]. These reports have 
highlighted the importance of phosphorylation on tyrosine residues during the initial 
steps of Rsk activation. Phosphorylation of Rsk2, but not Rsk1, on Tyr-529 by Fgfr3 
and/or Src and Fyn downstream of Egfr promotes the binding of inactive Erk to Rsk2 
and is required for further activation of Rsk2 by Erk [255]. Furthermore, phosphorylation 
of Tyr-707 by Fgfr3 contributes to Rsk2 CTKD activation by disrupting the 
autoinhibitory αL-helix in the C-terminus of Rsk2 [267]. Although, it does not appear to 
be phosphorylated by Fgfr3, Rsk1 has been shown to interact with active Kgfr to 
mediate some of its biological functions [266]. Furthermore, Fgfr1 has been shown to 
bind to the N-terminus part of Rsk1 in the nucleus and to a lesser extent in the 
cytoplasm [265]. Thus both Rsk1 and 2 interact with RTKs to regulate their activation 
and/or subcellular localisation. 
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Figure 12: Mechanisms of activation of Rsk isoforms. NTKD: N-Term Kinase Domain, CTKD: C-
Term Kinase Domain, D-d: D-domain (Erk docking site). (1) Phosphorylation of Rsk on Tyr-529 and 
Tyr-707 by RTKs and Src/Fyn induces the (2) recruitment of inactive Erk to the D-domain of Rsk. 
Parallel signalling through the Ras/Raf/Mek pathway leads to the activation of Erk which in turn 
phosphorylates Thr-573 within the activation loop of the CTKD. (3) Once activated, the CTKD 
autophosphorylates Rsk on Ser-380 within the hydrophobic motif. This site might also be targeted by 
other kinases. Erk may also phosphorylate Thr-359 and Ser-363. (4) Phosphorylation of the hydrophobic 
motif leads to the recruitment of Pdk1 which in turn phosphorylates Ser-221 within the activation loop of 
the NTKD. The NTKD is then responsible for the phosphorylation of downstream substrates. Finally, 
autophosphorylation of Ser-749 by the NTKD releases Erk from Rsk. 
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1.5.3.2 Cellular Processes regulated by Rsks 
More than 30 proteins have been identified to be substrates of Rsks. These are 
in all three cellular compartments (plasma membrane, cytoplasm and nucleus). A list of 
these targets is provided in Table 1. The variety of these substrates explains the 
involvement of Rsk isoforms in multiple cellular processes ranging from transcription 
and translation regulation to cell cycle progression, cell survival and cell motility 
(Reviewed by [251]). 
1.5.3.2.1 Regulation of transcription by Rsk                                                                                              
The regulation of transcription by Rsk is mainly mediated by the 
phosphorylation of transcription factors including the cAMP response element binding 
(Creb), Fos related antigen 1 (Fra1), serum response factor (Srf), the Ets transcription 
factor (Er81), oestrogen receptor-α (ER-α), nuclear factor-κB (Nf-κb) and the 
transcription initiation factor 1A (Tif1A) (Table 1) [251]. Once activated, these 
transcription factors induce the expression of immediate early genes (IEG) such as Fos 
and Myc. On the other hand, Rsk can also directly phosphorylate IEG including c-Fos, 
Jun, and Nur77 [268] [269] [270]. In the case of c-Fos, the phosphorylation of this protein by 
Rsk results in its stabilisation and promotes c-Fos mediated cell growth [271] [272]. 
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Protein name Biological process Phosphorylation site (organism) 
Function proposed for 
phosphorylation Refs 
Creb Transcription Ser-133 (m, h) Promotes cell survival [273][274][275] 
Nfatc4 Transcription Ser-676 (h, m) Potentiates DNA binding [276] 
Nfat3 Transcription Multiple Ser sites (m, h) Promotes myotube differentiation [277] 
Atf4 Transcription Ser-245 (h), Ser-251 (m) Promotes osteoblast differentiation [278] 
Tif-1A Transcription Ser-649 (h) Promotes cellular rRNA synthesis [279] 
Er81 Transcription Ser-191 (h), Ser-216 (m) Promotes DNA binding [280] 
Nur77, Nor1 Transcription Ser-354 (h), Ser-377 (h) Function unknown [270] 
IκBα Transcription Ser-32 (r) Activation of Nfκb [281][282] 
p65 Transcription Ser-536 (r, m) Activation of Nfκb [284] 
IκBβ Transcription Ser-19, Ser23 (r) Activation of Nfκb [285] 
Srf Transcription Ser-103 (h) Activation of c-fos transcription [286] 
Tsc2 Translation Ser-1798 (h) Promotes mTor signalling and translation 
[287] 
elF4B Translation Ser-422 (h) Enhances the interaction between elF4B and elF3 
[288] 
eEF2 kinase Translation Ser-366 (h) Inhibits the activity of eEF2 kinase and promotes translation elongation 
[289] 
RpS6 Translation Ser-235, 236 (h) Promotes cap-dependant translation [290] 
Er-α Proliferation Ser-167 (h, r) Regulates the transcriptional activity of estrogen receptor 
[291] 
Gsk3β Proliferation Ser-9 (r) Inhibits Gsk3β activity [292] 
Nhe-1 Proliferation Ser-703 (h) Stimulates serum-mediated Na
+/H+ 
exchange 
[293] 
Mi Proliferation Ser-409 (h) Activation followed by proteolytic degradation of Mi 
[294] 
Lkb1 Proliferation Ser-431 (m) Inhibits cell growth [295] 
Sos Proliferation  Downregulates Ras-MAPK activity [296] 
c-Fos Proliferation Ser-362 (r) Stabilizes c-Fos and promotes cell growth 
[269][297] 
p27kip1 Proliferation, Motility Thr-198 (h) 
Promotes 14-3-3 binding and 
cytoplasmic localization 
[298] 
Bub1 Cell cycle progress Xenopus Inhibition of Apc and metaphase arrest [299] 
Myt1 Cell cycle progress Xenopus Downregulates its inhibitory activity [300] 
Emi2/Erp1 Cell cycle progress Ser-335, Thr-336, Ser-342, Ser-344 (x) 
Promotes interaction of Emi2 with 
Pp2a 
[301][302] 
Bad Cell survival Ser-112 (h, r) Supression of Bad-mediated apoptosis [273][303] 
C/Ebpβ Cell survival Ser-105, Thr-217 (m) Promotes hepatic stellate cell survival [304] 
Dapk Cell survival Ser-289 (h) Suppresses its pro-apoptotic activity [305] 
Flna Motility Ser-2152 (h, r) Regulates actin-cytoskeleton [306] 
L1cam Motility Ser-1152 (r) Regulates neurite outgrowth [307] 
RanBP3 Nuclear transport Ser-58 (h) Regulates nuclear transport [308] 
nNos Brain function Ser-847 (h) Inhibits nNos enzyme activity [309] 
Mad1 Proliferation Ser-145 (h) Promotes cell proliferation and Myc-mediated transcription 
[310] 
As160 Glut4 translocation 
Ser-318, Ser-588, Thr-
642, Ser-341, Ser-751, 
Thr-568 
Inactivation of the GAP activity of 
As160 
[311] 
Raptor mTOR activation Ser-719, Ser-721, 722 Regulates mTorC1 activity independent of PI3K-AKT pathway 
[312] 
Yb-1 Proliferation, Motility Ser-102 (h) 
Promotes Egfr and Pik3CA 
transcription 
[313] 
Hsp27 Motility, Invasion Ser-78, Ser-82 (h) Regulates Actin cytoskeleton [256] 
Tcp-1 Cell proliferation Ser-260 (h) Mediates MAPK induced proliferation [314] 
Histone H3 Tumorogenesis Ser-10 (h) Promotes transformation [254] 
Mrlc Migration Ser-19 (h) Promotes acto-myosin contraction [315] 
 
Table 1: List of Rsk substrates. The table shows the protein names, biological processes in which the 
substrates are mainly involved, the phosphorylation sites affected if known, the functions associated to 
the phosphosites and the corresponding bibliographic references. (h): human, (m):mouse, (r): rat, (x): 
xenopus. The full protein names corresponding to the abbreviations used in this table are given in the 
Abbreviation section. This table has been modified from [251]. 
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1.5.3.2.2 Regulation of translation by Rsk    
The translation machinery can be fine-tuned to regulate protein synthesis in 
response to environmental cues. The mammalian target of rapamycin (mTor) pathway 
plays a central role in this phenomenon [316]. Rsk has been shown to modulate protein 
translation both in an mTor-dependent and independent manner. By phosphorylating 
and inhibiting the tumour suppressor tuberous sclerosis complex-2 (Tsc2), Rsk 
promotes mTorC1 mediated translation. mTorC1 activates p70 ribosomal S6 kinase 1 
and 2 (S6k1 and 2) which in turn phosphorylate the eukaryotic translation initiation 
factor 4E-binding protein 1 (4Ebp1) and the eukaryotic translation initiation factor 4B 
(eIF4B). Thus, there is a degree of overlap in the regulation of translation by Rsk and 
the closely related proteins S6k1 and 2 [288] [316]. However, Rsk can also directly 
phosphorylate elF4B independently of mTor. eIF4B phosphorylation promotes its 
interaction with eIF3 and correlates with an increase in translation rates [317] [318]. The 
phosphorylation of eIF4B by Rsk provides a transient response to mitogenic cues that 
contrasts with the more sustained and prolonged phosphorylation mediated by the mTor 
pathway [288]. In addition, Rsk also regulates translation by directly phosphorylating 
Rps6 on Ser-240 and 244 (also targeted by S6k1 and 2) as well as on Ser-235 and Ser-
236 (preferentially targeted by Rsk). The phosphorylation of the latter two sites 
correlates with increased translation and provides an mTor-independent mitogen-
induced control of protein synthesis.   
1.5.3.2.3 Regulation of cell survival by Rsk 
Rsk has been shown to promote cell survival by phosphorylating and 
inactivating the pro-apoptotic mitochondrial Bcl2 antagonist of cell death protein (Bad). 
Phosphorylation of Bad by Rsk enhances its ability to bind to the cytosolic 14-3-3 
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protein [273] [303] [319] and reduces its ability to antagonise the pro-survival factor Bcl-XL. 
Similarly, phosphorylation of Bcl-2 Interacting Mediator of cell death (BimEL) blocked 
its capacity to interact with the F-box containing protein called β-Transducin repeat 
containing protein (β-TrCP) leading to proteosomal degradation of BimEL and cell 
survival [320]. Rsk can also phosphorylate the death associated protein kinase 1 (Dapk1) 
to inactivate its pro-apoptotic function [305]. Furthermore, Rsk phosphorylation of Creb 
was found to promote survival by increasing the transcription of pro-survival genes 
such as the B-cell lymphoma protein-2 (Bcl2) family members, Bcl2, Bcl-XL, and Mcl1 
[273] [274] [275]. Finally, by phosphorylating the NF-κB inhibitor IκBα, Rsk induces IκBα 
degradation thereby allowing NF-κB to promote cell survival and proliferation [281] [282]. 
1.5.3.2.4 Regulation of cell cycle by Rsk 
Rsk activity has been shown to be involved in cell cycle progression. Indeed, 
Rsk1 and 2 promote G1 progression by phosphorylating the cyclin-dependent kinase 
(Cdk) inhibitor p27Kip1. In the nucleus, p27Kip1 inhibits G1 progression by sequestering 
and inactivating cyclin E–Cdk2 or cyclin A–Cdk2 complexes. Once phosphorylated by 
Rsk, cytosolic p27Kip1 associates with 14-3-3 preventing its translocation to the nucleus 
[298]. Furthermore, Rsk2 has been shown to promote the G2-M phase of meiosis by 
phosphorylating and inhibiting Myt1 kinase [300]. On the other hand, studies performed 
in Xenopus laevis oocytes have shown that Rsk mediates metaphase arrest via the 
cytostatic factor (Csf) [321] [322]. By phosphorylating and activating the kinase Bub1, 
Rsk1 inhibits the anaphase promoting complex (Apc) causing an arrest in metaphase II. 
Rsk also phosphorylates and stabilises the Apc inhibitor endogenous meiotic inhibitor 2 
(Emi2) thereby inhibiting Apc and inducing a metaphase arrest [301] [302]. 
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1.5.3.2.5 Regulation of invasion and metastasis by Rsk    
Initial reports suggested the involvement of Rsk in cell migration via the 
phosphorylation of proteins known to regulate the motility machinery. These include 
the membrane-associated and cytoskeletal protein, filamin A and the regulatory light 
chain of myosin II (Mrlc) [306, 315]. Recent publications have confirmed the importance 
of Rsk family members in modulating migration, invasion and metastasis [256, 323-324]. 
These studies propose Rsk1 and/or Rsk2 as determinant in mediating the pro-metastatic 
program driven by Erk. Over-expression of Rsk1 in two melanoma cell lines was 
shown to increase cell motility in a p27Kip1/RhoA-dependent manner [324]. 
Moreover, inactivation of Rsk activity using pan-Rsk inhibitors (fmk, SL0101 
and BI-D1870) inhibited Rsk-mediated migratory and invasive effects in multiple 
epithelial cell lines harbouring a hyperactive MAPK pathway [256, 323]. In contrast, 
isoform-specific down-regulation of Rsk family members using RNA interference in 
head and neck squamous cell carcinomas (HNSCC) did highlight the particular role of 
Rsk2 but not Rsk1 in this process [256]. However, Doehn et al. showed that combined 
silencing of Rsk1 and Rsk2 is necessary to significantly decrease invasiveness in the 
breast epithelial cell line, MCF10A. Thus, the involvement of each Rsk family member 
in cellular motility and invasiveness appears to be highly dependent on the cellular 
system studied. Two mechanisms have been proposed to mediate the effects of Rsk on 
cell motility and invasiveness. (1) The transcriptional activation of nuclear genes via 
the transcription factor Fra1 [323] and (2) the phosphorylation of cytoplasmic targets 
known to regulate cell motility and invasiveness [256, 324]. Hence, it is conceivable that 
the mode of action of Rsk family members will depend on the activation state and 
subcellular localisation (nucleus, cytoplasm or plasma membrane) of each Rsk isoform. 
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1.5.3.3 Expression of Rsk and mouse models 
Expression of mRNA for Rsk family members is ubiquitous in human [251]. 
However, important differences in expression patterns exist between isoforms. Rsk1 is 
mainly expressed in the kidney and pancreas while Rsk2 and 3 are predominantly found 
in skeletal muscle, heart and pancreas. In adult mice, Rsk4 protein was found in the 
heart, skeletal muscles and kidney although at much lower level than the other Rsk 
isoforms. However no detectable Rsk4 protein was found in the lung, liver, pancreas 
and adipose tissue [325]. All four isoforms were detected in human and mouse brain 
tissue although in different sub-compartments. The highest levels of Rsk2 expression in 
adult mice were found in the regions of the brain harbouring high synaptic activity such 
as the neocortex, the hippocampus and the Purkinje cells [251]. This localisation 
correlates with the reported involvement of Rsk2 in neuronal function. Indeed 
inactivating mutations of Rsk2 are associated with the Coffin-Lowry syndrome, a 
disease characterised by severe psychomotor retardation, digital and facial 
dysmorphisms, and a progressive skeletal deformation [326]. The generation of a knock-
out mouse model for Rsk2 has confirmed the human phenotype [327].  
1.6 Lung Cancer 
1.6.1 Lung cancer is the main cancer killer worldwide 
Lung cancer kills 1.3 million individuals per year worldwide and is the 
commonest cause of cancer death in the developed world including the UK [328] (Figure 
13 B and C). Smoking has been shown to be the major cause for this disease [329-330]. 
Epidemiology studies show an overall 5-year survival of 5-10% with a median survival 
that varies from 6 to 12 months in patient diagnosed with metastatic versus locally 
advanced disease, respectively [329]. This poor survival rate is explained by the high 
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metastasising potential of lung cancer and the development of resistance to therapy. 
Lung carcinomas are histologically classified into two subtypes; small cell lung 
carcinoma (SCLC) and the more prevalent non-SCLC (NSCLC) that accounts for 75-
80% of cases. NSCLC can be divided into three sub-types: squamous cell lung 
carcinoma (SCC), adenocarcinoma, and large cell lung carcinoma. Whereas SCLC 
shows sensitivity to several chemotherapeutic agents, chemotherapeutic treatment of 
NSCLC offers only marginal improvement in survival [329]. Although the appearance of 
metastatic disease in NSCLCs mostly correlates with the progression of the primary 
tumour and the infiltration of proximal lymph nodes [329], metastatic sites can already be 
detected with stage I disease in approximately 1.4% of the cases [331].  
85 
 
 
 
Figure 13: Lung cancer is the main cancer killer worldwide. (A) and (B) Comparison of the incidence 
and mortality of various cancers (A) worldwide and (B) in the UK (both sexes, all ages). Chart obtained 
from Globocan 2008 IARC [1]. 
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1.6.2 Lung cancer biology 
1.6.2.1 Pulmonary epithelium 
The pulmonary epithelium is a ramified structure starting from the trachea that 
divides into main bronchi, bronchioles and finally the alveoli which make the most of 
the lung surface (Figure 14). Specialised cell types localise all along the pulmonary 
epithelium. Those include the goblet, basal and ciliated cells mainly found in the upper 
airway, the Clara cells that localise in the upper airway and bronchioles, the pulmonary 
neuroendocrines cells (PNEC) that cluster into neuroepithelial bodies in the mid-level 
bronchioles and finally the epithelial alveolar cells that form the extremely thin 
(approx. 0.5 micrometres) alveolar wall (Figure 14B and C). Two subtypes of epithelial 
alveolar cells are known, the alveolar type-I cells (type I pneumocytes or squamous 
alveolar cells) and the alveolar type-II cells (type II pneumocytes or great alveolar 
cells). Although the most numerous are the type II alveolar cells, the type I cells cover 
the largest surface area. Each alveolus is closely wrapped in a fine mesh of thin 
capillaries composed of monolayers of endothelial cells [332] (Figure 14B). While their 
structure provides maximal surface for gas exchange, they do not offer great resistance 
to metastasising malignant epithelial cells attempting to disseminate to distant sites 
through the blood circulation. This fact alone might explain the high metastasising 
potential of lung cancer (Figure 14B and C)[330]. 
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Figure 14: Pulmonary epithelium and lung cancer. (A) Schematic diagram of a lung highlighting the 
spatial structure, the different cell types and tumour sub-type associated with each region. Box describes 
the different colour coded cell types. Figure adapted from [333]. (B) Image of a normal lung tissue section 
stained with haematoxylin and eosin showing several alveoli. (C) Image of a tissue section from the 
border of a lung adenocarcinoma stained with haematoxylin and eosin. Haematoxylin reveals the nuclei 
in blue while the eosin stains the protein rich structures. Images were courtesy of Dr Francesco Mauri. 
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1.6.2.2 Origins of lung cancer 
1.6.2.2.1 Cellular origins of lung cancer 
Lung tumour subtypes generally follow a proximal-to-distal distribution with 
the squamous cell carcinoma (SCC) mainly localised in the upper airways, the SCLC 
commonly found in the midlevel bronchioles and the adenocarcinoma typically found 
in the lower airway (Figure 14). Hence, it has been hypothesised that different tumour 
subtypes arise from specific cell types localised within defined lung compartment 
(reviewed by [333] and [334]). Several lines of evidence support this hypothesis. 
(1) The histopathology of SCC and the markers expressed by this tumour 
type, such as keratin 5 and 14, suggest that they may originate from tracheal basal cell 
progenitors located at the sub-mucosal gland duct junction [333-334].  
(2) SCLC is characterised by the expression of neuroendocrine markers. 
This tumour type commonly arises in the midlevel bronchioles where the pulmonary 
PNEC cluster into neuroepithelial bodies. [335]. Hence PNEC cells have been proposed 
to be the progenitors of SCLC [336]. 
(3) Evidence for initiating NSCLC cells came from mouse models where 
oncogenic activation of K-Ras (see section 1.5.1.1.1) in the lung generated early lesions 
at the bronchioalveolar duct junction (BADJ) (Figure 14A) [337]. The BADJ contains a 
sub-population of cells expressing the Clara cell marker, CC10, and the type II alveolar 
cell marker, Surfactant Protein C (SPC). These cells were named bronchioalveolar stem 
cells (BASC) due to their self-renewal and multipotent capacity [337-338]. Tumour 
progression into lung adenocarcinoma in these mice correlated with increased number 
of BASC suggesting that Clara and type II alveolar cells might be at the origin of 
NSCLC (Figure 14A)[333]. However since patients can present with tumours composed 
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of both SCLC and NSCLC cellular subtypes, or have tumours that progress from one 
phenotype to another, there is also a hypothesis that there may be a common cell of 
origin for these tumours.  
1.6.2.2.2  Molecular origins of lung cancer 
Genome-wide sequencing and single nucleotide polymorphism (SNP) arrays 
have enabled the systematic identification of somatic mutations as well as copy-number 
alterations associated with lung adenocarcinoma [206, 214, 339]. These approaches have 
confirmed the association with NSCLC of many genes previously known to be mutated 
in lung adenocarcinoma including the tumour suppressor genes Tumour protein (Tp53), 
p16INK4a, the serine threonine kinase 11 (Stk11), Nf1, adenomatous polyposis of the 
colon (Apc), Retinoblastoma (Rb) and Ataxia-telangiectasia mutated gene (Atm) as 
well as oncogenes such as K-Ras, N-Ras, Egfr, Erbb2 and 4 and the Vascular 
endothelial growth factor receptor 2 (Vegfr2). They also revealed chromosomic regions 
with high variability including amplification of the 14q13.3 region carrying genes such 
as the thyroid transcription factor 1 (Titf1) [339]. Variability in the 15q24–15q25.1 
regions was also frequently identified. These regions contain two genes encoding 
subunits of the nicotinic acetylcholine receptor alpha (Chrna3 and Chrna5) known to be 
regulated by nicotine exposure [340]. We will here concentrate on the importance of few 
of these genes reported to have critical roles in NSCLC initiation and development. 
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Histological Type Non–Small-Cell Lung Cancer Small-Cell Lung Cancer 
Histological Subtype 
Squamous-
Cell 
Carcinoma 
(SCC) 
Adenocarcinoma - 
Genetic changes - - - 
K-Ras mutation Very rare 10 to 30% (1) Very rare 
B-Raf mutation 3% 2% Very rare 
Egfr    
    Kinase domain mutation Very rare 10 to 40% Very rare 
    Amplification (2) 30% 15% Very rare 
    Variant III mutation 5% Very rare Very rare 
Erbb2 (Her2)    
    Kinase domain mutation Very rare 4% Very rare 
    Amplification 2% 6% Not known 
Eml4-Alk fusion (3) Very rare 7% Not known 
cMet    
    Mutation 12% 14% 13% 
    Amplification 21% 20% Not known 
Titf-1 amplification 15% 15% Very rare 
Tp53 inactivation 60 to 70% 50 to 70% 75% 
Rb inactivation 15 to 30% 90% 
p16INK4a (Cdkn2a) inactivation 30 to70% 0 to 10% 
Stk11 (Lkb1) mutation 19% 34% Very rare 
Pik3CA    
Mutation 2% 2% Very rare 
Amplification 33% 6% 4% 
 
Table 2: Genetic abnormalities in NSCLC and SCLC. NSCLC includes squamous-cell carcinoma 
(SCC) and adenocarcinoma. (1) Variations are based in part on smoking profiles. (2) Based on data 
acquired from resected cancers. (3) The fusion gene consisting of parts of Eml4 and Alk occurs in 
adenocarcinoma but not in other types of non–small-cell lung cancer or non lung cancers. (Table 
modified from [341] and [342]) 
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1.6.2.2.2.1 Egfr and RTK involvement in lung cancer 
Egfr is a plasma membrane bound tyrosine kinase receptor composed of an 
extracellular ligand-binding domain, a single trans-membrane domain linked to an 
intracellular tyrosine kinase domain and a non-catalytic carboxyl terminal tail [185]. Also 
known as Erbb-1, Egfr belongs to a family containing four members in mammals 
(Erbb-1 to 4) [343]. Both homo- and hetero-dimers of Erbb receptors have been 
described and are activated by eleven different ligands providing a range of activation 
options [344]. Three main regions have been identified to be frequently mutated within 
Egfr: the extracellular domain, the kinase domain and the C-terminal tail. These 
mutations lead to receptor activation by destabilising the inactive kinase conformation 
[345]. However, kinase mutated Egfr can still respond to ligand stimulation and get 
further activated [346] [347]. Yet, tyrosine phosphorylation in mutated Egfr is significantly 
lower than that of ligand-activated wild-type receptor. This difference has been shown 
to result in distinct gene expression signatures [348] in cells bearing mutant versus those 
with wild-type Egfr. Amongst the weakly phosphorylated tyrosine residues is the Tyr-
1045 located within the receptor’s tail. Phosphorylated Tyr-1045 promotes the 
recruitment of the ubiquitin-ligase Casitas B-lineage lymphoma proto-oncogene (Cbl) 
that targets the receptor for lysosomal degradation. Thus, aberrant Egfr activation 
induced by mutation in the kinase domain allows propagation of the signal downstream 
without triggering degradation of the receptor [178]. 
In lung cancer, several Egfr abnormalities are frequently detected including Egfr 
protein overexpression, gene amplification, and mutation [349] [350] [351]. These mutations 
frequently occur within the exons 18, 19, 20 and 21 coding for the kinase domain. In 
patients with adenocarcinoma, they are associated with female sex, Asian ethnic origin 
and no smoking history. Amongst these mutations, 46% involve in-frame deletions of 
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amino-acids 746 to 750 within exon 19 while 40% are mutations resulting in the 
substitution of the Lysine 858 to an Arginine (L858R) in exon 21. The remaining 14% 
of mutations are located within exons 18 and 20 [352] [353]. Initial experiments performed 
in vitro suggested that Egfr kinase domain mutations could transform fibroblasts and 
lung epithelial cells [354] [355] suggesting that these mutations were oncogenic. This was 
later confirmed using mouse models carrying inducible deletion of exon 19 or 
expression of a L858R mutant in type II alveolar cells. These mice developed atypical 
adenomatous hyperplasia, that progressed into lesions resembling bronchioalveolar 
carcinoma and finally invasive adenocarcinoma [356-357]. Thus, activating mutations in 
the Egfr kinase domain are sufficient to drive the development of lung adenocarcinoma. 
Moreover, de-induction of the expression of mutant Egfr in these mice led to regression 
of tumours, suggesting that persistent signalling from mutant Egfr is required for 
tumour maintenance in this model [356]. 
Other Egfr mutations have been described in NSCLC including the Egfr variant 
III mutation that correspond to an in-frame deletion of exons 2 to 7 that encode for part 
of the extracellular domain [358]. Mouse models engineered to express this mutation in 
the lung also developed tumours that were similarly dependant on the continuous 
expression of the mutant Egfr for their maintenance [359].  
These observations were later confirmed by Tang et al. who showed that Egfr 
gene mutation and protein overexpression can be observed in the normal epithelium 
adjacent to tumours. Disease progression then correlates with an increase in Egfr gene 
copy number with metastatic sites harbouring Egfr gene mutation, protein 
overexpression and increased gene copy number [360]. 
Other RTKs have been reported to be mutated in lung cancer. These include 
Erbb2 and 4 (also named Her2 and 4) and the hepatocyte growth factor receptor c-Met. 
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Mutations and amplification in Erbb2 have also been identified in lung adenocarcinoma 
although with lower frequency than Egfr (mutated in 4% and amplified in 8% of 
patients) but similar association with female sex, Asian ethnic origin and no smoking 
history [351]. Similarly, Erbb4 kinase domain mutations have been found in 2 to 3% of 
Asian patients with lung adenocarcinoma [361]. c-Met was found to be frequently 
mutated (26%) and amplified (41%) in NSCLC. Moreover, both amplification and 
activation of cMet were observed in early K-Ras-induced lesions [362]. 
1.6.2.2.2.2 K-Ras activation 
H-, K- and N-Ras are mutated in 19% of lung adenocarcinoma. The majority of 
these mutations (17%) are attributed to K-Ras [207] and frequently found in patients with 
smoking history [363]. Smoking-related K-Ras mutations affect the exon 12 in 90% of 
the patients and are substitutions of a purine for a pyrimidine leading to a transversions 
mutations from Guanine (G) to Thymine (T). They contrast with the transition 
mutations (Guanine (G) to Adenine (A)) associated with non-smoking related lung 
cancer [341, 364]. However, the functional relevance of this discrepancy is so far unclear. 
Although, K-Ras mutations can be detected in early lung lesions similarly to 
Egfr [365], K-Ras and Egfr mutations are mutually exclusive [206]. These early lesions are 
predominantly associated with G to T transversion mutations and precede smoking-
related lung adenocarcinoma. Mice models carrying oncogenic alleles of K-Ras 
activated by spontaneous recombination events throughout the animal are predisposed 
to a range of tumours with early lung lesions being predominant [337, 366]. Hence, 
similarly to Egfr, K-Ras mutations appear to be an early event in lung cancer 
development. 
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1.6.2.2.2.3 B-Raf activation 
Activating B-Raf mutations are found in 5% of all NSCLC [367]. Mice carrying 
an inducible oncogenic B-Raf mutation (B-RafV600E) develop early lesions in the lung 
similarly to the K-Ras model [337, 367]. 
1.6.2.2.2.4 Pi3k/Pten/Pkb/mTor involvement in lung cancer 
In their study, Ding et al. identified 17 genes taking part in the 
Pi3k/Pten/Pkb/mTor signalling pathway [206]. This set of genes were mutated in more 
than 30% of lung tumours (excluding the K-Ras mutated tumours) highlighting the 
importance of this pathway in lung cancer. Both mutations and amplification of 
Pi3kCA have been reported in lung cancer. While Pi3kCA mutations occur in only 4% 
of lung cancers, its amplification is more frequently reported and affect mainly SCC 
(33%), followed by adenocarcinoma (6%). Other proteins found mutated in the 
pathway include Akt1 (1.9%) and Pten (9%) [229]. Although the occurrence of Pi3kCA 
mutations appear independent of the Egfr or K-Ras mutation status [368], Pi3kCA was 
shown to be required for K-Ras-driven tumourigenesis in vivo [231, 369]. Indeed, mice 
harbouring a Pi3kCA mutant allele deficient in its ability to bind Ras displayed altered 
growth factor signalling and were protected from Kras‑driven tumourigenesis in the 
lung [231]. 
1.6.2.2.2.5 Tp53 inactivation 
Tp53 is a homotetrameric transcription factor activated by many forms of 
cellular stress including irradiation, drug-induced genotoxic damage, hypoxia, and 
oncogenic signal [370]. Upon activation, Tp53 induces a transcriptional response leading 
either to cell cycle arrest or apoptosis. Hence Tp53 is classified as a tumour suppressor 
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gene and is found frequently inactivated in human cancer (reviewed by [370-371]). In 
Lung cancer, Tp53 mutations occur in both SCC (60 to 70%) and adenocarcinoma (50 
to 60%) [341]. The mutations affecting Tp53 follow similar pattern to K-Ras mutations 
with transversion and transition mutations respectively associated with smoking and 
non-smoking related lung cancer [364]. Amongst the mutations affecting Tp53 is the 
substitution of the arginine 175 to a histidine (R175H) associated with the familial Li-
Fraumeni cancer susceptibility syndrome [372] and found in a subset of NSCLC patients 
[373]. This mutation inhibits Tp53 activity by abrogating its transcriptional activity [374] 
and is conserved in mice (R172H) [375]. Mice model carrying Tp53 mutation R172H 
rarely developed lung adenocarcinomas (13% of mice). As previously described, mice 
carrying oncogenic K-Ras mutation spontaneously developed early lung 
adenocarcinoma but these rarely metastasised [366]. The generation of mice carrying 
both oncogenic K-Ras mutation [366] and inactivating Tp53 R172H mutation did not 
result in an increase in the number of lung adenocarcinoma lesions as compared to mice 
with K-Ras mutation only (62.5% and 70.8%, respectively). However, the additional 
presence of a Tp53 mutation promotes the development of advanced tumours with 
increased frequency of metastases (36.5% in K-Ras/p53 mutants versus 4.5% in K-Ras 
mutants) [366, 376]. These secondary lesions were observed at sites frequently colonised 
by NSCLC metastasis in humans including the mediastinal lymph nodes, heart, liver, 
adrenal glands, kidney and pancreas. Similarly, the early lesions observed in the B-
RafV600E mouse model rarely progressed into adenomas and adenocarcinoma unless 
the mice also carried an inactivating mutation in Tp53 [367]. Hence, inactive Tp53 and 
oncogenic K-Ras or B-Raf mutations cooperate in animal models to reproduce more 
accurately the human disease. 
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1.6.2.2.2.6 Retinoblastoma (Rb) inactivation 
Rb was identified as a protein mutated in both inherited and sporadic 
Retinoblastoma. It is part of a family of proteins containing two other members: p107 
and p130 [370, 377]. Its functions include the regulation of cell cycle progression, 
apoptosis and differentiation [370]. In its hypophosphorylated state, Rb inhibits the 
activity of the family of transcription factors E2Fs that regulates the expression of 
genes required to initiate DNA synthesis. Thus, Rb is a critical regulator of the G1/S 
transition of the cell cycle [378]. Phosphorylation of Rb by cyclin dependent kinases 
(Cdk) in response to mitogenic signals, abrogates Rb-mediated repression of E2F and 
allows cell to proliferate. Hence inactivating mutations of Rb dissociate the cell cycle 
machinery from the extracellular mitogenic signals and promotes uncontrolled cell 
proliferation [371]. Rb inactivation can also be mediated by Tp53 via inhibition of p21 
which in turn inhibits Cdk mediated Rb phosphorylation [370]. However, Tp53 has been 
reported to prevent tumour development by inducing apoptosis when Rb is inactive 
[379]. Indeed mouse models where both Tp53 and Rb are absent, frequently develop 
tumour due to defect in apoptosis [380] [381] suggesting that inactivation of Tp53 allows 
the development of Rb negatives tumours. In support of this notion, inactivation of both 
Tp53 and Rb are frequent in many cancers. In lung cancer, loss or mutation of Rb has 
been reported to be frequent, affecting more than 90% of SCLCs and 15 to 30% of 
NSCLCs [342]. Moreover, inactivation of Rb in NSCLC was found to be more frequent 
in advanced tumours [382]. 
1.6.2.2.2.7 p16INK4a inactivation 
p16INK4a also named cyclin-dependent kinase inhibitor 2a (Cdkn2a) is a tumour 
suppressor gene frequently altered in human neoplasms. It functions as an inhibitor of 
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the Cdks leading to inactivation of Rb. p16INK4a inactivation has been reported in up to 
70% of NSCLC but rarely occurs in SCLC. It can be mediated by mutations  or deletion 
in the gene or through hypermethylation of p16INK4a promoter to prevent its expression. 
While mutations in p16INK4a are rarely found in NSCLC primary tumours, homozygous 
deletion of the gene occurs in 10 to 40% of cases [342]. Furthermore, both mutations and 
homozygous deletion of p16INK4a have been associated with tumours from patient with 
smoking history. In contrast, inactivation of p16INK4a in non-smokers correlates with 
promoter hypermethylation and occurs early in tumour development [383] [384]. Mice 
carrying oncogenic K-Ras mutations develop early adenomas that are positive for 
p16INK4a immunohistological staining. Progression of these lesions into advanced 
adenocarcinoma correlates with disappearance of p16INK4a staining suggesting that 
inactivation of this protein is necessary for progression of early lung tumour into 
advanced adenocarcinoma [385]. Indeed, mice carrying oncogenic K-Ras or B-Raf 
mutations together with deletion of p16INK4a develop advanced lung adenocarcinoma 
[367, 386]. Hence, similarly to Tp53 mutations, p16INK4a inactivation cooperates with 
oncogenic K-Ras or B-Raf in animal models to promote the development of advanced 
tumours that more closely mirror the human disease. 
1.6.2.2.2.8 Eml4-Alk 
Eml4-Alk is the result of an inversion within the chromosome 2p that generates 
a fusion gene made of the C-terminal part of echinoderm microtubule-associated 
protein-like 4 (Eml4) gene and the N-terminal part of the anaplastic lymphoma kinase 
(Alk) gene containing its kinase domain. Ectopic expression of the fusion protein in 
fibroblast induces cellular transformation [387]. In NSCLC, this gene fusion product was 
detected in 6.7% of patients and seems to be exclusive to Egfr, K-Ras or B-Raf 
mutations [387]. The translocation occurs in adenocarcinoma but not in other types of 
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NSCLC or other cancers [341]. Recent reports have described two new variants, Eml4-
Alk variants 3a and 3b that both were able to transform fibroblast in vitro [388]. 
1.6.2.2.3 Lkb1 
The serine/threonine kinase Stk11, also named Lkb1, was reported mutated or 
deleted in 19% of SCC and 34% of adenocarcinomas [341]. However, these alterations 
occur in less than 5% of adenocarcinoma from Asian patients [389-390]. While Lkb1 
mutations were exclusive from Egfr mutations, they associated with K-Ras mutations 
and thus were frequent in patients with a smoking history [390]. Recent reports suggest 
that Lkb1 is involved in lung cancer progression from early tumorigenesis to the 
development of metastasis [391] [392]. Indeed, reduced Lkb1 protein levels were 
associated with high grades of lung dysplasia [393]. While Lkb1 mutation alone is not 
sufficient to initiate lung cancer in mice, inactivation of Lkb1 together with expression 
of oncogenic K-Ras in mice increased the incidence of lung tumours and promoted the 
development of metastasis. Furthermore, these lung tumours developed into all NSCLC 
histological subtypes including adenocarcinoma, SCC and large-cell carcinoma [391]. 
1.6.2.3 NSCLC treatment 
The majority of patients diagnosed with lung cancer present with NSCLC (75 to 
80%). Early symptoms of the disease are often non-specific for cancer and the final 
diagnosis often reveals tumours at an advanced stage [330]. Although surgery offers the 
best chance of cure, only a small proportion of patients are ever suitable for this 
procedure due to early dissemination of the disease. Instead, the majority of sufferers 
must rely on non-surgical therapies [329]. 
The identification of genomic alterations driving NSCLC has enabled major 
progress in the understanding of the molecular mechanisms driving this disease (see 
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section 1.6.2.2.2). This, in turn, led to the development of novel drugs. Amongst these 
are the Egfr reversible inhibitors gefitinib and erlotinib. These have been reported to 
provide considerable clinical benefit in patients diagnosed with tumours carrying Egfr 
kinase domain mutations such as non-smoker Asian females with lung adenocarcinoma 
[341]. However, treatment with these inhibitors of patients with tumours deprived of Egfr 
mutations can worsen their outcome. Furthermore, patients with lesions carrying K-Ras 
mutations do not respond to these drugs [352]. Hence, screening for Egfr mutations as 
well as K-Ras mutations in all patients with lung cancer is required to predict the 
clinical benefit of these inhibitors. However, even in patients that do initially respond to 
Egfr inhibitors, resistance to these drugs eventually occurs [352]. Several mechanisms 
have been reported to mediate this resistance including the appearance of additional 
mutations in Egfr such as the substitution of threonine 790 for a methionine (T790M) 
that alters the binding kinetic of the inhibitor to the receptor. Recently developed 
irreversible Egfr inhibitors have been shown to suppress T790M-mutant tumour cells in 
vitro and are promising candidates for future treatment of the disease [394] [395]. Another 
mechanism reported to mediate this resistance is the amplification of the oncogene c-
Met which compensates for Egfr inhibition and drives cell proliferation [396]. 
Development of a c-Met inhibitor to treat patients with c-Met amplification following 
Egfr inhibitor treatment might provide clinical benefit. Several other inhibitors directed 
against proteins involved in NSCLC are currently under evaluation in clinical trials 
(Table 3). 
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Target Inhibitor name (therapeutic) Target Company 
Stage of 
development 
(tumour type) 
p110α  PX-866 (in combination with gefitinib) Pi3k 
ProlX 
Pharmaceuticals 
Preclinical 
(NSCLC) 
mTOR 
Sirolimus (in combination 
with 
Gefitinib) 
mTor Wyeth 
Phase I/II 
(NSCLC, 
glioblastoma) 
Temsirolimus (CCI-779; in  
combination with erlotinib) mTor Wyeth 
Phase I/II 
(glioblastoma) 
Everolimus (RAD001; in 
combination with gefitinib or 
erlotinib) 
mTor Novartis 
Phase I/II 
(NSCLC, 
glioblastoma, 
breast) 
AP23573 (single agent) mTor Ariad Phase I/II (endometrial) 
MAPK 
pathway 
Sorafenib (BAY49-9006; 
alone or in 
combination with erlotinib) 
Raf 
 Bayer 
Phase I/II 
(NSCLC, 
glioblastoma) 
PD-325901 (single agent) Mek Pfizer Phase II (NSCLC) 
Eml4-Alk PF-02341066 (single agent) Alk Pfizer Phase III (NSCLC) 
 
Table 3: Therapeutic inhibitors under development. Examples of inhibitors that are under evaluation 
in phase I, II or III clinical trial.  (Modified from [352]) 
 
 
Despite the recent therapeutic improvement, the overall survival of most 
patients diagnosed with advanced NSCLC remains modest. Thus, identification of the 
mechanisms promoting the dissemination of this disease is required if we aim at 
efficiently targeting advanced disease. 
1.7 RNA interference and cell motility screen 
1.7.1 RNA interference 
RNA interference was initially described in plants (petunia) [397] and fungus 
(Neurospora crassa) [398] as a post-transcriptional gene expression inhibition 
mechanism mediated by mRNA degradation. Later work, led by Andrew Fire and Craig 
C. Mello, showed a potent gene silencing effect following injection of double stranded 
RNA (dsRNA) into Caenorhabditis elegans [399]. They showed that neither mRNA nor 
antisense RNA injections had an effect on gene expression, but that dsRNA 
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successfully silenced the targeted gene thus identifying for the first time the initiator of 
the silencing. Following its discovery, the RNA interference (RNAi) machinery was 
progressively found to be conserved in a variety of organisms. This included higher 
mammals allowing individual cells to control the expression of ‘undesirable’ mRNAs 
from endogenous (e.g. microRNA [400]) or exogenous (e.g. viral dsRNA [401]) origins. 
Indeed, its role has been extensively described in eukaryotes as an immune molecular 
defence preventing viral dsRNA from integrating into the host genome [402]. The RNAi 
pathway (Figure 15) is initiated in the cytoplasm by the ribonuclease DICER which 
recognises long double stranded RNAs (dsRNA) and cleaves them into short double-
stranded RNA fragments of 21–25 base pairs called small interfering RNA (siRNA) 
duplexes [403]. Following DICER cleavage, one strand of the siRNA duplex (the guide 
strand) is recognised by the multiprotein RNA-induced silencing complex (RISC) 
catalytic component, the endoribonuclease Argonaute 2 [404]. Argonaute 2 slices the 
non-guide (passenger) strand while keeping the guide strand to further associate and 
slice complementary mRNA. Finally, the RISC complex is recycled for further round 
of slicing [405]. Thus, by degrading specific RNAs, the RNAi pathway can prevent their 
translation to regulate the expression of the corresponding proteins. 
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Figure 15: RNA interference pathway. Gene expression starts by the transcription of the genomic 
sequence into a messenger RNA (mRNA) by an RNA polymerase in the nucleus. Once exported into the 
cytoplasm the mRNA is translated by the ribosomal machinery into a protein (right panel). In the case of 
RNA interference (left panel), the presence of a complementary RNA sequence in the cytoplasm leads to 
the formation of a double stranded RNA (dsRNA) cleaved by the complex DICER into small interfering 
RNAs of 21 to 25 base pairs (bp). Alternatively synthetic siRNA duplex can be introduced into the cell 
using transfection. The RNA-induced silencing complex (RISC) and its catalytic subunit, Argonaute 2 
(Ago2) load the siRNA duplex, slice the passenger strand and use the guide strand to further recognise 
and slice complementary mRNA before being recycled [405]. 
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1.7.2 Screening signalling pathways involved in cell migration, 
invasion and metastasis 
The use of RNA interference to silence the expression of specific genes has 
been expanded leading to the design of siRNA libraries targeting the entire genome. By 
performing an siRNA screen, one can specifically and systematically assess the effect 
of single-gene silencing on a cellular process of interest. This approach has been 
successfully used with small targeted [406] [407] as well as genome-wide libraries [408] 
[409]. Because cell motility involves large numbers of interacting players, all of which 
are not yet characterised, screens for signalling pathways involved in cell migration 
have been undertaken [406] [407]. However, no such screen has been performed in non-
small cell lung cancer (NSCLC) where metastasis is a leading cause of death [329]. We 
propose that identifying kinases involved in NSCLC migration and invasion might 
reveal novel therapeutic targets to improve the treatment of patients suffering from this 
disease. Indeed, recent developments in the delivery of siRNA in vivo has enabled the 
efficient silencing of gene expression in animal models suggesting the possibility of 
RNA interference being used as a therapeutic strategy in the future [410]. 
104 
 
1.8 The Thesis 
The aims of this thesis are: 
1. The identification of kinases regulating NSCLC cell migration and invasion 
using RNAi technology. 
2. Elucidating the mechanisms of action of some promising candidates. 
3. Highlighting the potential relevance of our in vitro findings in vivo using animal 
models and clinical samples. 
The data collected here may provide valuable information that will help design 
novel therapeutic strategies to prevent NSCLC metastasis. 
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2.1 Materials 
2.1.1 Reagents 
A small interfering RNA (siRNA) library targeting the kinome as well as siRNA 
SMARTpools and deconvoluted single sequences were obtained from Dharmacon 
(Lafayette, CO, USA). FlexiTube siRNA sequences, RNAeasy RNA extraction and 
one-step RT-PCR kits were purchased from Qiagen (Qiagen, West Sussex, UK). 
Oligofectamine transfection reagent was obtained from Invitrogen (Oregon, USA). Cell 
Tracker Green CMFDA, the nuclear dye 4',6-diamidino-2-phenylindole (DAPI) and 
Alexa Fluor 488-conjugated Phalloidin were obtained from Molecular Probe, 
Invitrogen (Oregon, USA). Forskolin and Tetramethylrhodamine B isothiocyanate 
(TRITC) coupled phalloidin were purchased from Sigma-Aldrich (Steinhelm, 
Germany). Matrigel and type I rat tail Collagen were obtained from BD Bioscience 
(Erembodegem, Belgium). Foetal calf serum (FCS) was obtained from FirstLink 
(Birmingham, UK). L-glutamine and penicillin-streptomycin solutions were purchased 
from Biowhittaker (Verviers, Belgium). A 30% solution of acrylamide and bis-
acrylamide (37.5:1 ratio) was purchased from National Diagnostics (Hull, UK). 
Phosphate Buffered Saline (PBS) was purchased from OXOID (Hampshire, UK). 
Glycine and paraformaldehyde were purchased from BDH Chemicals (Poole, UK). 
Milk was obtained from Fluka BioChemika (Buchs, Switzerland). Bromophenol blue 
and the Bio-Rad protein assay were obtained from Bio-Rad (Munich, Germany). 
Agarose was purchased from Fisher Scientific (Loughborough, UK). DNA 100 bp and 
1kbp ladder were obtained from New England Biolabs (Hertfordshire, UK). Crystal 
violet was obtained from GURR (High Wycombe Bucks, UK). The enhanced 
chemiluminescence (ECL) kits were obtained from Amersham (Buckinghamshire, 
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UK). X-Ray films were purchased from Fujifilm (Minato-ku, Japan). Human 
recombinant Vasp was obtained from Origene (Rockville, MD, USA). Human 
recombinant active GST-Rsk1 was purchased from Cell Signaling (Danvers, USA). 
Recombinant GST-S6 peptide (A-K-R-R-R-L-S-S-L-R-A) was obtained from Professor 
Ivan Gout (University College London, Institute of Structural and Molecular Biology, 
London, UK). 
2.1.2 Antibodies 
Rsk1 (sc-231), Rsk2 (sc-9986), Csnk1a (sc-6477), Csnk1e (sc-6471) antibodies 
were purchased from Santa Cruz (California, USA). An antibody against Csnk1g2 
(H00001455-M01) was obtained from Abnova (Taipei, Taiwan). The Vimentin 
antibody (AF2105) was purchased from R&D System (Minneapolis, USA). E-Cadherin 
(ab1416), N-Cadherin (ab12221) and Gapdh (ab9484) antibodies were obtained from 
Abcam (Cambridge, UK). Vasp (V40620) and Mena (610692) antibodies were 
purchased from BD Transduction Laboratories (Erembodegem, Belgium). Vasp 
phospho-Ser-157 (3111) and phospho-Ser-239 (3114) antibodies were obtained from 
Cell Signaling (Danvers, USA). The anti phospho-Thr-278 VASP antibody was a kind 
gift from Thomas Renne (Karolinska Institutet, Stockholm, Sweden). Secondary 
horseradish peroxidise (hrp) -coupled antibodies were purchased from Amersham. 
 
2.2 Methods 
2.2.1 Cell culture 
A549, H23, HCC15 and H522 were obtained from (Cancer Research 
UK/London Research Institute cell services, London, UK). LNM35 cells were obtained 
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from Prof. Eric O. Aboagye (Imperial College London, School of Medicine).  All five 
cell lines were adherent and cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 
units/ml penicillin and 100μg/ml streptomycin. Cells were grown in a humidified 
atmosphere at 37°C and with 10% CO2 and maintained at sub-confluent density by sub-
culturing 1/10 twice a week following trypsinisation (0.5mg/ml solution of trypsin in 
0.2 mg/ml ethylenediaminetetraacetic acid (EDTA) in Dulbecco’s Phosphate Buffered 
Saline). 
2.2.2 RNAi transfection 
A549, H23 and LNM35 cells were plated and incubated overnight at 37oC, 10% 
CO2 prior to transfection with the relevant siRNA. Table 4 summarises the transfection 
condition for each assay. 
Cell line Cell density Plate format Assay 
Volume of 
Oligofectamine per 
well 
A549, H23 
and LNM35 
1 x 103 / well 96-well plate Migration assay 0.7 µL 
3 x 103 / well 96-well plate Invasion assay 0.7 µL 
2 x 103 / well 96-well plate Viability assay 0.7 µL 
10 x 103 / well 24-well plate RT-PCR 1.5 µL 
100 x 103 / well 6 well plate SDS-PAGE western blotting 3 µL 
 
Table 4: siRNA transfection conditions. RT-PCR; Reverse transcriptase – Polymerase chaine reaction, 
SDS-PAGE; Sodium dodecyl sulphate polyacrylamide gel electrophoresis. 
 
Each protein was targeted using a mixture of 4 different sequences 
(SMARTpool) from Dharmacon (Lafayette, CO, USA). Deconvolution experiments 
were performed using each single sequence from the pool. Cells were transfected in the 
presence of 35 nM RNAi using Oligofectamine as a transfection reagent (Invitrogen, 
Oregon, USA) according to the manufacturer’s instructions (Table 4). Cells were then 
incubated at 37°C/10% CO2 for 48 h to allow for target down-regulation. Controls used 
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included untransfected cells and cells transfected with a non-targeting scramble 
sequences siRNA pool. Further validation of Rsk1 was performed using FlexiTube 
siRNA sequences from Qiagen (Qiagen, West Sussex, UK). A list of the sequence 
numbers used for the validation of the screen is provided in the Table 5. 
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Target 
Gene Ref Seq ID 
Dharmacon sequences 
numbers 
Rsk1 NM_002953 06, 07, 08, 12 
Rsk2 NM_004586 05, 06, 07, 08 
Rsk4 NM_014496 01, 02, 03, 04 
Csnk1g2 NM_001319 01, 02, 03, 04 
Csnk1g3 NM_004384 02, 05, 06, 07 
Csnk2b NM_001320 01, 02, 03, 04 
Csnk1a1 NM_001892 09, 10, 11, 12 
Csnk1a1l NM_145203 01, 02, 04, 05 
Csnk1e NM_001894 01, 02, 04, 05 
Adck2 NM_052853 02, 03, 04, 05 
Adck4 NM_024876 01, 02, 04, 05 
Adck5 NM_174922 01, 02, 03, 04 
Clk1 NM_004071 01, 02, 03, 04 
Clk2 NM_001291 05, 06, 07, 08 
Clk4 NM_020666 01, 02, 03, 04 
Ckb NM_001823 01, 02, 03, 05 
Mark4 NM_001823 01, 02, 03, 05 
  Qiagen sequences numbers 
Rsk1 NM_002953 01, 09, 10, 14 
 
Table 5: siRNA sequence numbers used for the validation of the migration screen. Ref Seq ID ; 
National Center for Biotechnology Information (NCBI)  reference number for each transcript targeted.  
 
 
2.2.3 Reverse transcriptase – Polymerase chain reaction (RT-PCR) 
Following siRNA transfection, the efficiency of downregulation of the targeted 
mRNA was assessed by RT-PCR. Total cellular RNA was extracted using the Qiagen 
RNAeasy kit according to the manufacturer’s instructions. Total RNA concentration 
was measured using a NanoDrop ND1000 spectrophotometer (Labtech international, 
East Sussex, UK). RT-PCRs were carried out using the Qiagen one-step RT-PCR kit 
(QIAGEN, West Sussex, UK). RT-PCR reactions of 25 μl (final volume) were prepared 
on ice. Each reaction contained 1X RT-PCR buffer, 400 μM of each dNTP (dATP, 
dTTP, dGTP dCTP), 600 nM of each primers (forward and reverse) (Table 6), 2 μl of 
RT-PCR enzyme mix [1mM dithiothreitrol (DTT), 0.1 mM EDTA, 0.5% (v/v) Nonidet 
P-40 (NP-40), 0.5% (v/v) Tween 20, 50% glycerol (v/v), pH 9.0] and 100 ng of RNA 
template. RT-PCR reactions were carried out using a DNA Engine Dyad thermal cycler 
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(BioRad, Munich, Germany) with a heated lid. The amplification programme followed 
7 steps:  
- Step 1: Reverse transcription: 30 min at 50 ºC 
- Step 2: Hot start PCR activation: 15 min at 50 ºC 
- Step 3: Denaturation of the template: 1 min at 94 ºC 
- Step 4: Annealing of the primers: 30 sec at 55 ºC (Ta) 
- Step 5: Extenssion: 1 min at 72 ºC 
- Step 6: Repeation of the step 3 to 5 over 29 cycles. 
- Step 7: Final extension: 10 min at 72 ºC 
 
Forward and reverse primers were designed on separate exons for each target 
transcript to be amplified (Table 6). RT-PCR products were resuspended 1:5 in 6X 
DNA loading buffer [30% (v/v) glycerol, 0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol] and loaded on a 1.2% agarose gel containing  0.7 µg/mL ethidium 
bromide (BET). A 100 bp DNA ladder was used to confirm the size of the amplified 
RT-PCR products. Amplification of a fragment of the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a loading control. The absence of contaminant in 
the reagents was confirmed by performing an RT-PCR without template in parallel. 
 
Target Ref Seq 
ID 
Forward sequence Reverse sequence 
Ta 
( ̊ C) 
Product 
size (bp) 
Rsk1 NM_002953 TCGTGAGATCAAGCCACCCTTCAA AAACCAAAGTCACAGATGCGCAGG 55 687 
Rsk2 NM_004586 AGGCTCTGATGCTAGGCAGCTTTA AGACTCTGCGCTTCAGGACTCAAA 55 627 
Rsk4 NM_014496 TGGCTGGCTACACTCCATTTGCTA TGAAAGGTCTTGTGAGTCAGGGCA 55 313 
Csnk1a1 NM_001892 TCTGAGGCAGCTATTCCGCATTCT GCTTGCAGACAAGAAGCCAACCAT 55 709 
Csnk1a1l NM_145203 AGCCGACCAGATGATCAGCAGAAT AGAATGCGGAATAGCTGCCTCAGA 55 504 
Csnk1e NM_001894 TGTTCCCGCAAATTCAGCCTCAAG AGCCCAGGTTGAAGTACATGAGCA 55 343 
Csnk1g2 NM_001319 AGCATGCCATCCACATCATCGACT ACAGCAGCATTTGGTTTCATCGGC 55 662 
Csnk1g3 NM_004384 AGTGTTGAACATGTGGTGCTGCTG CCATTCACTGATGGGCAAAGCACT 55 317 
Csnk2b NM_001320 TTGGACCTGGAGCCTGATGAAGAA ATGGCTTCACCTGGGATGTCTGAA 55 236 
Gapdh NM_002046 AAGGTCGGAGTCAACGGATTTGGT AGTGATGGCATGGACTGTGGTCAT 55 534 
 
Table 6: Forward and reverse sequences used for the RT-PCRs. Ref Seq ID ; National Center for 
Biotechnology Information (NCBI)  reference number for each transcript amplified. Ta; annealing 
temperature. The RT-PCR products size is given in base pair (bp). 
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2.2.4 Protein extraction and Sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) 
Cellular proteins were extracted using a lysis buffer [20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid HEPES-NaOH (pH 7.4), 150 mM NaCl, 
2 mM  EDTA, 0.5% (w/v) Triton X-100, 10% (w/v) glycerol]. This buffer was used for 
SDS-PAGE analysis of protein extracts, immunoprecipitation and co-
immunoprecipitation. This lysis buffer was supplemented with a cocktail of protease 
inhibitors (Roche Diagnostics). Although the exact composition of this cocktail is not 
disclosed, it contains 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride 
(AEBSF), aprotinin (a trypsin inhibitor), leupeptin (a lysosomal protein inhibitor) and 
pepstatin (an aspartyl proteases inhibitor). The buffer was further supplemented with 
inhibitor of phosphatases, 1 mM sodium orthovanadate (Na3VO4) (a tyrosine 
phosphatases inhibitor), 10 mM β-Glycerophosphate and 10 mM sodium fluoride (NaF) 
(serine/threonine phosphatases inhibitors). The lysates were clarified by centrifugation 
for 10 min at 14 000 rpm (G-force equivalent: 12500 g) and equalised for protein 
amount using the Bio-Rad protein assay based on the method of Bradford [411]. Equal 
protein amounts were analysed by SDS-PAGE. SDS-PAGE was performed according 
to the method of Laemmli [412]. Slab gels were prepared with a 5% acrylamide stacking 
gel [5% acrylamide, 0.125 M Tris, pH 6.8, 0.1% SDS, 0.075% ammonium persulphate 
(APS) and 0.083% Tetramethylethylenediamine (TEMED)] and a 8 or 10% acrylamide 
resolving gel [8-10% acrylamide, 0.375 M Tris, pH 8.8, 0.1% SDS, 0.06% APS, 0.07% 
TEMED] depending on the size of proteins being analysed. Samples diluted 1:1 in 2 x 
sample buffer [4% SDS, 20% glycerol, 10% β-mercaptoethanol, 0.125M Tris-HCl, 
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0.004% bromophenol blue, pH 6.8] were boiled at 95oC for 5 min and pelleted by 
centrifugation for 1 min at 14 000 rpm (G-force equivalent: 12500 g) prior to either 
electrophoresis or storage at –20oC. Stored samples were re-boiled at 95oC for 5 min 
and pelleted by centrifugation for 1 min at 14 000 rpm (G-force equivalent: 12500 g) 
before SDS-PAGE separation. Electrophoresis was performed using a Tris-glycine 
running buffer [2.5 mM Tris, 0.2 M glycine and 0.1% SDS] at 20mA per gel using the 
SE 400 Sturdier Vertical Electrophoresis Unit (Hoefer, Holliston, MA, USA) for the 
large gels and the Mini-Protean BioRad gel electrophoresis for smaller gels (BioRad, 
Munich, Germany).  
2.2.5 Western blotting 
Following SDS-PAGE, the gels were electrophoretically transferred onto 
nitrocellulose membranes using a Hoefer wet-blotting apparatus for 2 h at 400 mA in 
4oC transfer buffer [20% methanol, 39mM glycine, 48mM Tris-HCl, pH 9.5]. 
Following the transfer, membranes were blocked for 1 h at room temperature (RT) in 
PBS containing 5% (w/v) fat-free milk before incubation with the relevant antibody 
diluted in PBS containing 3% (w/v) BSA overnight at 4oC. Membranes were then 
washed four times 15 min in PBS, 0.05% (v/v) Tween 20 (PBS-T) prior to 1 h 
incubation at room temperature with the relevant secondary HRP-conjugated antibody 
diluted in PBS containing 1% (w/v) fat-free milk. The immunoblots were subsequently 
washed four times 15 min in PBS-T and subjected to enhanced chemo-luminescence 
(ECL) according to the manufacturer’s instructions (Amersham, GE Healthcare). ECL 
signals were revealed using X-Ray films (Fujifilm, Minato-ku, Japan). 
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2.2.6 Immuno and co-Immunoprecipitation 
100 x 103 A549 cells were plated in 6-well plates and incubated overnight at 
37oC, 10% CO2 prior to siRNA transfection or not. In the case of Vasp phosphorylation 
on Ser-157 and Ser-239, A549 cells were stimulated with Forskolin 10µM for 30 min. 
DMSO was used as a diluent-alone control. Fokskolin is a potent activator of Pka and 
Pkg previously reported to stimulate the phosphorylation of those two residues [149]. 
Cells were lysed at 4 ºC in 0.5 ml of LB (see above). Cell lysates were clarified by 
centrifugation for 10 min at 14 000 rpm (G-force equivalent: 12500 g), 4 oC, and 
equalised for protein amount using the Bio-Rad protein assay as previously explained. 
0.5mg/mL of protein extract were immunoprecipitated for 2 h at 4 oC using 1 μg/ml of 
anti Vasp mouse monoclonal IgG1 antibody (BD, V40620), anti Rsk1 rabbit polyclonal 
IgG antibody (Santa Cruz, sc-231) or Rsk2 mouse monoclonal IgG1 antibody (Santa 
Cruz, sc-9986) together with Protein A- or G–Sepharose (Sigma-Aldrich, Steinhelm, 
Germany) (25 μl of a 50% slurry solution previously washed three time in PBS). 
Protein A-Sepharose was used with rabbit polyclonal IgG while the protein G–Sepharose 
was used with the mouse monoclonal IgG1 antibody. The immune complexes were 
then washed three times in 1mL of ice-cold LB (see above) (centrifugation step was 
performed at 5000 rpm (G-force equivalent: 2100 g) 30 sec at 4 °C). 
Immunoprecipitates were resuspended 1:1 in 2 x sample buffer and subjected to SDS-
PAGE/ Western blotting as previously described. 
2.2.7 In vitro kinase assay 
1 μg human recombinant Vasp (Origene, Rockville, MD, USA) was incubated 
on ice in 5mM MOPS (pH 7.2), 2.5 mM β-glycerophosphate, 1mM EGTA, 0.4 mM 
EDTA, 5mM MgCl2 and 0.05mM DTT in the presence or absence of 10ng of human 
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recombinant active GST-Rsk1 (Cell Signaling, Danvers, USA). The reaction was 
started by adding an ATP-mix resulting in a final concentration of 100 μM ATP with or 
without 10 nCi/μl [γ-
32
P]ATP (Perkin Elmer, Waltham, MA, USA) and incubated for 
30 min at 30ºC. As a positive control 1 μg recombinant GST-S6 peptide (A-K-R-R-R-
L-S-S-L-R-A) was used as a substrate for Rsk1. Reactions were terminated in SDS-
sample buffer and analysed by SDS-PAGE and autoradiography. 
2.2.8 Autoradiography 
32P-labelled samples were resolved by SDS-PAGE. Prior to drying, gels were 
fixed and stained with Coomassie Brilliant Blue R-250 (Sigma-Aldrich, Steinhelm, 
Germany) in 40% (v/v) methanol, 10% (v/v) acetic acid. Gels were then dried under 
vacuum for 2 h at 80oC and exposed to X-Ray films. 
2.2.9 Cell migration assay 
Random migration speed was measured as previously reported [413]. 1 x 103 
A549 cells were plated in a 96 well-plates and incubated overnight at 37oC, 10% CO2 
prior to siRNA transfection with the relevant RNAi. 48h later, cells were fluorescently 
stained using either DioC6 (Molecular Probe, Invitrogen) or Cell tracker Green 
5’chloromethylfluorescein diacetate (CMFDA) (Molecular Probe, Invitrogen) 
according to the manufacturer’s instructions in phenol red-free DMEM supplemented 
with 10% foetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin and 
100μg/ml streptomycin. Cells were washed twice with fresh medium to remove the 
excess of dye and left 1h in the incubator to allow the pH to equilibrate before imaging. 
Cell tracker green CMFDA was used at a dilution of 1/20,000 in phenol red-free 
DMEM supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 100 
units/ml penicillin and 100μg/ml streptomycin. Time-lapse imaging was performed 
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over 18 h (1 image every 10 min) using a motorised-staged environment-controlled 
Nikon microscope with the Metamorph imaging software (Molecular Devices). Each 
condition was performed in duplicate with two fields acquired for each replicate. Sixty 
cells per conditions were subsequently tracked using the Metamorph tracking module. 
Tracks were analysed using a previously published Mathematica notebook [413] 
(Wolfram Research). A one way ANOVA statistical test was used to assess the 
statistical significance of the results obtained with cells transfected with scrambled 
sequences used as reference. 
2.2.10 Cell viability assay 
2 x 103 A549 cells were plated at 50% confluence in 96 well-plates and 
incubated overnight at 37oC, 10% CO2 prior to transfection. 48h following RNAi 
transfection, cells were subjected to a CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega, Madison, WI) according to the manufacturer’s instructions. Parallel 
experiments were performed using crystal violet staining. For the latter, 48h following 
RNAi transfection, cells were fixed and stained with 0.5% (w/v) crystal violet prepared 
in 25% (v/v) Methanol for 20 min. Fixed specimens were then washed in water three 
times, dried and resuspended for 30min in 10% (v/v) acetic acid.  Crystal violet 
absorption was read on a spectrophotometer at 590nm. Mean and standard error of the 
mean (SEM) of independent experiments were calculated. Statistical analysis was 
performed using a two-tailed Student’s t-test to determine the statistical significance of 
the differences observed. A p-value below 0.05 was considered significant. 
2.2.11 Actin cytoskeleton staining and lamellipodia counting 
Cells in 96 well-plates were fixed with 50μL of 4% (w/v) phosphate buffered 
paraformaldehyde (PFA) solution for 15 min, washed 3 times in PBS, permeabilised 
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using 50μL of 0.1% (v/v) Triton X-100 in PBS for 5 min, washed 3 times in PBS, and 
blocked using 50μL of 3% (w/v) Bovin Serum Albumin (BSA) in PBS for 1 hour. The 
staining of the actin cytoskeleton was achieved using Alexa Fluor 488-conjugated 
Phalloidin (Molecular Probe, Invitrogen) and the nuclear DNA revealed using 4',6-
diamidino-2-phenylindole (DAPI) (Molecular Probe, Invitrogen). Image acquisition 
was performed for 36 fields per well using an ImageXpress high-throughput 
microscope (Molecular Devices) driven by the MetaXpress software (Molecular 
Devices). The average number of lamellipopdia per cell from 36 fields of view was 
determined by two independent observers. Cells partially outside the field of view were 
excluded. Mean and standard error of the mean (SEM) of independent experiments 
were calculated. Statistical analysis was performed using a two-tailed Student’s t-test to 
determine the statistical significance of the differences between conditions.  
2.2.12 Invasion assay 
3 x103 A549 cells were plated in 96 well-plates and incubated overnight at 
37oC, 10% CO2 prior to RNAi transfection. 24h following RNAi transfection, different 
extra cellular matrix were laid over the cells. These include Matrigel alone (final 
concentration ~10mg/mL), type I rat tail collagen (final concentration 3mg/mL) or a 
mixture of type I collagen diluted 1 in 10 in Matrigel (type I collagem final 
concentration: 1mg/mL). The collagen was prepared in 1x final concentration DMEM 
supplemented with 1% FCS. The plates were incubated for 4h at 37oC, 10% CO2 to 
allow for the matrix to polymerise. 25 µl of DMEM/1% FCS were added on the gel 
prior to incubation for 16h at 37oC, 10% CO2. 25 µl of DMEM/1% FCS supplemented 
or not with Egf (ranging from 10ng/mL to 2µg/mL) to stimulate invasion. A 
concentration of 1µg/mL Egf corresponding to a final concentration in the well of 166 
ng/mL was used during the screen. Cells were then allowed to invade upward through 
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the matrix for 48h. The plates were then fixed in 150µL of 4% (w/v) PFA for 45 min, 
washed 3 times in PBS, permeabilised using 150μL of 0.1% (v/v) Triton X-100 in PBS 
for 30 min, washed 3 times in PBS and blocked using 150μL of 3% Bovin Serum 
Albumin (BSA) in PBS for 2 hour. The staining of the actin cytoskeleton was achieved 
using TRITC-conjugated phalloidin (Sigma-Aldrich, Steinhelm, Germany). Each 
condition was performed in triplicate. An autofocus, based on the reflection at the 
bottom of the plate of the 633nm wavelength laser, was performed for each field prior 
to acquisition of the stack. Nine fields of view were acquired at the centre of each well 
using a motorised Zeiss Invert confocal microscope using a 10x lens with a 0.45 
numerical aperture (NA). Stacks of 150 µm were acquired for each field of view with a 
distance of 4μm between focal planes. The image stacks were analysed using a 
Mathematica notebook (Wolfram Research) programmed by Dr Alastair Nicol (Light 
Microscopy Department, CRUK, London, UK) to determine the extent of cell invasion 
(see Chapter 4 section 4.2.1.3). Results of nine stacks per well in triplicates were 
pooled before performing a one way ANOVA statistical analysis with scramble 
transfected cells as a reference. An siRNA pool targeting non-erythroid protein 4.1 
brain types (4.1B) was used as a pro-invasive control (see section 4.2.1.5). 
2.2.13 Zebrafish metastatic model. 
Zebrafish embryos at 4 h post-fertilisation (hpf) were microinjected under 
stereomicroscopic observation with Histone 2B-GFP expressing A549 cells into the cell 
mass using a 12 µm guage borosilicate pipettes mounted on a Narishige microinjector. 
The embryos were then imaged under anaesthetic by widefield fluorescent microscopy 
at 48 hpf and the presence of A549 cells in 3 different compartments (head, middle and 
tail) recorded. H2B-GFP expression had no effect on baseline motility or invasiveness 
of A549 cells (data not shown). This work was performed in collaboration with the 
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laboratory of Prof. Maggy Dalman (Division of Cell and Molecular Biology, 
Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, 
London, UK) and involved Dr. Olivier Pardo, Harriet Taylor, Alice Shia and Prof. 
Jonathan R Lamb. My participation to this work was marginal. Hence these results can 
be found in Annexe 1. 
2.2.14 Bioinformatic analysis 
A human protein-protein interaction (PPI) database was compiled from two 
previously published databases [414] [415]  containing both predicted and demonstrated 
interactions. The query of the PPI database with our hit list of 70 kinases was 
performed using Python programming and Cytoscape (Cytoscape, www.cytoscape.org) 
tools. First-node level interactions amongst our hits as well as between our hits and 
other proteins in the interactome were determined. The positive interactions false-rate 
was assessed using 10 randomly generated lists of 70 proteins from the kinome library 
using Mersenne Twister random number generator under python programming. 
2.2.15 Immuno-histopathology 
A syngeneic primary tumour/metastasic tissue microarray (TMA) was compiled 
from 11268 post-mortem (PM) reports performed at the Hammersmith Hospital NHS 
Trust between 01.01.1970 and 31.12.2005 and reviewed (Ethic Reference: 
06/Q0406/154). Lung cancer was identified in 499 cases with complete PM of which 
213 did not receive any chemotherapy or radiotherapy treatment. All slides from these 
cases were reviewed to confirm histotype as well as metastatic distribution and evaluate 
tissue quality. Immunostaining for pan-cytokeratin MNF116 and Vimentin were 
performed to evaluate the suitability of the tissue for immunohistochemical studies. 
Subsequently, 100 cases were considered suitable to be included in the TMA.  
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The available data related to these cases including metastatic distribution were 
recorded. Three 1mm cores were obtained from the most representative and better 
preserved areas of the primary tumours and their metastases and re-embedded in 
microarray blocks. Antigen retrieval was carried out using a modification on a 
previously published method [416]. Briefly, the sections were rehydrated in graded 
alcohols, heated in a microwave oven at 900W for 20 min in Citrate buffer at pH6 and 
cooled at room temperature before immunostaining. Endogenous peroxidase activity 
was suppressed by incubation with a 3% solution of H2O2 for 5 min. The primary 
antibodies were used at the following concentrations Rsk1 (Santa Cruz, sc-231) 1/1200, 
Rsk2 (Sigma, HPA003221) 1/300, Rsk4 (Sigma, HPA002852) 1/100. The TMAs were 
incubated with the antibodies for 1 hour at room temperature and then processed using 
the Polymer-HRP Kit (BioGenex) with Diaminobenzidine development and Mayer’s 
Haematoxylin counterstaining. External positive controls were used according to the 
antibodies’ datasheets. Negative controls included omitting the primary antibody, 
competition with the peptide used to raise the primary antibody and staining of A549 
cells treated with a non-targeting scramble sequences or a relevant (Rsk1, 2 or 4) 
siRNA. A semi quantitative immunohistochemical score (IHS) was used as previously 
described [417] including assessment of both the percentage of positive cells and the 
intensity of staining. For the intensity, a score of 0 to 3, corresponding to negative, 
weak, moderate and strong positivity, was recorded. The range of possible scores was 
thus 0 to 300. Each core was scored individually with three cores evaluated from each 
tumour/metastasis and the mean of the 3 readings calculated. If one core was 
uninformative the score applied was the mean of the remaining two cores. Two 
observers, blinded to all the clinical data, scored all cases and results were found to be 
consistent. TMAs for syngeneic primary non-small cell lung tumours and surrounding 
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normal tissue were purchased from US Biomax Inc. and treated as described above. 
This work was performed in collaboration with Dr. Francesco A. Mauri 
(Histopathology, Imperial College London, Hammersmith Campus, London, UK) and 
involved Dr. Robert J Shiner. 
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3 Chapter 3: A high-throughput screen identifies novel regulators of 
cell motility in lung cancer cells 
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3.1 Introduction 
Lung cancer is the commonest cancer killer and most deaths are due to the 
presence of metastatic disease. Consequently, understanding the underlying 
mechanisms that govern metastasis in lung cancer could provide new therapeutic 
targets and are biomarkers predictive of outcome for this disease.  
During the metastatic process, cells are required to change their morphology and 
develop a pro-motile phenotype. Hence, to increase our understanding of lung cancer 
cell metastasis, it was essential that we first identify molecules that regulate cell 
migration in this system. 
RNA interference (RNAi) has become a powerful approach to characterise gene 
function. The use of small interfering RNA (siRNA) libraries has enabled investigators 
to systematically screen for the role of individual genes in various phenotypes [418].  
Similarly, we have developed an automated kinome-based siRNA screen for cell 
migration. The optimisation, validation and results of this screen are presented in this 
chapter. We identified 48 novel regulators of A549 non-small cell lung cancer cell 
motility among which several kinase families were over represented. These were the 
Ribosomal protein S6 kinase (Rsk), Casein kinase, Adck (AarF domain containing 
kinase) and Clk (CDK-like kinase) families. We focussed our attention on the Rsk 
family and show that knockdown of these proteins leads to changes in cell morphology 
and modulation of the EMT markers E-Cadherin and Vimentin in agreement with the 
migration phenotype. 
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3.2 Results 
3.2.1 Motility Screen set-up 
3.2.1.1 Choice of the cell system 
The screen was developed in a 96-well plate format to allow high-throughput 
processing of the library. BD Falcon™ Black 96-well Microtest™ Optilux™ Plate (BD 
Bioscience) were selected for their good optical property.  
Prior to starting our siRNA screen, an appropriate cell system and adequate 
controls had to be identified. Four different non-small cell lung cancer cell lines (A549, 
HCC15, H23 and H522) were tested for their migratory ability. Among these, A549 
and H23 cells migrated significantly faster than HCC15 and H522 cells (Figure 16A). It 
has been previously reported that A549 cells have invasive capabilities both in vitro and 
in vivo [419] [420] [421] [422] [423] [424] [425]. Hence we decided to perform our migration 
screen in this well characterised cell line. 
3.2.1.2 Automated tracking 
To enable us to perform automated cell tracking, fluorescent labelling of the cell 
was used to improve contrast between the image background and the migrating cells. 
Two different cell dyes were tested, DioC6, an ER and mitochondria stain [426] and Cell 
Tracker Green (Invitrogen (C2925)), a molecule that binds the cellular thiol moieties 
(Figure 16). We performed dose-range experiments to identify concentrations for both 
dyes that would provide an optimum signal to noise ratio without affecting the ability 
of the cells to migrate. While DiOC6 still inhibited cell migration at the lowest 
concentration tested, Cell Tracker Green used at 0,5nM gave a robust signal throughout 
the 18h of the assay with no detectable effect on cell migration (Figure 16B). The 
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signal was sufficient for migrating cells to be easily detected using Metamorph 
(Molecular Devices) and followed using the automated tracking plug-in available in 
this software (Figure 16C and D). 
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Figure 16: Optimisation of the migration assay. (A) Random migration assay results for the NSCLC 
cell lines A549, HCC15, H23 and H522. The average random migration speed distribution of 60 cells per 
condition is represented as a box and whisker plot. A549 cells were used as a reference for the statistical 
ANOVA analysis. A representative of 3 independent experiments performed in duplicate is shown. (B) 
Random migration assay results in A549 cells upon staining with the viable fluorescent cell dyes DioC6 
and Cell tracker Green. The average random migration speed distribution of 120 cells per condition is 
represented as a box and whisker plot. Unlabelled cells imaged in phase were used as reference for the 
ANOVA statistical analysis. Random migration assays were performed by filming cells over 18h and 
tracked using Metamorph software. Tracks were then analysed using Mathematica to generate box and 
whisker plots of cell migration speed. Box represents 75% and side bar 12.5% of the cell population. Dot 
represents median speed.  Statistical test were performed using ANOVA analysis. *; p<0.05, , ***; 
p<0.001, n.s.; not significant. A representative of 3 independent experiments performed in quadruplicate 
is shown. (C) Representative field of view showing A549 cells stained with Cell Tracker Green. (D) 
Corresponding cell tracking obtained using a Metamorph plug-in following binarisation and 
segmentation of the films. 
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3.2.1.3 Transfection control 
To control for equivalent transfection efficiency between experimental plates 
throughout the screen, transfection of olinucleotides directed against Plk1 (Polo-like 
Kinase1), a kinase known to regulate the exit from mitosis, were used [427]. Plk1 siRNA 
transfection induced changes both in A549 migration and morphology (Figure 17). In 
the migration assay, cells silenced for Plk1 showed a reduction in their migration speed 
as compared to non-targeting scramble sequences (Sc) (Figure 17A). Morphological 
changes included increased cell spreading and the appearance of multiple nuclei 
accompanied by a decrease in total cell number (Figure 17B). 
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Figure 17: Plk1 as a transfection control in A549 cells. (A) Representative random migration results 
from the migration screen showing decreased A549 migration speed upon Plk1 knock-down compared to 
treatment with a non-targeting Scramble sequences (Sc). The speed of cell migration is represented as a 
box and whisker plot. ANOVA analysis was performed using Scramble transfected cells as reference. 
Box represents 75% and side bar 12.5% of the cell population. Dot represents median speed.  Statistical 
tests were performed using ANOVA analysis. * corresponds to p<0.05. (B) Actin cytoskeleton staining 
of A549 cells using Alexa Fluor 488 phalloidin (green) together with the nuclear dye 4',6-diamidino-2-
phenylindole (DAPI) (blue).  An increased cell spreading and the appearance of multiple nuclei (white 
arrow) can be observed upon Plk1 knock-down. Representative experiment taken from the migration 
screen. 
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3.2.2 Migration screen results 
At the end of the screening process, mean speed values for each condition were 
calculated and normalised to the scramble control for each plate. Amongst the 779 
proteins targeted by the library, 160 conditions showed a significant modification of 
migration speed as compared to transfection with non-targeting scramble sequences 
(Figure 18B). Plotting of the mean speed distribution revealed a reduction of cell 
motility speed following silencing of two third of the proteins targeted by our library.  
In contrast, only one third of the targets enhanced cell migration speed upon 
downregulation (Figure 18A). This difference could be correct or might be explained 
by the high baseline motility level of A549 cells (Figure 16A) that may limit our ability 
to further increase A549 migration speed upon siRNA treatment. Alternatively, siRNA-
mediated down regulation of some targets might be toxic to the cells, leading to an 
artifactual reduction in cell migration. In order to assess this possibility, our list of hits 
was compared against results from a parallel screen for cell toxicity performed in A549 
cells using the same library [428]. Any hit showing toxicity greater than 10% was 
sidelined, reducing the hit list to 70 proteins (Table 7). Among those 70 hits, 56 showed 
a reduction, whereas 14 enhanced migration speed. Finally, 22 of these proteins had 
already been reported in the literature as being involved in cell migration. Those 22 hits 
included Akt2 [429], Map4k4 [406] and Ephb6 [430] and provided a measure of the validity 
of our screen (Figure 18). Hence, our screen revealed 48 previously unreported 
regulators of cell migration. 
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Figure 18: Cell motility screen result (A) Distribution of the mean migration speed ratio obtained 
following the downregulation of the 779 targets of the Dharmacon kinome library.  Mean migration 
speed for each RNAi condition was normalised to the scramble mean migration speed of the 
corresponding plate and plotted in an ascending order. Green spots indicate three targets (Erythroblastic 
Leukemia Viral Oncogene Homolog 2 (Erbb2), Sarcoma viral oncogene (Src) and Macrophage 
Stimulating 1 Receptor (Mst1r)) previously reported to regulate NSCLC cell motility. The p90 
Ribosomal S6 Kinase 2 and 4 (Rsk2 and 4) (gray spots) that decrease and p90 Ribosomal S6 Kinase 1 
(Rsk1) that increase cell migration speed upon knockdown are highlighted. (B) Overview of the 
migration screen showing the successive steps in the selection of hits based on the migration speed 
results, the control for cell toxicity of the siRNAs and previously published reports. 
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Amongst our 70 hits, four families were represented by several members 
modulating A549 mobility. These were the Ribosomal protein S6 kinase, Casein 
kinase, Adck (AarF domain-containing kinase) and Clk (CDK-like kinase) families 
(Table 8). Each family contained both members that increased and decreased A549 
migration speed suggesting the possible existence of a balance between the different 
isoforms.  RNAi screens have inherent rates of false positives and false negatives and 
various validation steps are required to address this issue [431]. For further validation 
work, we decided to focus on these 4 families as well as the best hits decreasing 
(Map/microtubule affinity-regulating kinase 4; Mark4) and increasing (creatine kinase 
brain type; Ckb) cell migration speed upon knockdown. 
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Table 7: List of 70 Hits modulating A549 cell migration speed. List of hits identified in the migration 
screen to increase (red) or decrease (black) migration speed upon RNAi downregulation. siRNA library 
Gene Symbol Protein Name Ref Seq ID Ratio to Sc ANOVA 
 ACK1 Activated p21cdc42 kinase NM_005781 0.86 * 
ADCK2 AarF domain containing kinase 2 NM_052853 0.72 * 
ADCK4 AarF domain containing kinase 4 NM_024876 0.72 * 
ADCK5 AarF domain containing kinase 5  NM_174922 1.67 ** 
AKT1 V-akt murine thymoma viral oncogene homolog 1  NM_005163 0.61 * 
AKT2 V-akt murine thymoma viral oncogene homolog 2 NM_001626 0.83 * 
ALS2CR2 Amyotrophic lateral sclerosis 2 juvenile chromosome region gene2 NM_018571 0.81 ** 
ANGPT4 Angiopoietin 4 NM_015985 0.71 ** 
AURKC Aurora kinase C NM_003160 0.49 *** 
CDC42BPB Cell division cycle 42 binding protein kinase β NM_006035 0.79 * 
CDKL3 Cyclin-dependent kinase-like 3 NM_016508 0.76 * 
CDKL5 Cyclin-dependent kinase-like 5 NM_003159 0.75 * 
CDKN2B Cyclin-dependent kinase inhibitor 2B NM_004936 0.76 * 
CDKN2D Cyclin-dependent kinase inhibitor 2D NM_001800 0.74 * 
CHEK2 Checkpoint kinase 2 NM_007194 1.37 * 
CHKB Choline kinase β NM_005198 0.79 * 
CKB Creatine kinase, brain type NM_001823 1.59 * 
CLK1 Cdc-like kinase 1 NM_004071 1.40 * 
CLK2 Cdc-like kinase 2 NM_001291 0.71 * 
CLK4 Cdc-like kinase 4 NM_020666 0.79 * 
CSNK1A1L Casein kinase 1 α-1 like NM_145203 0.73 ** 
CSNK1G2 Casein kinase 1 γ-2 NM_001319 1.29 ** 
CSNK1G3 Casein kinase 1 γ-3 NM_004384 1.28 ** 
CSNK2B Casein kinase 2β NM_001320 1.26 * 
DDR2 Discoidin domain receptor family, member 2 NM_006182 1.46 * 
EDN2 Endothelin 2 NM_001956 1.49 * 
EPHB6 Ephrin receptor ephb6 NM_004445 1.30 * 
GALK1 Galactokinase 1 NM_000154 0.86 * 
GMFG Glia maturation factor, γ NM_004877 0.85 * 
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 NM_004834 0.82 * 
MAPK11 Mitogen-activated protein kinase 11 NM_002751 0.76 ** 
MAPK13 Mitogen-activated protein kinase 13 NM_002754 0.82 * 
MAPK3 Mitogen-activated protein kinase 3 NM_002746 0.84 * 
MARK4 Map/microtubule affinity-regulating kinase 4 NM_002747 0.53 *** 
MELK Maternal embryonic leucine zipper kinase NM_014791 0.75 * 
MGC45428 Doublecortin-like kinase 2  NM_152619 0.69 * 
MGC8407 Cam kinase-like vesicle-associated NM_024046 0.73 ** 
MPP3 Membrane protein, palmitoylated 3 NM_001932 1.23 * 
MVD Mevalonate pyrophosphate decarboxylase NM_002461 0.77 * 
MYO3A Myosin 3a NM_017433 1.38 * 
NAGK N-acetylglucosamine kinase NM_017567 0.75 * 
NEK6 Never in mitosis gene a-related kinase 6 NM_014397 0.78 * 
NPR1 Natriuretic peptide receptor a/guanylate cyclase a NM_000906 0.68 *** 
PANK4 Pantothenate kinase 4 NM_018216 0.83 * 
PCK2 Phosphoenolpyruvate carboxykinase 2 NM_004563 0.80 * 
PDK3 Pyruvate dehydrogenase kinase, isoenzyme 3 NM_005391 0.79 * 
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 NM_002625 0.73 * 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4  NM_004567 0.79 * 
PIK3C2G Phosphatidylinositol 3-kinase, class 2 γ NM_004570 0.64 * 
PIP5KL1 Phosphatidylinositol-4-phosphate-5-kinase-like 1 NM_173492 0.68 ** 
PKIB Protein kinase cAMP-dependent catalytic inhibitor β NM_032471 0.74 * 
PKN3 Protein kinase N3 NM_013355 0.82 * 
PPP2CA Protein phosphatase 2a catalytic subunit α isoform NM_002715 0.81 ** 
PPP4C Protein phosphatase 4 catalytic subunit NM_002720 0.84 * 
PRKACB Protein kinase camp-dependent catalytic β NM_002731 0.79 ** 
PRKAG1 Protein kinase, amp-activated, noncatalytic γ-1 NM_002733 0.87 * 
PRKCL2 Protein kinase C-like 2 NM_006256 0.68 * 
PRKCM Protein kinase C μ NM_002742 0.77 * 
PRKCSH Protein kinase C substrate, 80-kd, heavy chain NM_002743 0.76 * 
PRKWNK1 Protein kinase lysine-deficient 1 NM_018979 0.77 * 
PTPRG Protein-tyrosine phosphatase receptor-type γ NM_002841 0.78 * 
RFK Riboflavin kinase NM_018339 0.87 * 
RSK1 Ribosomal S6 kinase 1 NM_002953 1.46 * 
RSK2 Ribosomal S6 kinase 2 NM_004586 0.86 * 
RSK4 Ribosomal S6 kinase 6 NM_014496 0.83 ** 
RPS6KC1 Ribosomal protein S6 kinase, 52kDa, polypeptide 1 NM_012424 0.71 ** 
STK23 Serine/threonine-protein kinase 23 NM_014370 0.76 ** 
STK29 Serine/threonine-protein kinase 29 NM_003957 0.75 ** 
STK6 Serine/threonine-protein kinase 6 NM_003600 0.73 ** 
TRIB3 Tribbles, drosophila, homolog 3 NM_021158 0.67 * 
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Gene symbol, corresponding protein name, alternative symbol and NCBI GenBank Reference Sequence 
ID (Ref Seq ID) are shown. Ratio of migration speed to Scramble (Sc) is given with the result of the 
ANOVA statistical analysis performed with the scramble condition used as reference.*; p<0.05, **; 
p<0.005, ***; p<0.001.  
 
 
 
Table 8: Families of proteins over-represented in our migration screen hit list. The identified 
isoforms are shown including those having more than 10% toxicity (right panel). Red text denotes targets 
that enhance whilst black text indicates targets that suppress migration upon RNAi downregulation. 
 
3.2.3 Migration screen validation 
First, a second toxicity assay was performed using the cell viability assay 
CellTiter-Glo® (Promega) following the initial toxicity screen procedure [428]. By doing 
so, we were able to confirm that the changes in cell viability did not account for the 
observed motility effects (Figure 19A). Then, we repeated the cell migration speed 
acquisition on A549 cells treated with the pool of four sequences used for the initial 
screen as well as the deconvoluted four individual sequences. Amongst the 17 targets 
selected, 14 validated with at least 2 of the 4 deconvoluted individual sequences (Figure 
19A). Figure 19B and C shows representative validation experiments for Rsk1, Rsk2 
and Rsk4. These effects correlated with target downregulation at the protein and/or 
mRNA levels (Figure 19C and Figure 20). A large number of somatic mutations 
identified in lung adenocarcinomas are located within the MAP Kinase pathway leading 
to phosphorylation and activation of Erk [206, 214]. Erk activation has been associated 
with cell migration and invasion in epithelial cells [200, 432]. Rsk family members being a 
Family 
Proteins 
Toxicity ≤ 10% Toxicity > 10% 
RPS6 kinase 
Rsk1(RPS6KA1),  Rsk2 
(RPS6KA3), Rsk4 
(RPS6KA6), Rps6kc1 
Msk1 (RPS6KA5) (30%) 
Caseine kinase Csnk2b, Csnk1g2, Csnk1g3, Csnk1a1l 
Csnk1a1 (25%), Csnk1d (25%), 
Csnk1e (12%) 
Adck Adck2, Adck4, Adck5  
Clk Clk1, Clk2, Clk4  
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direct downstream target of Erk [197], we decided to focus our subsequent work on 
these. 
Validation work in two additional NSCLC cell lines (LNM35 and H23) 
confirmed the effects on cell migration seen in A549 cells in response to Rsk1 
downregulation (Figure 19, Figure 21A and B). However, in these cells, knockdown of 
Rsk2 and 4 did not significantly decrease cell motility despite efficient target 
downregulation (Figure 21A and B). A possible reason for this discrepancy may be that 
the functions of Rsk2 and 4 are more cell-line specific than that of Rsk1. To further 
confirm that Rsk1 effect in those three cell lines was on target we tested the effect of 
sequences from a different provider (Qiagen) (Figure 21C).  Transfection of both pool 
and deconvoluted individual oligonucleotides showed an increased migration speed 
upon Rsk1 knockdown thus confirming the role of this kinase in modulating cell 
migration in NSCLC. 
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Figure 19: Validation of a selected subset of our hits. (A) Validation rate for targets from four families 
of proteins over-represented in our hit list. Effects of siRNA down regulation on cell migration speed (+, 
increase; -, decrease), Toxicity (Tox.) as % of scramble and validation of the migration phenotypes using 
the pooled or deconvoluted (Deconv.) oligonucleotides. A representative of 2 independent experiments 
performed in duplicate is shown. (B) Representative cell trajectory plots in an acquired field of view 
(n=15). A549 cell were transfected with either Rsk1, 2, 4 or scramble (Sc) siRNA pools made of 4 
oligonucleotide sequences. (C) Representative validation experiment following transfection with Rsk1, 2 
and 4 sequences. P; pool, 1-4; deconvoluted single oligonucleotides. The average random migration 
speed distribution of 60 cells per condition is represented as a box and whisker plot. Box; 75% and side 
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bar; 12.5% of the cell population. Dot represents median speed. ANOVA analysis performed with 
Scramble (Sc) as reference: *; p<0.05, **; p<0.005, ***; p<0.001. Representative RT-PCRs (RT) 
performed following siRNA down regulation of Rsk1, 2 and 4 using primers directed against the mRNA 
for each isoform. Primers directed against Gapdh mRNA were used as loading control. 
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Figure 20: Validation of target down regulation for the Rsk and Csnk family members. Validation 
was performed using both Smartpools (P) and deconvoluted single oligonucleotides (1-4). Target knock-
down was assessed at the mRNA level (RT-PCR) using specific primers for each target and protein level 
(Western blotting) when a working antibody was identified. Gapdh mRNA and protein levels were used 
as loading control. A representative of 3 independent experiments is shown. 
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Figure 21: Validation of the results obtained in A549 cells upon downregulation of Rsk isoforms in 
additional NSCLC cell lines. (A) Cell migration experiments following transfection with pool of 4 
sequences directed against Rsk1, 2 and 4 in H23 and LNM35. A representative of 3 independent 
experiments performed in duplicate is shown. (B) Comparison of the efficiency of Rsk1 and 2 silencing 
following transfection with oligonucleotides directed against these two isoforms in A549, H23 and 
LNM35 cells. Cell lysates were subjected to western blotting (WB) using Rsk1 and 2 antibodies. 
Detection of Gapdh was used as a loading control. A representative of 3 independent experiments is 
shown. (C) Cell migration validation experiments for Rsk1 in A549, H23 and LNM35 cell lines using 
oligonucleotides from a different provider (Qiagen). P; pool, 1-4; deconvoluted single oligonucleotides. 
The average random migration speed distribution of 60 cells per condition is represented as a box and 
whisker plot. Box; 75% and side bar; 12.5% of the cell population. Dot represents median speed. 
ANOVA analysis performed with Scramble (Sc) as reference: *; p<0.05, **; p<0.005. A representative 
of 3 independent experiments performed in duplicate is shown. 
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3.2.4 Balance between the activity of Rsk isoforms may regulate cell 
motility 
An alternative explanation for the lack of validation of Rsk2 and Rsk4 in 
LNM35 and H23 could be that Rsk1 acts as a dominant Rsk isoform regulating NSCLC 
cell motility. If so, changes observed upon knock-down of other Rsks could be 
mediated via Rsk1. To test this hypothesis, we silenced Rsk 1, 2 and 4 and looked for 
changes in protein expression of Rsk1 and 2 (no suitable Rsk4 antibody could be 
identified). Downregulation of Rsk4 led to a concomitant increase in Rsk1 protein 
levels but not Rsk2 (Figure 22A). This might explain why Rsk4 and Rsk1 knock-down 
have opposing effects in A549 cells migration and suggest that the effects of Rsk4 on 
cell motility might be mediated through Rsk1. To confirm this hypothesis, we looked at 
the effect on cell migration of the concomitant knockdown of several Rsk isoforms. 
Figure 22B shows that Rsk1 downregulation appeared dominant over the migratory 
effects of Rsk4 silencing in A549 cells. Indeed, concomitant suppression of Rsk4 and 
Rsk1 did not significantly differ from the effects of Rsk1 targeting alone (Figure 22B). 
In contrast, Rsk2 downregulation could repress the pro-migratory effects of Rsk1 
silencing (Figure 22B), suggesting that a balance may exist between the activity of 
these two isoforms on cell motility. Consistent with our finding that Rsk4 
downregulation leads to Rsk1 upregulation, the effects of Rsk4 silencing on cell 
migration were additive to those of Rsk2 targeting (Figure 22B). Taken together, our 
data suggest the possible existence of a balance between the biological activities of 
Rsk1 and Rsk2 on cell migration, while the effects of Rsk4 might be mediated through 
modulating Rsk1 protein levels. 
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Figure 22: Balance between the activity of Rsk isoforms. (A) Modulation of Rsk1 and 2 protein levels 
upon knock-down of Rsk family members. Following downregulation using scramble (Sc), Rsk1, 2 and 4 
siRNAs, cell lysates were extracted analysed by SDS-PAGE/Western blotting (WB) using antibodies 
against Rsk1 and 2. Detection of Gapdh was used as a loading control. A representative of 3 independent 
experiments is shown. (B) Effect of multiple Rsk knock-down combinations on random cell migration 
speed. Sc; Scramble. The average random migration speed distribution of 60 cells per condition is 
represented as a box and whisker plot. Box; 75% and side bar; 12.5% of the cell population. Dot 
represents median speed. ANOVA analysis performed with Sc (Scramble) as reference: *; p<0.05, **; 
p<0.005, ***; p<0.001. A representative of 3 independent experiments performed in duplicate is shown. 
A.
B.
Sc R
sk
1
R
sk
2
R
sk
4
RNAi
WB:
Rsk1
Gapdh
Rsk2
+ Rsk1
R
sk
2
R
sk
4
+ Rsk2
ScSc Sc
R
sk
4 Rsk1
+Rsk2
+Rsk4R
N
A
i
1S
pe
ed
 (A
rb
itr
ar
y 
U
ni
ts
)
2
3
**
**
**
*
141 
 
3.2.5 Rsk family members modulate cell morphology 
The staining of the actin cytoskeleton following the downregulation of Rsk 
isoforms in A549 cells reveals changes in cell morphology that correlate with the 
observed effects on cell motility. Figure 23A shows that increased cell migration speed 
in response to Rsk1 downregulation (Figure 19B and C) was matched by a rise in the 
numbers of actin-based lamellipodia (Figure 23A white arrows) and a pronounced cell 
scattering as compared to that observed in cells transfected with non-targeting 
sequences (Sc). In contrast, inhibition of cell migration speed following Rsk2 silencing 
(Figure 19B and C) correlated with increased cellular clustering (Figure 23A). The 
morphological changes observed as a consequence of Rsk1 targeting suggested an 
increase in cell polarisation, such as that observed during epithelial to mesenchymal 
transition (EMT). Typical markers for this phenomenon include a decrease in the levels 
of epithelial marker E-cadherin, as well as an increase in the mesenchymal marker 
vimentin [16]. We therefore compared the expression of these two markers in A549 cells 
transfected with Rsk1, Rsk2 or non-targeting scramble sequences (Sc) siRNA pools. 
Rsk1 downregulated cells demonstrated decreased E-cadherin and increased Vimentin 
protein levels (Figure 23B). However, N-cadherin levels were unaffected by Rsk1 
downregulation suggesting that the pro-motile phenotype induced by Rsk1 
downregulation might not reflect a true EMT programme such as described in the 
literature [16] but rather a change in cell-cell contacts. In contrast, no changes in E-
cadherin, Vimentin or N-cadherin occurred upon silencing of Rsk2 downregulation in 
A549. Hence, the clustering phenotype observed upon Rsk2 silencing (Figure 23A) 
cannot be attributed to a changes in E-Cadherin protein levels but may reflect a change 
in E-Cadherin subcellular localisation. 
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Figure 23: Rsks regulate cell morphology and the expression of EMT markers. (A) Actin 
cytoskeleton staining of A549 cells using Alexa Fluor 488 phalloidin upon Rsk1 and 2 downregulation. 
White arrows show the lamellipodia induced upon Rsk1 knock-down. Sc; Scramble. A representative of 
3 independent experiments performed in duplicate is shown. (B) Representative Western blotting 
showing the expression of EMT markers following Rsk1 and 2 knock-down or transfection with 
scramble siRNAin A549 cells. Cell lysates were analysed by SDS-PAGE/Western blotting (WB) using 
antibodies against Rsk1, Rsk2, Vimentin (Vim), E-Cadherin (E-Cadh) and N-Cadherin (N-Cadh). 
Detection of Gapdh was used as a loading control. A representative of 3 independent experiments is 
shown. 
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3.3 Discussion 
Lung cancers, like other common neoplasms, are fatal for several reasons 
including the dissemination of tumour cells to distant sites. Therefore, a better 
understanding of the molecular mechanisms responsible for this phenomenon should 
yield novel therapeutic approaches to prevent, and biomarkers to predict, this process. 
Although much has been learnt about key events in the metastatic process, only a few 
kinases have been shown to play a role. This is somewhat surprising given that there 
are more than 500 kinases in the human kinome. Here we describe an RNA interference 
screen to identify genes influencing cell migration in A549 cells. Based on a previously 
reported assay measuring random cell migration [413], an automated version of this assay 
was set-up in a 96-well plate format using fluorescent labelling and autotracking of 
A549 NSCLC cells. This enabled us to identify 48 kinases, previously unknown to 
regulate cell migration, as modulators of A549 cell motility. Amongst these, four 
families of kinases were overrepresented. These are the Ribosomal protein S6 kinase 
(Rsk), Casein kinase, Adck (AarF domain containing kinase) and Clk (CDK-like 
kinase) families (Table 8). Those families include proteins that have been heavily 
investigated for their role in other biological phenomenons such as Rsk1 (RPS6KA1) 
and Rsk2 (RPS6KA3) [251]. However, they also contain less-well characterised proteins 
such as Rps6kc1 and Adck proteins. Interestingly, we noticed that hits from the same 
family could induce opposite effects on cell migration speed suggesting the existence of 
an equilibrium between protein isoforms. Indeed downregulation of Rsk1 dramatically 
increases cell migration whilst silencing of Rsk2 and 4 impairs this process in A549 
cells. The changes seen in cell migration upon knockdown of our targets were 
reproduced across multiple siRNA targeting sequences suggesting that the effects seen 
were target-related. Further validation in two more NSCLC cell lines (H23 and 
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LNM35) confirmed the role of Rsk1 in NSCLC cell motility. However, similar 
experiments performed for Rsk2 or 4 did not reproduce in additional cell lines the 
effects seen for these isoforms in A549 cells. One reason for this discrepancy may be 
that the functions of Rsk2 and 4 are more cell-line specific than that of Rsk1. 
Alternatively, Rsk1 might act as a dominant Rsk isoform regulating NSCLC cell 
motility. Here we show some preliminary evidence that Rsk4 effects on cell motility 
might indeed be mediated by an increase in Rsk1 protein levels (Figure 22A). Our data 
further suggest the existence of a balance between the biological activities of Rsk1 and 
Rsk2. Indeed, concomitant silencing of Rsk1 and 2 in A549 cells cancels out the cell 
motility effects of downregulating each isoform separately (Figure 22B). 
The effects on cell motility seen upon Rsk1 and Rsk2 knockdown correlated 
with changes in the actin cytoskeleton as Rsk1 knockdown led to an increase in the 
number of lamellipodia, promoting cell scattering, while Rsk2 silencing increased cell-
cell contact. The effects of Rsk1 silencing on lamellipodia formation suggest an 
involvement of Rsk1 with the actin machinery. However, Rsk1 does not harbour 
domains reported to be involved in regulating actin dynamics [251] and it is therefore 
unlikely that these effects are directly mediated by this protein. Alternatively, Rsk1 
might regulate the activity of proteins implicated in regulating the actin cytoskeleton. 
We will show in Chapter 5 that this is the case as Rsk1 phosphorylates Vasodilator-
Stimulated Phosphoprotein (Vasp), a protein known to be involved in actin 
polymerisation [107]. Moreover, the effects of Rsk1 on the epithelial marker E-Cadherin 
and mesenchymal marker Vimentin suggest that Rsk1 might regulate the entire 
metastatic process by participating to the Epithelial to mesenchymal transition (EMT) 
[15]. 
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4.1 Introduction 
Cell motility has previously been heavily studied using two-dimensional 
experimental systems providing important insights into the molecular machinery 
driving cell migration [82]. However, the mechanical properties of the rigid surfaces 
used in 2D migration assays are not comparable to those found in the in vivo setting. 
Indeed, epithelial cells in vivo are supported by both a basal membrane and the 
extracellular matrix (ECM) (Chapter1 Figure 2). These structures play a dual role 
during the invasion process by providing both a mechanical barrier preventing the 
invasion of the deeper tissue and a substratum allowing malignant cells to adhere and 
migrate (Chapter1 section 1.1.2 and 1.2.1.1.1). Tumour cells leaving the primary 
tumour must become deformable and acquire the ability to invade the surrounding 
matrix in order to reach the vasculature. We previously identified 70 proteins capable 
of modulating A549 cell migration (Chapter 3). To assess the ability of our motility hits 
to regulate cell invasion, we developed a secondary 3-dimensional invasion screen 
based on a 96-well plate format where cells invade upward from the bottom of the well 
through a collagen matrix in response to a chemo-attractant. This chapter describes the 
development and results of this invasion screen using the NSCLC cell line, A549. 
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4.2 Results 
4.2.1 Invasion Screen set-up 
The invasion assay was developed in a 96-well plate format to enable high-
throughput screening of our 70 motility hits. A workflow of the assay is represented in 
Figure 24A and B. The cellular system (A549) and siRNA transfection protocol were 
the same as those used for the migration screen to enable direct comparison of the 
results obtained in the two assays. 24 hours following siRNA transfection, a matrix was 
overlaid on top of the transfected cells. A day later, medium containing a 
chemoattractant was added over the gel to provide the cells with a directional stimulus. 
Cells were allowed to invade upward through the matrix for 48 hours before being 
fixed. The gels were then stained using Tetramethylrhodamine B isothiocyanate 
(TRITC) coupled phalloidin to reveal the cellular actin cytoskeleton. Finally, three-
dimensional stacks were acquired across the 96 well-plate using a motorised inverted 
confocal microscope.  
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Figure 24: Overview of the invasion screen setup. (A) Overview of the invasion assay. (B) Workflow 
of the invasion assay describing the parameters to be optimised at each step of the assay. 
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In order to reduce the number of variables influencing the invasion readout, a 
set of parameters were fixed. 
1. A plating cell number of 3000 per well was found to provide a confluent 
monolayer at the time when the chemo-attractant is added on the gel 48 
h later. This cell number was chosen to limit the lateral migration and 
proliferation of the cells at the bottom of the well while cell invasion is 
being assessed. 
2. A final concentration of 1% Foetal Calf Serum (FCS) was used to 
prepare the matrix. This concentration reduces cellular stress without 
compromising further stimulation by the chemo-attractant (Figure 25 
and Figure 27). 
3. Epidermal growth factor was selected as a chemo-attractant due to its 
capacity to stimulate lung cancer invasion in vitro [420, 433] and in vivo 
[434].  
Based on this initial protocol, the matrix and concentration of chemo-attractant 
were optimised in order to increase to sensitivity of the assay.  
4.2.1.1 ECM and chemo-attractant 
Previous reports have shown the capacity of A549 cells to invade within 
Matrigel and type I collagen matrices using Egf as a chemoattractant [420, 433, 435]. 
Matrigel is a commercial name for a preparation of the ECM secreted by Engelbreth-
Holm-Swarm (EHS) mouse sarcoma cells. Using the highly invasive fibrosarcoma 
HT1080 and breast cancer MDA-MB-231 cell line, Wolf et al. have previously shown 
that low concentrations of  type I collagen (3mg/mL) allowed cell invasion without the 
requirement for proteolytic activity [45]. This contrasts with what can be observed in the 
presence of higher collagen concentrations (10 to 12 mg/mL) when proteolytic activity 
150 
 
is required for cells to infiltrate the dense matrix [45].  In order not to limit the hits to 
those that would regulate protease activity, we decided to use a low concentration of 
collagen (3mg/mL) for our assay. Hence, we tested in our invasion assay the capacity 
of A549 cells to invade in Matrigel (~10mg/mL), type I collagen (3mg/mL) or a 
mixture of type I collagen diluted 1 in 10 in Matrigel (type I collagen final 
concentration: 1mg/mL). Each type of matrix was overlaid on the cells and left to 
polymerise over-night. Various concentrations of Egf were then added on top of the 
gels. Cells were allowed to invade upward for two days before fixation, staining and 
microscopy acquisition. Figure 25A and B shows that in the presence of Matrigel or 
Matrigel mixed with Collagen, A549 cells were unable to invade in response to Egf. 
However, the same stimulus enabled A549 cells to invade through a collagen-alone 
matrix (Figure 25C). Hence, a 3mg/mL type I collagen matrix was selected to perform 
the screen. 
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Figure 25: Test of A549 invasion through different extra cellular matrix (ECM). Side views of 
representative confocal stacks showing TRITC-conjugated phalloidin stained A549 cells (white) overlaid 
with (A) Matrigel (B) a mixture of Matrigel with type I collagen diluted 1 in 10 (1mg/mL final 
concentration) or (C) a type I collagen matrix (3mg/mL) and stimulated with different concentrations of 
Egf.  Stacks are acquired from the bottom of the well (red arrows) over 150μm upward. Orientations of 
the stacks are given by the x- and z-coordinates. A representative of 3 independent experiments 
performed in triplicate is shown. 
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4.2.1.2 Microscopy acquisition 
Microscopy acquisition was performed using a motorised inverted confocal 
microscope.  Stacks of 150μm were acquired upward from the bottom of the plate with 
a distance of 4μm between focal planes. The acquisition of each stack was preceded by 
an autofocus based on the reflection at the bottom of the plate of the 633nm wavelength 
laser. To increase the acquisition coverage, a tile of nine stacks was acquired per well 
using a 10x lens with a 0.45 numerical aperture (NA). These settings allowed the 
acquisition of a surface of 1.3 mm2 representing 40.6% of the total well surface. 
Increased invasion was observed at the border of each well independently of the 
treatment applied. One reason explaining this experimental artefact could be an 
increased surface tension at the border of the well affecting the collagen matrix 
polymerisation and/or cellular behaviour [436]. To avoid this impacting on our readout, 
tiles were only acquired at the center of each well.  
4.2.1.3 Quantification 
Two parameters were considered to evaluate the extent of invasion in our assay; 
the number of cells invading and the distance of invasion from the bottom of the well. 
By plotting the total intensity of the Phalloidin-TRITC staining for each plan of the 
stack (Ʃ[intensity (x, y)]) as a function of the distance of invasion (z axis), we were able 
to reliably represent the proportion of cells present at each level of the stack (Figure 
26B). Results obtained by staining the cell nuclei, instead of the actin cytoskeleton, and 
counting the number of cells per plane using a specially-written Mathematica notebook 
provided similar results (data not shown). However, the first method was more 
amenable to high-content analysis as the determination of cell numbers required 3D 
image analysis and consequently a far lengthier computation. The acquisition of each 
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stack was preceded by an autofocus based on the reflection at the bottom of the plate of 
a 633nm wave-length laser. The inherent lack of accuracy of the autofocus was 
responsible for a shift in the stack acquisition as represented in the Figure 26B. To 
overcome this pitfall, acquisition of the stacks were started 30μm further down from the 
bottom of the well. By doing so, we were able to reproducibly collect in our acquisition 
all the cells present at the bottom of the well and include their fluorescent intensity to 
our invasion plot (see arrow on Figure 26B and C). The curves for various experimental 
conditions were then aligned to overlay the picks corresponding to the cells at the 
bottom of each well, thereby correcting the autofocus inaccuracy (Figure 26C). 
Following alignment of the curves, a cut-off was applied in the z stack to highlight the 
level beyond which cells could be considered asinvading the matrix (Figure 26C). This 
cut-off was determined to give the maximum difference between Egf stimulated and 
un-stimulated scramble transfected conditions. To estimate the proportion of cells 
invading in a given condition, the area under the curve representing the invading cells 
was then compared to the total area under the curve including all cells. Finally, the 
results of nine stacks per well in triplicates were pooled before performing an ANOVA 
statistical test. This quantification process was programmed into a Mathematica 
notebook by Dr Alastair Nicol (Light Microscopy Department, CRUK, London, UK) to 
automate data processing. 
  
154 
 
 
 
Figure 26: Quantification of the invasion in each stack acquired. (A) 3D rendering of a representative 
stack using IMARIS® 7.0. Red; Phalloidin-TRITC staining. Orientations of the stack are given by the x-, 
y- and z-coordinates. (B) Representative raw data plot showing the total intensity of the staining as a 
function of the distance from the bottom of the well for 9 stacks. (C) Alignment of the raw data plots and 
determination of the cut-off. Red arrows indicate the cells at the bottom of the well. 
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4.2.1.4 Chemo-attractant concentration 
We previously showed that A549 cells were able to invade in a type I collagen 
matrix in response to Egf (Figure 25C). To determine the concentration of Egf 
saturating the assay we extended the dose range of Egf and quantified the invasion 
using our Mathematica notebook. Figure 27A shows that neither 10 nor 100 ng/mL 
(final concentration 1.66 and 16.6 ng/mL) of Egf were sufficient to significantly 
increase A549 cell invasion. However, A549 cells stimulated with Egf 1000 ng/mL 
(final concentration 166 ng/mL) or 2000 ng/mL (final concentration 333 ng/mL) were 
reliably invading into the collagen matrix. We therefore chose a concentration of 1000 
ng/mL Egf to perform the screen. 
4.2.1.5 Positive control 
To control for invasion efficiency between experimental plates and confirm that 
A549 invasiveness could be further enhanced, transfection of oligonucleotides directed 
against non-erythroid protein 4.1 brain types (4.1B) was tested. 4.1B is a tumour 
suppressor gene [437] the downregulation of which has been shown to increase cell 
migration and correlate with metastasis in rat sarcoma cells [438]. In our assay, RNAi 
directed against 4.1B increased A549 cell invasion as compared to scramble transfected 
cells (Figure 27B). Furthermore, scramble tranfection did not significantly affect cell 
invasion as compared to untransfected cells stimulated with Egf (Figure 27B). Hence, 
scramble and 4.1B transfection were respectively used as reference and positive control 
throughout our invasion screen. 
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Figure 27: Determination of the Egf concentration and siRNA control to be used for the invasion 
screen. (A) Egf titration experiment. A representative of 3 independent experiments performed in 
triplicate is shown. (B) Effect of 4.1B downregulation on A549 invasion under Egf stimulation. (A and 
B) Sc; Scramble. Confocal stacks were analysed using Mathematica to generate box and whisker plots of 
A549 cell invasion. Box represents 75% and side bar 12.5% of the data population. Dots represent 
median intensities.  Statistical significance was determined using ANOVA analysis. *; p<0.05, **; 
p<0.005. A representative of 3 independent experiments performed in triplicate is shown. 
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4.2.2 Invasion screen results 
Amongst the 70 targets tested, 60% decreased, 19% increased and 21% had no 
effect on A549 cell invasiveness when compared to scramble transfected cells (Figure 
28A and B). Figure 28A shows a comparative analysis of our motility and invasion 
screen results. 54% (thirty eight) of the hits tested similarly modulated cell migration 
(primary screen) and cell invasion (secondary screen) (Figure 28C). In addition, 20% of 
the targets tested did not alter invasion despite changing cell motility while 26% of our 
hits showed opposite effects in the two screens (Figure 28C). This demonstrated that 
changes in cell migration cannot be directly extrapolated to cell invasiveness. However, 
hits that decreased cell migration had a better correlation rate with invasion than those 
that increased motility (Figure 28D). This suggested that while impairment of cell 
migration will often thwart cellular invasiveness, increased motility is not sufficient to 
produce an invasive phenotype. 
Within the Rsk family, silencing of Rsk1 increased invasiveness of A549 cells 
further than our positive control 4.1B (Figure 29A and B). In contrast to Rsk1, Rsk4 
targeting decreased cell invasiveness (Figure 29A and B). These effects mirrored those 
seen in the migration assays (Chapter3 Figure 19B and C). However, Rsk2 
downregulation did not impair invasion despite its effects on cell motility (Figure 29A 
and B). Hence, silencing of Rsk1 and Rsk4 similarly alter invasion and migration. 
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Figure 28: Cross-correlation between the effects of silencing the 70 migration screen hits on cell 
motility and invasion. Comparative tables showing the effects on A549 cell migration and invasion of 
silencing the migration hits. The left table shows hits for which effects on migration correlated with those 
on invasion. The right table shows hits that do not cross-correlate in the two assays. (-); decrease, (+); 
increase, (0); no effect. ANOVA for the invasion alone with Sc as reference: *; p<0.05, **; p<0.005, 
***; p<0.001. (B) Percentage of hits decreasing, increasing or having no effect on cell invasion. (C) 
Percentage of hits showing cross-correlation, inverse (Inv) correlation or no correlation between the 
migration and the invasion phenotypes. (D) Percentage of cross-correlation between invasion and 
migration depending on whether the hits decreased or increased cell migration speed. 
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Figure 29: Effect of Rsks silencing on cell invasion. (A) Side views of representative confocal stacks 
of A549 cells invading upward into a collagen matrix upon silencing of Rsk family members. Sc; 
Scramble. Red arrows represent the bottom of the wells for each condition. Stack size 150 µm. (B) Box 
and whisker plots of A549 cell invasion following Rsk1, 2 and 4 silencing. 27 fields of view similar to 
those pictured in (A) were acquired for each condition. Box represents 75% and side bar 12.5% of the 
data population. Dot represents median speed.  Statistical test was performed using ANOVA analysis 
with Sc as reference. * correspond to p<0.05, n.s.; non-significant. A representative of 3 independent 
experiments performed in triplicate is shown. 
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4.3 Discussion 
We previously performed a kinome-wide RNA interference screen for cell 
motility in a 2D environment using the NSCLC cell line, A549. Our screen identified 
70 hits modulating the migration of these cells. To further assess how our motility hits 
could be involved in the metastatic process we performed a secondary invasion screen 
for the same cell line using a 3D collagen matrix. 
We show that A549 cells were able to invade in a Type I collagen matrix in 
response to Egf. However, contrary to previous reports [420, 433], A549 cells were unable 
to invade in Matrigel in our assay. Matrigel is a preparation of ECM components 
secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells. EHS cells produce a 
large amount of basement membrane (BM) components including Laminin and 
Collagen type IV [439] as well as various growth factors such as transforming growth 
factor-β (Tgf-β), fibroblast growth factor (Fgf), and tissue plasminogen activator. The 
exact composition of Matrigel is unknown and subject to variability in composition and 
concentration that might explain this discrepancy. Furthermore, the Matrigel we used 
was not reduced for its content in growth factors. Thus, it is possible that the effects of 
the Egf stimulation in our assay were masked by the growth factors already present in 
the matrix. Indeed Hauck et al. used growth factor depleted matrigel in their study [433].  
Several points need to be taken into account in the interpretation of the results of 
our screen: 
(1) Type I collagen is the most abundant structural protein in the interstitial 
tissue. However, Collagen matrices lack other ECM components such as 
fibronectin and laminin that play an important role during invasion [48]. Thus, 
our invasion screen might select for invasion dependent on the type I collagen 
receptor (integrin α2β1) as well as on proteases known to have type I 
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collagenolytic activity such as the matrix metalloproteinases Mmp-1, Mmp-2, 
Mmp-8, Mmp-9, Mmp-13 and the membrane-type-1 matrix metalloproteinase 
MT1-Mmp (also known as Mmp-14) [47]. Indeed, MT1-Mmp has been 
reported to be required for tumour cells to invade through type I collagen 
matrices [440]. 
(2) It has previously been shown that different concentrations of collagen were 
associated with different type of invasion. Low collagen concentrations 
(3mg/mL) promote non-proteolytic amoeboid-type invasion while high 
concentrations (10 to 12 mg/mL) promote proteolytic-dependent 
mesenchymal-type invasion [45, 441] (Chapter 1 section 1.2.1.1.1.1). Here we 
decided to use a low collagen concentration of 3mg/mL in order to lower the 
stringency of the assay. However, by doing so, we might have biased our 
assay towards the identification of siRNA treatments affecting amoeboid type 
invasion.  
(3) In contrast to invasion assays performed using Boyden chambers [420, 433], our 
screen allowed cells to adhere to the well before overlaying the collagen 
matrix. Hence, cells needed to detach first in order to invade upward. 
Although this made the assay more stringent, it might mimic more closely the 
in vivo setting where tumour cells need to detach from the primary tumour 
before invading.  
 
Our screen showed 54% of correlation between the motility and invasion 
phenotypes, suggesting that changes in cell migration cannot be directly extrapolated to 
cell invasiveness using our experimental approach. One reason explaining this 
discrepancy could be the nature of our experimental approach that limits our readout to 
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invasion through a type I collagen matrix and in response to Egf. Further development 
of our protocol using different ECM compositions as well as chemo-attractants might 
reveal a higher degree of correlation between changes in motility and invasiveness. 
Alternatively, tumour cells do not require to be invasive per se to metastasise in vivo as 
mesenchymal cells have been shown to create tracts that cancer cells can passively 
follow [51]. In this setting, changes on cell migration will dictate the ability of the 
tumour cells to disseminate. Finally, Rsk1 and Rsk4 but not Rsk2 showed correlation 
between motility and invasiveness in A549 cells. Considering that neither Rsk2 nor 
Rsk4 motility phenotype validated across multiple cell lines, Rsk1 appears to be 
dominant Rsk isoform in the regulation of cell migration and invasion. 
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5.1 Introduction 
Cell motility is a complex biological process that has been shown to involve 
several cellular signalling pathways [82] (Chaper 1 section 1.3). While these pathways 
have frequently been described as linear cascades it is now generally accepted that they 
are part of evolutionary conserved signalling networks [442]. Indeed, analysis performed 
in Saccharomyces cerevisiae has shown that the phenotypic consequence of a single 
gene deletion is affected to a large extent by the topological localisation of the protein 
product within these networks [443]. Similarly, cancer progression is associated with 
multiple genomic alterations that are likely to affect the structure and dynamic of these 
protein networks [442]. We previously identified 70 hits on the basis of their ability to 
modulate A549 cell motility. We now wished to investigate the possibility that these 
proteins might be part of one such network. To assess the likelihood of this possibility, 
we queried a human protein-protein interactome (PPI) database with our 70 motility 
hits and found that 21 of our hits were linked in a highly interactive hub containing 
members from the Rsk and Casein kinase families. By extending our network analysis 
to first-node interactions between our hits and the rest of the proteome, we revealed the 
possibility of Rsks interacting with the actin regulator Vasp. We confirmed this 
biochemically and identified specific phosphosites on Vasp that are modulated by 
Rsk1. Rsks also interacted with the actin regulator Mena, possibly via its ability to 
heterotetramerise with Vasp. Finally we show that Vasp and Mena downregulation 
prevented the migratory effects of Rsk1 silencing suggesting that both proteins mediate 
the effects of Rsk1 on cellular motility. 
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5.2 Results 
5.2.1 Protein–Protein Interactome analysis 
To gain insight into whether the Rsks and our other identified targets interact 
with each other we performed an interactome analysis. A human protein-protein 
interaction (PPI) database was assembled that integrated two previously published 
collections containing both experimentally verified and in-silico predicted interactions  
[414] [415] (Figure 30A). This database was queried for first-node level interactions 
between our 70 hits (Figure 30B). Although most hits did not show interaction with 
other members of the list, a subgroup of highly interactive 21 proteins was identified 
(Figure 30B). This subgroup contained several proteins from the S6 kinase and Casein 
kinase families. To ensure that this high frequency of association was not due to 
chance, we also analysed 10 randomly generated lists of 70 targets from our siRNA 
library. None of these lists produced groupings of >13 proteins (Figure 30C), 
suggesting that our hit-list genuinely is enriched for interacting partners. To shed light 
on why our hits might regulate cell motility, the PPI database was next queried for 
interactions between these hits and proteins outside the kinome. This analysis predicted 
that several well-known modulators of cell migration, including Vasp [107], Vinculin 
(VCL) [444] and Vimentin (VIM) [445], might interact (average of 3 first-node 
interactions) with our network of 21 hits (Figure 30B and D), including the Rsk family 
members (Figure 30D). The changes in the actin cytoskeleton mediated by the 
downregulation of Rsk isoforms (Chapter 3 Figure 23), suggested a link with 
modulators of actin dynamics. 
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Figure 30: Bioinformatics analysis. (A) Human protein-protein interaction (PPI) database. Nodes 
represent individual proteins. Links symbolise protein-protein interactions. Proteins from the cell 
migration hit list (70) are represented in yellow. The rest of the proteome is in red. (B) A query for the 
first-node level interaction between our hits reveals a subgroup of 21 highly interactive hits (lower panel) 
and 3 smaller groupings of interactors (middle panel), while most do not cross-interact (upper panel) . 
(C) The “false-rate” of interaction was assessed using 10 randomly generated lists of 70 kinases to query 
the PPI for first-node interaction. The graph displays the size of interaction groupings obtained with the 
experimental hit list as compared to those generated with the 10 random lists. Each individual grouping 
is represented as a dot. (D) Representative first-node interactions between our grouping of 21 hits and the 
rest of the proteome. Only proposed interactors with a documented effect on cell migration are shown. 
The link between Rsk2 (RPS6KA3) and Vasp is highlighted in red. Proteins within the group of 21 hits 
are colour-coded from grey (decreased migration speed (-)) to red (increased migration speed (+)) 
according to the effect of their downregulation on cell migration speed. RPS6KA1 and RPS6KA3 stand 
for Rsk1 and 2 respectively. 
A. B.
0
5
10
15
20
25
N
um
be
r 
of
 in
te
ra
ct
io
ns
H
it 
L
is
t
R
an
do
m
 1
R
an
do
m
 2
R
an
do
m
 3
R
an
do
m
 4
R
an
do
m
 5
R
an
do
m
 6
R
an
do
m
 7
R
an
do
m
 8
R
an
do
m
 9
R
an
do
m
 1
0
C.
167 
 
 
 
5.2.2 Rsk1 and Rsk2 interact with Vasp and Mena 
Vasp is a known mediator of actin dynamics [143-144]. Hence, we tested whether 
the predicted interaction between Vasp and Rsks could be validated. Figure 31A (upper 
panel) shows that immunoprecipitation of Rsk2 pulled down endogenous Vasp in A549 
cells grown in serum-containing medium. Similarly, immunoprecipitates for Vasp 
demonstrated immunoreactivity for Rsk2. While the interaction of Rsk2 with Vasp was 
predicted by our PPI database, an interaction with Rsk1 was not. This was surprising 
given the high degree of homology for Rsk family members. We found that Rsk1 co-
immunoprecipitated with Vasp whether the immunoprecipitating antibody was directed 
towards Rsk1 or Vasp (Figure 31A lower panel). Since Vasp is known to 
heterotetramerise with its close homologue Mena [446], another protein regulating actin 
dynamics [447], we next tested the potential for Mena to associate with Rsks. Co-
immunoprecipitation experiments confirmed that both Rsk1 and Rsk2 associate with 
endogenous Mena in A549 cells (Figure 31B). Reverse co-immunoprecipitation could 
not be performed as our Mena antibody was not immunoprecipitating. Our PPI database 
also predicted that Rsk1 and 2 should interact and we confirmed this by co-
immunoprecipitation of the 2 proteins in A549 cells (Figure 31C). Although the 
preceding results do not demonstrate whether these interactions are direct or indirect, 
our observation that Rsk1 and 2 associate with two well-known actin regulators could 
explain the migratory phenotypes observed upon Rsk downregulation.  
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Figure 31: Vasp and Mena interact with Rsk1 and 2. (A, B and C) Co-immunoprecipitation 
experiments validating interactions between Rsk2 (upper panel), Rsk1 (lower panel) and Vasp (A), 
between Rsk1, Rsk2 and Mena (B) and between Rsk1 and Rsk2 (C). Cell lysates were 
immunoprecipitated (IP) for Rsk1, Rsk2 or Vasp. Unspecific antibody (UA) and Beads without antibody 
(B) were used as control. (Ly) stands for total cell lysate. Blots shown are representative of at least 3 
independent experiments. A representative of 3 independent experiments is shown. 
 
 
 
A.
BLy
Rsk2
Vasp
WB:
UA
Vasp
Rsk1
IP
IP: Rsk2
BLy UA IP
IP: Vasp
BLy UA IP
IP: Rsk1
BLy UA IP
IP: Vasp
WB:
B.
BLy UA IP
IP: Rsk2
Rsk2
Mena
WB:
Rsk1
Mena
BLy UA IP
IP: Rsk1
WB:
C.
BLy UA IP
IP: Rsk2
BLy UA IP
IP: Rsk1
Rsk2
Rsk1
WB:
169 
 
To investigate the functional relevance of the Rsk1/2-Vasp interaction and 
determine whether these proteins directly interact, we performed in vitro kinase assays 
using purified proteins. Figure 32A shows that both human recombinant (hr) activated 
Rsk1 and 2 could directly phosphorylate hrVasp in vitro more efficiently than Rsk’s 
classical substrate, S6 protein. To determine the nature of the phosphorylation sites 
targeted, the phosphorylated Vasp was analysed by mass spectrometry following 
trypsin or thermolysin digestion (Figure 32B). This work was performed by our 
collaborators Dr. Rita Derua and Pr. Etienne Waelkens (Labo Proteïne Fosforylatie en 
Proteomics, Katholieke Universiteit Leuven). Figure 32B and C shows that Thr-278, a 
site known to be involved in actin polymerisation [149], was the only site specifically 
phosphorylated by Rsk1. Indeed, neither recombinant Rsk2 nor Rsk4 induced 
phosphorylation of this site. On the other hand, Rsk2 targeted specifically the Ser-2 
and/or Thr-4, Ser-8 and/or Ser-9 as well as the Ser-322 and/or Ser-323, Ser-324, Ser-
325. The mass spectrometry resolution could not distinguish if one or more of these 
sites were preferentially phosphorylated (Figure 32B and C). While the Ser-2, Thr-4, 
Ser-8 and Ser-9 have never been described before, the Ser-322, Ser-323 and Ser-234 
have previously been identified in high throughput proteomic analysis and reported in 
the online PhosphositePlus repository (http://www.phosphosite.org). Although Rsk4 
was capable of phosphorylating Vasp, no phosphorylation site was specific for this 
enzyme (Figure 32B). Finally, all three RSK isoforms were able to phosphorylate the 
Thr-12, the Ser-255 and/or Ser-258, as well as the Thr-315 and/or Thr-316 (Figure 32B 
and C).  
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Figure 32: Vasp is phosphorylated by Rsk1, 2 and 4 in vitro. (A) Representative experiments in which 
Human recombinant Vasp was subjected to in vitro kinase assays using human recombinant Rsk1 or 
Rsk2 in the presence of 32P-γATP. Ribosomal S6 peptide was used as a positive control. Upper panel: 
autoradiogram; black bars indicate Molecular Weight markers (MW). Lower panel: The gel was 
Coomassie stained as a loading control. (B) Mass-spectrometric analysis of Vasp phosphorylation sites 
targeted by Rsks isoforms in vitro. Recombinant Vasp was incubated in vitro in the presence or absence 
of the relevant human recombinant Rsk isoform and 32P-γATP. “*” represents the detection of 
phosphorylation in the identified peptides by mass spectrometry following trypsin or thermolysin 
digestion. The sequence of the corresponding peptide and the putative phosphorylation site(s) within that 
sequence are presented. (Mr) Relative molecular mass. (C) Schematic representation of Vasp functional 
domain showing Rsk1 and 2 specific phosphorylation sites identified by mass spectrometry. Ena/Vasp 
homology domain 1 and 2 (EVH1 and 2), Proline-rich region (PRR) 
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Previous reports have described three principal phosphorylation sites on Vasp, 
against which phospho-specific antibodies have been raised [149] [448] [449] [450] [451] [452]. 
These include the Ser-157, Ser-239 and the newly identified Rsk1 target, Thr-278. We 
therefore tested whether Rsk1 might modulate the phosphorylation of Thr-278 in intact 
cells. Figure 33A, demonstrates that Rsk1 silencing prevented phosphorylation of Vasp 
on Thr-278 in A549 cells growing in 10% serum while Rsk2 and 4 silencing had no 
effect on this site. Knockdown of Vasp confirmed that the Thr-278 phosphosignal 
detected was specific for Vasp. We further confirmed the role of Rsk1 in the 
phosphorylation of Thr-278 on Vasp in H23 NSCLC cell line (Figure 33B). We also 
examined the phosphorylation of Ser-157 and Ser-239, two other sites involved in the 
binding of Vasp to actin. Unlike Thr-278, basal phosphorylation of these sites was low 
and was unaffected by Rsk1 downregulation. However, treatment with forskolin, a 
potent stimulator of Protein kinase cAMP-dependent (Pka) and Protein kinase cGMP-
dependent (Pkg) activity, could induce both Ser-157 and Ser-239 phosphorylation as 
previously reported [155] (Figure 33C and D). Thus, using phosphospecific antibodies, 
we were able to validate the mass-spectrometric data and confirm that Rsk1 specifically 
modulates phosphorylation of Vasp on the Thr-278. 
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Figure 33: Vasp Thr-278 phosphorylation is dependent on Rsk1 expression. (A, C and D) A549 or 
(B) H23 cells grown in serum were washed then transfected in serum free medium with siRNAs targeting 
Rsk1, 2, 4, Vasp or a scrambled control (Sc) as indicated. (C and D) Untransfected A549 cells were 
stimulated with Forskolin 10µM for 30 min as a positive control for Ser-157 and Ser-239 Vasp 
phosphorylation. DMSO was used as a diluent-alone control. (A-D) Cell lysates were subjected to Vasp 
immuno-precipitation before being analysed by SDS-PAGE/Western blotting (WB) using antibodies 
against the indicated targets. A representative of 3 independent experiments is shown. 
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5.2.3 Vasp and Mena mediate the effects of Rsk1 on cell motility and 
morphology 
In addition, because Vasp heterotetramerises with Mena and the latter protein 
was found to associate with Rsk1 in A549 cells, Mena might participate in controlling 
Rsk1 effects on cell migration. Figure 34A, B and C shows that knockdown of either 
Vasp or Mena decreased A549 cell migration to a similar extent to that observed upon 
Rsk2 downregulation (Chapter 3 Figure 19C and Figure 34B). Moreover, reminiscent 
of data shown in Chapter 3 Figure 22, combined silencing of Vasp and Rsk1 or Mena 
and Rsk1 produced similar effects on migration as concomitant Rsk1 and 2 knockdown 
(Figure 34A). Also, combined knockdown of Vasp and Mena completely reversed the 
effects of Rsk1 silencing (Figure 34A). In addition to these effects on cell migration, 
Vasp or Mena silencing alone reproduced the changes in the actin cytoskeleton (Figure 
35A) previously seen following Rsk2 downregulation (Chapter 3 Figure 23A). 
Furthermore, while Rsk1 silencing induced a 10-fold increase in the number of 
lamellipodia per cell, combined Vasp and Mena knockdown dramatically reduced this 
effect (Figure 35B). In contrast to their modulation of the outcome of Rsk1 silencing, 
Vasp downregulation did not and Mena’s only slightly potentiated the inhibition of cell 
migration triggered by Rsk2 and/or Rsk4 knockdown (Figure 34B and C). Taken 
together, these data suggest that Vasp and/or Mena mediate the opposing effects of 
Rsk1 and Rsk2 on A549 cell migration. 
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Figure 34: Effects of Vasp and Mena silencing on the motility phenotypes induced by Rsks 
downregulation. (A) Both Vasp and Mena knockdown are required to counterbalance the effects of 
Rsk1 silencing. (B and C) Effect of co-silencing of Vasp (B) or Mena (C) on the motility changes 
induced by downregulation of Rsk2 and 4. The average random migration speed distribution of 60 cells 
per condition is represented as a box and whisker plot. The box contains 75% and each side bar 12.5% of 
the cell population. The spot represents the median speed. ANOVA with Sc as reference: *; p<0.05, **; 
p<0.005, ***; p<0.001. A representative of 3 independent experiments performed in duplicate is shown.  
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Figure 35: Effects of Vasp and Mena silencing on the cytoskeletal phenotypes induced by Rsks 
downregulation. (A) Representative images from the actin cytoskeleton staining of A549 cells upon 
Rsk1, 2 and 4 downregulation with or without co-silencing of Vasp and Mena. Staining was performed 
using Alexa Fluor 488 phalloidin (white). 36 Images per condition were acquired using the high-
throughput microscope ImageXpress Micro (IMX). (B) Effect of VASP and Mena co-silencing with 
RSK1 on the number of lamellipodia per cell. The average numbers of lamellipopdia per cell from 36 
fields of view as in (A) were determined by two independent observers. Cells partially outside the field 
of view were excluded. Error bars represent SEM. Statistical analysis was performed using a Student’s t-
test. ***; p<0.001. A representative of 3 independent experiments performed in duplicate is shown. 
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5.3 Discussion 
Bioinformatic analysis using the hit list from our cellular motility screen 
highlighted a sub-group of 21 proteins including several members from the S6 kinase 
and Casein kinase families (Figure 30). This in silico analysis further revealed that 
Rsk1 and 2 interact with Vasp, a well known regulator of actin dynamics (Figure 
30)[107]. Using co-immunoprecipitation, we confirmed this interaction in A549 and H23 
NSCLC cell lines (Figure 31, Figure 32 and Figure 33). As in other published reports 
[140, 453], we showed that silencing of Vasp and Mena decreases cell migration speed 
(Figure 34). Moreover, co-silencing of these proteins with Rsk1 abolished the 
promigratory and cytoskeletal effects of selective Rsk1 downregulation (Figure 34 and 
Figure 35). Using in vitro kinase assays on purified proteins, we show that Rsk1, Rsk2 
and Rsk4 can phosphorylate Vasp (Figure 32). Helpfully, three principal 
phosphorylation sites (Ser-157, Ser-239 and Thr-278) have been described on Vasp that 
regulate its activity and for which antibodies are available [448] [449] [450] [451] [452]. Our 
results suggest that Thr-278 might be of particular importance here as Rsk1, but not 
Rsk2 or Rsk4, silencing reduces phosphorylation on this site (Figure 33) in intact cells. 
In keeping with this hypothesis, the phosphorylation of Thr-278 was previously 
predicted to suppress migration [149] [155]. Furthermore, our data show that Vasp 
knockdown partially reversed the effects of Rsk1 silencing (Figure 34). However, Vasp 
and/or Mena knockdown mimics the effects of Rsk2 and Rsk4 silencing on cell 
migration and actin organisation (Figure 35). This suggests that Vasp and Mena might 
still mediate the effects of Rsk2 and 4 but through a mechanism distinct from Thr-278 
phosphorylation. Indeed, mass-spectrometric analysis of our in vitro kinase assay 
products suggests that Rsk2 and 4 are capable of phosphorylating Vasp in vitro on 
residues distinct from Thr-278. Although this analysis did not highlight residues 
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selectively targeted by Rsk4, the specific effects of this isoform could result from its 
ability to phosphorylate Vasp in distinct sub-cellular localisations. Alternatively, we 
showed that Rsk4 downregulation leads to an increase in Rsk1 protein levels (Chapter 3 
Figure 22), an effect that might in itself explain the modulation of cell migration by 
Rsk4. However, additional experimental work is warranted to test these or other 
potential hypotheses.  
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CHAPTER 6 
 
 
 
Rsks mediate metastasis 
in vivo 
6 Chapter 6: Rsks mediate metastasis in vivo 
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6.1 Introduction 
Activating Mutations within the MAP Kinase pathway have been reported in 
greater than 30% of human cancers [205]. These mutations are typically gain of function 
mutations leading to Erk activation [190] [206] and have been reported to drive cell 
motility, invasiveness and metastasis [200] [454] [455]. Using two successive screening 
approaches, we previously identified Rsk1, 2 and 4 as regulators of lung cancer 
migration and invasion. Previous reports have demonstrated Rsk over expression in 
cancer including breast cancer [252] and head and neck squamous cell carcinomas [256]. 
However, to our knowledge, Rsk expression in lung tumour and associated metastatic 
sites remains unknown. To address the clinical relevance of our findings, we first 
examine the expression of Rsk family members in tissue microarrays (TMA) containing 
matched primary non-small cell lung cancers (adenocarcinomas) and adjacent normal 
lung. We then compiled a TMA containing isogenically-matched primary and 
metastatic tumour samples from 100 untreated patients with lung cancer to compare 
Rsk1, 2 and 4 expressions between these two sites. This work was performed in 
collaboration with Dr. Francesco A. Mauri (Histopathology, Imperial College London, 
Hammersmith Campus, London, UK) and involved Dr. Robert J Shiner. We show that 
lung cancers, like other neoplasms, over express Rsk family members. Furthermore, in 
keeping with our in vitro findings, we reveal that Rsk1 was downregulated, while Rsk2 
and 4 were overexpressed in metastatic lung cancer samples compared to isogenically 
matched primary tumours. To further demonstrate the relevance of our findings in vivo, 
we developed a zebrafish model based on previous reports [59] [456] [457]. This work was 
performed in collaboration with the laboratory of Prof. Maggie Dallman (Division of 
Cell and Molecular Biology, Department of Life Sciences, Faculty of Natural Sciences, 
Imperial College London, London, UK) and involved Dr. Olivier Pardo, Harriet Taylor, 
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Alice Shia and Prof. Jonathan R Lamb. My involvement in this work was confined to 
some analysis only so these results can be found in Annexe 1. Using this model we 
showed that Rsk1 silencing enhanced the metastatic potential of A549 cells in vivo. In 
short, our data propose that Rsk family members are important determinants of lung 
cancer metastatic potential. 
6.2 Results 
6.2.1 Rsk family members expression in lung tumour 
Prior to performing immunohistochemical staining of the TMA, we verified the 
specificity of the Rsk antibodies using formalin fixed paraffin-embedded pellets of 
A549 cells treated with scramble or Rsk1, 2 or 4 siRNAs. Figure 36A (left panel) 
shows that Rsk1, 2 or 4 antibodies reveal a clear staining in scramble treated A549 
cells. Silencing of Rsk1, 2 or 4, abrogated the staining for the corresponding antibody 
compared to scramble transfected cells (Figure 36A right panel) and thus confirmed the 
specificity of each antibody. Figure 36B shows representative tissue staining of normal 
lung as well as adenocarcinoma using Rsk1, 2 or 4 antibodies. Positive staining in 
adenocarcinoma revealed both nuclear and cytoplasmic localisation of the signal for all 
three Rsk isoforms (Figure 36B). Our in vitro results suggested the existence of an 
equilibrium between the expression levels of Rsk1 and Rsk4 as Rsk4 downregulation 
led to an increase in Rsk1 protein levels (Chapter 3 Figure 22). Thus, we wondered 
whether these findings would extend to expression of these two Rsk isoforms in vivo. 
To address this possibility, we used tissue microarrays (TMA) containing matched 
primary non-small cell lung cancers (adenocarcinomas) and adjacent normal lung.
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Figure 36: Representative immunohistochemistry (IHC) staining for Rsk1, 2 and 4. (A) Controls for 
Rsk1, 2 and 4 antibody specificity. A549 cells treated with scramble (Sc), Rsk1, 2 or 4 siRNAs were 
fixed and paraffin-embedded prior to IHC with the relevant antibody. (B) Representative IHC of tissue 
samples using Rsk1, 2 and 4 antibodies. Staining of a normal lung specimen together with 
adenocarcinoma samples positive and negative for expression of the indicated proteins are shown. (A) 
and (B) Immunoreactivity was revealed using HRP together with Diamino-benzidine (DAB) secondary 
staining. Blue; haematoxylin counter-stain, Brown; HRP/DAB.  
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In agreement with previous reports (Zeniou et al., 2002), Rsk1 and Rsk4 protein 
expression was not detected in normal lung tissue (Figure 36B). However, 49% and 
57% of lung tumours were positive for Rsk1 and 4, respectively (Figure 37A), 
suggesting a possible role for these kinases in tumourigenesis. In keeping with our in 
vitro data, absence of Rsk4 associated with the presence of Rsk1 expression and vice 
versa in 71% of cases (Figure 37B). These results lend weight to the hypothesis of an 
equilibrium between Rsk1 and 4 expression in lung cancer. 
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Figure 37: Rsk1 and  4 expression pattern in matched normal lung and primary lung 
adenocarcinoma samples. (A) and (B) Histoimmunopathological analysis of a human lung tissue micro-
array (TMA) containing primary tumours and surrounding normal tissue. (A) Percentage of cases with 
Rsk1 and Rsk4 variation of positive staining in primary tumours and surrounding normal tissue. (B) 
Percentage of primary lung tumours samples where Rsk1 or Rsk4 staining was exclusive. 
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6.2.2 Loss of Rsk1 correlates with increased metastatic frequency 
Our previous results demonstrating enhanced migration and invasion upon 
knockdown of Rsk1 raised the possibility that this kinase might be lost during the 
metastatic process. To test this hypothesis, we compiled a TMA containing isogenically 
matched primary and secondary tumour samples from 100 untreated patients with lung 
cancer. Figure 38A and B demonstrates that in patients where primary tumours stained 
positively for Rsk1, most showed reduced expression of this protein in the metastatic as 
compared to the matched primary lesions (I > II). In addition, the 37% of patients with 
primary tumours negative for Rsk1 staining (I & II neg) demonstrated increased 
numbers of metastatic lesions when compared to patients with Rsk1-positive tumours 
(Figure 38C). Moreover, in cases with Rsk1-positive primary tumours, most of the 
patients within the “0-3 metastatic sites” group had a single secondary lesion. Taken 
together, these results correlate with our in vitro findings and suggest that Rsk1 
negativity in primary tumours may be a clinical biomarker for metastasis and poor 
prognosis.
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Figure 38: Changes in Rsk1 expression levels correlate with the occurrence of distant metastasis. 
(A) to (C) A TMA containing matched primary and secondary tumour samples from 100 untreated 
patients were stained for Rsk1. (A) Comparison of Rsk1 staining score between primary and secondary 
sites. “I & II neg”;  both primary and secondary lesions are negative for Rsk1. “I > II” ; staining higher in 
primary than secondary sites.  “I < II” ; staining lower in primary than secondary sites. (B) Percentage of 
Rsk1 scores in the primary (“I”) and the secondary (“II”) tumours of cases with positive Rsk1 staining. 
Error bars are SEM. Statistical analysis was performed using a Student’s test. (C) Number of secondary 
lesions per patients depending on Rsk1 positive or negative staining in the primary tumour. Numbers 
represent percent of cases. 
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6.2.3 Rsk2 and/or 4 expression increases in metastasis versus primary 
lesions 
Because of the effects of both Rsk2 and 4 knockdown on A549 cell migration 
and those of Rsk4 siRNA on A549 cell invasion in vitro, we next examined 
immunohistochemical staining for Rsk2 and 4 in the same TMAs. Figure 39 A – D 
show that neither protein alone could predict for metastases. A possible explanation for 
this is that for a given tumour these two isoforms act inter-changeably. This hypothesis 
predicts that where altered Rsk2 levels do not correlate with metastasis, changes in 
Rsk4 expression would substitute and vice versa. In agreement with this notion, 59% of 
patients showed increased Rsk2 or 4 staining in the secondary compared to their 
primary lesions (Figure 39E). Also, a greater number of metastatic lesions were 
observed in cases where Rsk2 or 4 were increased in the secondary sites compared to 
the primary tumour (Figure 39F). Interestingly, increase in Rsk2/4 expression could 
account for the metastatic status of half the cases where Rsk1 staining had failed to do 
so (Figure 39G). Thus, 75% of all cases could have their metastatic status explained 
based on staining for these 3 Rsk isoforms (Figure 39G). A much larger cohort of 
patients is now required to examine the predictive power of these proteins for 
metastasis in the clinic. 
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Figure 39: Rsk2 and 4 immunohistochemistry (IHC) scores in primary vs metastatic lesions. (A-F) 
A TMA containing matched primary and secondary tumour samples from 100 untreated patients were 
stained for Rsk2 or 4. (A) and (C) Comparison of Rsk2 (A) or Rsk4 (C) staining between primary and 
secondary sites. (B) and (D) Number of secondary lesions per patients depending on Rsk2 (B) or Rsk4 
(D) staining in the primary vs the secondary tumours. Numbers represent percent of cases in each 
category. (A-D) “I & II neg”; both primary and secondary lesions are negative for Rsk2 or 4. “I > II” ; 
staining higher in primary than secondary sites.  “II > I”; staining higher in secondary than primary sites. 
“No. of sites”; number of metastatic sites reported per clinical case. (E) Comparison of Rsk2 or 4 staining 
intensity between primary and secondary sites. “Rsk2 or 4 II>I”; Rsk2 and/or 4 staining higher in the 
secondary than the primary lesion. (F) Number of secondary lesions per patients depending on Rsk2 or 4 
expression status in the secondary vs the primary tumour. Numbers represent percent of cases. (G) 
Proportion of cases where the metastatic status can be explained by Rsk1, 2 or 4 comparative staining 
between primary and secondary tumours. “Explained Rsk1”; cases that can be explained based on Rsk1 
staining alone. “Explained Rsk2/4 not 1”; cases explained by by Rsk2 or 4 but not Rsk1 staining.  “Not 
explained by Rsks”; cases where Rsk1, 2 or 4 staining cannot account for the patients metastatic status. 
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6.2.4 Rsk1 modulates invasion in vivo 
Our preceding results indicated that Rsk1 downregulation enhanced cell motility 
and invasion in A549 cells in vitro. We further correlated these in vitro findings in 
human clinical samples and showed that Rsk1 was downregulated in metastatic lung 
cancer samples compared to isogenically matched primary tumours. To demonstrate 
that Rsk1 downregulation can induce dissemination of tumour cells in vivo we 
established a cancer metastasis zebrafish model. In this model, A549 cells stably 
expressing a histone 2B-GFP fusion protein were established to allow for convenient 
visualisation of the cells by fluorescence microscopy. Cells expressing high levels of 
GFP were selected using flow cytometric cell sorting to obtain a more homogenous cell 
population. 30 cells were injected into the cell mass of 4 h post-fertilisation zebrafish 
embryos. Annexe 1A shows that the injected tumour cells could easily be visualised 
using widefield fluorescent microscopy. Whole fish imaging after 48 h demonstrated 
that the injected cells formed a tight tumour mass in the head of all injected fish with 
only very limited dissemination into the fish body (Annexe 1B). Using this model, we 
hypothesised that down-regulation of Rsk1 might enhance dissemination of A549 cells 
away from this mass. Indeed, injection of A549 cells silenced for Rsk1 resulted in a 
more diffuse tumour mass in the fish head accompanied by single cell invasion 
throughout the fish body including the tail (Annexe 1B). In contrast, fish injected with 
A549 cells transfected with a scrambled siRNA displayed tight tumours in the head 
with control levels of invasion and total absence of dissemination to the fish tail 
(Annexe 1B). This difference in phenotype could be quantified by scoring for the 
presence or absence of tumour cells within 3 defined regions of the fish body; Head, 
Middle and Tail (Annexe 1C, n=120 fish per condition). We further imaged the 
dissemination of the Rsk1 silenced cells to the tail at different time-points (Annexe 
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1D). Importantly, the cells which had migrated to the tail, retained the ability to 
proliferate, a condition required for the formation of metastatic tumours (Annexe 1D). 
Thus, Rsk1 knockdown enhances the ability of A549 cells to invade and disseminate in 
vivo. 
6.3 Discussion 
We previously revealed Rsk1, 2 and 4 as modulators of NSCLC motility. We 
further established that Rsk1 and 4 knockdowns could modulate A549 cell invasiveness 
in vitro suggesting that these isoforms might be important in regulating metastasis in 
human lung cancer. To show the clinical relevance of our findings, we compared the 
expression of Rsks family members in a TMA containing matched primary non-small 
cell lung cancers (adenocarcinomas) and adjacent normal lung. While expression of 
Rsk1 and Rsk4 was not detected in normal lung tissue, primary adenocarcinoma 
showed a positive staining for Rsk1 and Rsk4 in more than 50% of the cases (Figure 
37A). Previous reports also revealed increased expression of Rsk2 in breast [252] and 
prostate cancer [253] hence suggesting a possible involvement of these kinases in 
tumourigenesis. In addition, in 71% of cases, absence of Rsk4 associated with the 
presence of Rsk1 expression and vice versa (Figure 37B). This result supports our 
previous in vitro findings (Chapter 3 Figure 22) suggesting an equilibrium between 
Rsk1 and 4 expression in lung cancer. Furthermore, we assembled a second TMA 
comprising primary human lung cancers isogenically matched with their metastases 
from 100 post-mortem cases. In this TMA, while Rsk1 was often highly expressed in 
the primary tumours, its expression was downregulated in secondary lesions (Figure 
38A and B). Moreover, loss of Rsk1 in the primary tumour correlated with an increased 
incidence of metastasis (Figure 38C) in accordance with our in vitro data. Although 
Rsk2 did not alter invasion in vitro, its control of cell migration alone could still 
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contribute to the metastatic process in vivo. Indeed, Rsk2 and 4 were upregulated in 
59% of the metastatic lesions compared to the primary tumours. Thus, our results show 
that the Rsk family targets identified in the in vitro screens can translate into clinically 
relevant findings in patient samples. To further demonstrate our findings in vivo, we 
established a zebrafish model for lung cancer metastasis. In this system A549 cells 
stably expressing a histone 2B-GFP fusion protein were injected into the cell mass of 4 
h post-fertilisation zebrafish embryos. After 48 h, these cells formed a tight mass of 
cells in the head of the developing zebrafish and only slowly invade and disseminate 
down the body of the fish towards the tail. We show that Rsk1 silencing markedly 
increased the dissemination of cells in the fish body as compared to scramble treated 
cells (Annexe 1) thus confirming our previous in vitro results. Since Rsk1 and 2 effects 
might be mediated by Mena and/or Vasp in vitro, one might expect that the expression 
of the latter proteins in cancers could also correlate with metastatic potential in vivo. In 
agreement with this notion, several reports have recently shown that upregulation of 
Vasp, Evl or Mena correlates with increased metastasis and disease progression in 
xenograft models or clinical biopsies [458] [172] [171] [173]. The preceding results suggest 
that Rsks might be useful biomarkers for lung cancer metastasis. Indeed, 75% of our 
100 post-mortem cases could have their metastatic status explained by a decrease in 
Rsk1 and/or an increase in Rsk2 or 4 expressions. However, since all patients in our 
TMA had metastases and the number of cases was limited, further work is required to 
determine the true predictive value for these potential biomarkers. 
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7 Chapter 7: General discussion 
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In the course of this thesis, we performed an siRNA kinome library screen to 
identify modulators of cell migration in A549 human lung adenocarcinoma cells. In a 
secondary 3D invasion screen, we revealed a set of hits that modulated A549 cell 
invasion in vitro. Our data highlighted the importance of the Rsk family members in 
modulating NSCLC metastasis. We show that Rsk isoforms mediate opposite effects on 
NSCLC metastasis and identify Vasp, a regulator of cell migration, as a novel substrate 
of Rsks. This knowledge provides us with new insights into the biology of NSCLC 
metastasis and we believe will help us design new treatments for this disease. 
7.1.1 Results from the high-throughput screens for cellular motility 
and invasion show limited overlap 
Our migration and invasion screen show 54% of correlation suggesting that 
changes in cell migration cannot be directly extrapolated to cell invasiveness. Several 
screens looking for changes in cancer cell motility, invasiveness and metastasis have 
recently been reported (Table 9). The overlap between these and our own screen is very 
limited. Indeed, we identified four hits (Csnk1g2, Prkce, Als2cr2 and Akt1) in common 
with a published screen performed in the non-tumorigenic breast epithelial cell line 
MCF10A [407] and one (Map4k4) that similarly decreased the migration of the ovarian 
SKOV-3 cells [406]. However, when comparing seven other migration screens, two 
invasion screens and an in vivo metastasis screen, the results generated by these screens 
show limited if any overlap between them (Table 9). This is somewhat surprising. 
Indeed, if a gene signature was to drive cancer metastasis, one expects that it would be 
highlighted by such a comparison. 
One reason explaining this discrepancy could be that the experimental 
approaches (e.g. cellular system, library, assay) used were different. Moreover, each of 
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these screens measured a single parameter (e.g. migration speed, migration distance, 
number of cells invading) to identify proteins regulating a complex multistep 
mechanism (metastasis) (Chapter 1 section 1.2.1). The comparison of our migration and 
invasion screens using the same cellular system suggests that the measurement of a 
single parameter taking part in the metastatic cascade cannot be extrapolated to 
metastasis itself. The emergence of multiparametric screens [459] [460] [461] [462] that use a 
set of parameters to characterise gene-specific effects regulating a phenotype 
successfully identified gene signatures controlling complex biological processes such as 
mitosis [462] and endocytosis [459]. The implementation of similar approaches to 
investigate metastasis might reveal a gene signature common to a wide range of tumour 
cell types. 
Alternatively, the discrepancy observed amongst the screens performed so far 
may suggest that the network of kinases regulating cell migration, invasiveness and 
metastasis is adaptive and variable between cancer types. In that case, screening 
approaches centred on the downregulation or overexpression of one gene at a time will 
remain informative for the cellular system or the cancer type studied but will have 
limited wider relevance. 
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7.1.2 The involvement of Rsk in cellular motility 
Our motility screen revealed several Rsk family members as regulators of 
NSCLC migration. In particular, Rsk1 increased while Rsk2 and 4 decreased A549 
migration speed upon downregulation. The effects of Rsk1 silencing could be reversed 
by Rsk2 suggesting that a balance between the activities of these two Rsk isoforms may 
exist. On the other hand, silencing of Rsk4 increased the expression levels of Rsk1. 
Unfortunately, the reverse experiment could not be performed due to the absence of a 
Rsk4 antibody suitable for Western blotting. Nevertheless, these results suggest that 
Rsk1 and Rsk4 may regulate each others activity through cross-modulation of their 
expression levels. Taken together, our data potentially indicate a complex and intricate 
relationship between Rsk isoforms. 
We also show that Rsk1 downregulation strongly increased cell invasiveness in 
vitro and metastasis in an in vivo zebrafish model. In contrast, Rsk4 silencing inhibited 
invasion in vitro. However, the effects of Rsk2 on A549 cell migration did not extend 
to cell invasiveness in our assay. Recent reports have highlighted the importance of Rsk 
family members in modulating migration, invasion and metastasis [256, 323-324]. These 
studies propose Rsk1 and/or Rsk2 as being determinant factors in mediating the pro-
metastatic programme driven by Erk. Over-expression of kinase active Rsk1 in two 
melanoma cell lines was shown to increase cell motility in a p27Kip1/RhoA-dependent 
manner [324]. However, contradictory reports suggest that loss of p27Kip1 leads to 
increased cellular motility and invasiveness [463] [464]. While treating cells with pan-Rsk 
inhibitors (fmk, SL0101 and BI-D1870) inhibited Rsk-mediated migratory and invasive 
effects [256, 323], isoform-specific down-regulation of Rsk family members using RNA 
interference in head and neck squamous cell carcinomas (HNSCC) did highlight the 
particular role of Rsk2 in this process. Indeed, silencing of Rsk1 alone in HNSCC does 
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not reproduce the effects observed in melanoma cells [256, 324]. On the other hand, Doehn 
et al. showed that the silencing of either Rsk1 or Rsk2 alone is unable to significantly 
decrease invasiveness in the normal breast epithelial MCF10A cells but that 
downregulation of both isoforms is required to achieve this effect. Thus, it would 
appear that the contribution of each Rsk isoform to cellular motility and invasiveness is 
cell type-dependent. 
Our data show that Rsk1 silencing in NSCLC leads to an increase in cell 
motility, invasiveness and metastasis. Interestingly, in their cell migration screen, 
Simpson et al. showed that Rsk1 silencing was impairing migration of MCF10A cells. 
However, in a secondary screen using the same cell line overexpressing the receptor 
tyrosine kinase Erbb2, Rsk1 silencing increased cell migration in a similar fashion as 
that observed in our screen [407]. This suggests that the involvement of Rsk1 in cell 
migration might be dictated by the signalling context of the cell system considered. 
In Drosophila melanogaster, Rsk is represented by a single gene [465]. 
Development of Rsk-null mutant flies revealed an increased dependency on Erk for 
cellular differentiation. In contrast, over expression of Rsk in flies suppressed Erk-
dependent differentiation by preventing Erk translocation to the nucleus, thereby 
inhibiting the Erk transcriptional programme [466]. Recently, Erk2 has been shown to 
activate the expression of pro-motile and pro-invasive genes via the transcription factor 
Fra1 [200]. Hence, it is tempting to speculate that Rsk isoforms might regulate cell 
motility by differentially affecting Erk localisation (e.g. membranous, cytoplasmic or 
nuclear). 
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7.1.3 The role of Rsk isoforms in the regulation of the actin 
cytoskeleton 
We have shown that the effect of Rsk1 and 2 downregulation on cell motility 
correlated with changes in cell shape and actin cytoskeleton. In Particular, Rsk1 
downregulation led to an increase in number of lamellipodia suggesting an involvement 
of Rsk1 in actin dynamics. Indeed, using a combination of bioinformatic analysis and 
co-immunoprecipitation experiments, we have demonstrated that Rsk 1 and 2 interact 
with Vasp and Mena, two proteins involved in the regulation of actin polymerisation. 
Moreover, we showed that silencing of Vasp and Mena decreases cell migration speed 
and that co-silencing of Vasp and Mena with Rsk1 abolished the promigratory and 
cytoskeletal effects of selective Rsk1 downregulation. Using mass spectrometry 
analysis, we identified Vasp residues phosphorylated by Rsk1, 2 and 4. In particular, 
we show that the Thr-278 is specifically targeted by Rsk1. 
7.1.3.1 Rsk1 phosphorylates Vasp on the Thr-278 
Vasp and Mena act as anti-capping, anti-branching, actin bundling proteins via 
their EVH2 domain and promote profilin-actin recruitment to the actin filament barbed 
end via their central proline rich region (reviewed by [144]). While recruitment of 
profilin-actin is not a requirement for Vasp activity, the anti-capping, anti-branching, 
actin bundling activities are essential for it to promote F-actin polymerisation [144]. 
These functions are mediated via separated motifs within the EVH2 domain that 
interact with G-actin, F-actin and promote Vasp tetramerisation. Previous reports have 
highlighted the importance of the phosphorylation of the Ser-239 located next to the G-
actin binding motif (GAB: residues 234 to 237) and the Thr-278 adjacent to the F-actin 
binding motifs (FAB: residues 260 to 277) in the regulation of Vasp activity. Indeed, 
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actin filaments and profilin-actin are negatively charged and show high affinity for 
Vasp-located F- and G-actin binding domains respectively. Hence, the addition of 
negative charges by phosphorylation of these sites (or phospho-mimetic mutation) 
reduces the affinity of Vasp for actin and impairs Vasp-mediated actin filament 
assembly [149] [155]. The Ser-239 is a known substrate of the cyclic-nucleotide-dependent 
kinases Pka and Pkg [149]. Interestingly, double phospho-mimetic mutation of the Ser-
239 and Thr-278 has an additive and maximising effect on Vasp function [149]. This 
suggests the possibility that Rsk1 and Pka/Pkg collaborate in the regulation of Vasp 
activity. Indeed, recent reports have shown that Rsk1 (but not Rsk2) and Pka regulate 
each other’s activities and localisation [467].  
7.1.3.2 Rsk family members differentially phosphorylate Vasp 
Our mass spectrometry analysis of Vasp phosphorylation by Rsk1, 2 and 4 
revealed that Rsk1 and 2 could target distinct residues on Vasp while Rsk4 did not. 
This analysis identified Ser-2 and/or Thr-4, Ser-8 and/or Ser-9 as well as Ser-322 
and/or Ser-323, Ser-324, Ser-325 as potential Rsk2 specific substrates. Furthermore, all 
three Rsk isoforms were able to phosphorylate Thr-12, Ser-255 and/or Ser-258, as well 
as Thr-315 and/or Thr-316. Interestingly, recent proteomic high-throughput screens 
support our in vitro findings. Indeed, the phosphorylation of Ser-321, Ser-322, Ser-323, 
Ser-324, Thr-315 and Thr-316 located in the EVH2 domain were also highlighted in 
HeLa cells [468]. However, the effect of these phosphorylation sites on Vasp function 
remains to be demonstrated. The EVH1-located Ser-2, Thr-4, Ser-8 and Ser-9 targeted 
by RSk2 could potentially affect the function of Vasp by modulating the binding of the 
EVH1 domain to proline-rich sequences (PRS) containing proteins such as Vinculin 
and Zyxin [469]. Indeed, Vasp interaction with these proteins is particularly important for 
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Vasp localisation to the tips of the filopodia, the lamellipodia and the focal adhesion 
complexes [107]. 
7.1.3.3 Implications for the design of new therapies for Lung Cancer 
metastasis 
Three pan-inhibitors have been described that inhibit Rsk kinase activity 
specifically. These are SL0101 and BI-D1870 that target the NTKD [179, 252, 470] and the 
pyrolopyrimidine fmk that target the CTKD of Rsk [471]. Our data, showing that 
downregulation of Rsk2 and/or Rsk4 suppresses migration, suggest that a Rsk2/4 
inhibitor might prevent metastasis in human lung cancer cells. Unfortunately, all Rsk 
inhibitors currently available target the kinase domains (NTKD or CTKD) which are 
well conserved amongst all Rsk isoforms [251, 471] [252, 470, 472]. This could be of concern 
as inhibition of Rsk1 may not be desirable. Indeed, siRNA-mediated silencing of this 
protein enhances cell migration/invasion and knockdown of all 3 Rsk isoforms (Rsk1/2 
and 4) cancels out the effects of each one individually in NSCLC (Chapter 3 Figure 
22). Consequently, at best, a pan-inhibitor may simply exert no effect on metastatic 
potential of NSCLC while in the worst case scenario it might actually promote tumour 
cell dissemination. However, this hypothesis needs to be validated experimentally.  
7.1.4 Future directions 
 
In the light of the results presented in this thesis, several questions remain to be 
addressed. 
 How do the 70 migration hits affect the invasiveness of additional cell types 
and how does ECM composition modulate this effect? 
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The comparison of our two screens revealed a limited correlation (54%) 
between cell migration and invasion. One reason explaining this discrepancy could lie 
in the type of ECM used to perform our 3D invasion screen. Indeed, by using a type I 
collagen matrix, we might have selected migration hits that require this component to 
modulate invasiveness. In vivo, metastasising tumour cells are exposed to a more 
complex extracellular environment (Chapter 1 section 1.1.2 and 1.2.1.1.1.1). Hence, the 
use of additional ECM components as well as different chemo-attractants might reveal 
a higher degree of correlation between cell motility and invasiveness modulators. 
Furthermore, re-screening the 70 motility hits for cellular motility and invasiveness in a 
panel of cell lines from various origins should provide a better appreciation of the 
correlation between the two processes. 
 
 Can we extend our observation on the role of Rsk isoforms in NSCLC to 
additional cancer types? 
Several reports suggest that our observations on the role of Rsk1 in NSCLC cell 
migration cannot be extended to other cancer types [256, 323-324]. However, a systematic 
assessment of cell migration following silencing of each Rsk isoforms in a panel of cell 
lines of various origins should provide a more complete understanding of the roles of 
Rsks in this process.  
 
 What are the molecular mechanisms responsible for the different 
phenotypes observed following Rsk1, 2 and 4 targeting in NSCLC? 
Our data suggest that Rsk1 might act as a dominant Rsk isoform regulating 
NSCLC metastasis. Indeed, we showed that Rsk4 silencing leads to an increase in Rsk1 
protein levels suggesting that Rsk4 effects on cell motility might be mediated by Rsk1. 
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However, we have not uncovered the mechanism underlying this balance. Several 
hypotheses could be proposed. First, Rsk4 downregulation could enhance expression of 
Rsk1 by transcriptional or translational mechanisms. Alternatively, Rsk4 silencing 
could lead to a stabilisation of Rsk1 protein. Furthermore, our data show that Rsk1 and 
2 co-immunoprecipitate in A549 cells and that concomitant silencing of Rsk1 and 2 
cancel their respective effects on cell migration. This suggests the existence of a 
balance between the biological activities of Rsk1 and Rsk2. Different molecular 
mechanisms could account for this effect. First, Rsk1 and 2 could inhibit each other 
through interaction. Second, Rsk1 and 2 could induce a mislocalisation of the other 
isorform thereby preventing it from interacting with its substrates. Finally, Rsk1 and 2 
might be competing for their downstream binding partners or upstream activators such 
as Erk.  
 
 
 What is the importance of Vasp phosphorylation by Rsk1 during invasion 
and metastasis? 
Using both mass spectrometry and phospho-specific antibodies, we have shown 
that Rsk1, but not Rsk2 or Rsk4, phosphorylates Vasp on the Thr-278. Phosphorylation 
of Thr-278 was previously predicted to suppress cell migration [149] [155] suggesting that 
Thr-278 might be of particular importance in mediating Rsk1 effect on cell motility. 
Indeed, Vasp knockdown partially reversed the effects of Rsk1 silencing. To address 
this hypothesis, it would be necessary to assess how Rsk1 silencing affects the 
migration of cells over-expressing phospho-mimetic (Thr-278 to Glutamic acid) or non-
phosphosphorylable (Thr-278 to Alanine) mutants of Vasp. However, the endogenous 
expression levels for Vasp are high and likely to mask the effects of the overexpressed 
cDNAs if their effects are not dominant. Alternatively, mouse embryonic fibroblasts 
202 
 
(MEF) obtained from Vasp knockout mice could be used. However, previous reports 
have shown that re-expression of Vasp in these cells decreases migration speed in 
contradiction to what is observed in epithelial tumour cells [140]. Finally, the relevance 
of the phosphorylation of Vasp by Rsk1 during invasion and metastasis needs to be 
assessed. 
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7.1.5 Final comments 
This work has enabled us to identify novel modulators of lung cancer cell 
motility, invasiveness and metastasis. In particular, we have highlighted the importance 
of Rsk isoforms in these processes. Our data suggest that the phosphorylation of the 
actin binding protein Vasp by Rsk1 might be relevant to the effects of this kinase on 
cell motility. However, further work is needed to fully demonstrate this hypothesis and 
assess the importance of this interaction to invasion and metastasis. Our in vitro data 
correlated with findings in human tissue arrays of primary and metastastatic lung 
cancer suggesting that expression levels for Rsks may be useful biomarkers to follow 
the progression of this disease in patients. Moreover, it is conceivable that the 
development of isoform-specific Rsk inhibitors might provide novel therapeutic agents 
to prevent metastasis in lung cancer patients. 
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Annexe 1: Rsk1 silencing promotes metastasis in zebrafish. H2B-GFP expressing A549 cells were 
injected into zebrafish embryos 4 h post-fertilisation (hpf). (A) Representative picture showing injected 
cells in the cell mass of 4 hpf embryos. (B) Cells treated with Rsk1 or Scramble (Sc) RNAi were injected 
at 4 hpf. Representative fish (from n=120 per condition) are shown at 48 hpf. Red arrows point to single 
invading cells. (C) Quantification of invasion from fish injected as in (B). Percent of cases refers to 
presence or absence of tumour cell in the “Head”, “Middle” or “Tail” compartment as indicated in (B). 
n=120 per condition. *; p<0.05 (t-test). (C) Representative fish injected with H2B-GFP A549 cells 
imaged at the indicated time points. Lower panels show detail of single invading cell dividing. 
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